| Unchecked |
Control |
= |
143.0 |
% |
Compounds was tested for the effect of L-nucleosides of ribavirin on SEB (staphylococcal enterotoxin B)-stimulated T-cell expression of the type 1 cytokine IL-2. |
CHEMBL1133712 |
| Unchecked |
Control |
= |
131.0 |
% |
Compounds was tested for the effect of L-nucleosides of ribavirin on SEB (staphylococcal enterotoxin B)-stimulated T-cell expression of the type 1 cytokine IFN-gamma |
CHEMBL1133712 |
| Unchecked |
Control |
= |
124.0 |
% |
Compounds was tested for the effect of L-nucleosides of ribavirin on SEB (staphylococcal enterotoxin B)-stimulated T-cell expression of the type 1 cytokine TNF-alpha |
CHEMBL1133712 |
| E6SM |
MIC |
> |
1600000.0 |
nM |
Minimum inhibitory concentration (MIC) required to elicit a microscopically visible alteration of cell morphology in E6SM cells |
CHEMBL1131121 |
| HeLa |
MIC |
> |
1600000.0 |
nM |
Minimum inhibitory concentration (MIC) required to elicit a microscopically visible alteration of cell morphology in HeLa cells |
CHEMBL1131121 |
| Vero |
MIC |
> |
1600000.0 |
nM |
Minimum inhibitory concentration (MIC) required to elicit a microscopically visible alteration of cell morphology in Vero cells |
CHEMBL1131121 |
| E6SM |
EC50 |
= |
960000.0 |
nM |
concentration required to inhibit HSV-1(KOS)-induced cytopathicity by 50% in E6SM cells |
CHEMBL1131121 |
| E6SM |
EC50 |
= |
960000.0 |
nM |
concentration required to inhibit HSV-2(G)-induced cytopathicity by 50% in E6SM cells |
CHEMBL1131121 |
| E6SM |
EC50 |
= |
128000.0 |
nM |
concentration required to inhibit HSV-1/TK (B2006) or VMW1837-induced cytopathicity by 50% in E6SM cells |
CHEMBL1131121 |
| E6SM |
EC50 |
= |
192000.0 |
nM |
concentration required to inhibit vaccinia virus-induced cytopathicity by 50% in E6SM cells |
CHEMBL1131121 |
| E6SM |
EC50 |
= |
192000.0 |
nM |
concentration required to inhibit VSV-induced cytopathicity by 50% in E6SM cells |
CHEMBL1131121 |
| HeLa |
EC50 |
= |
192000.0 |
nM |
concentration required to inhibit VSV-induced cytopathicity by 50% in HeLa cells |
CHEMBL1131121 |
| HeLa |
EC50 |
= |
320000.0 |
nM |
concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cells |
CHEMBL1131121 |
| Vero |
EC50 |
> |
1600000.0 |
nM |
concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in Vero cells |
CHEMBL1131121 |
| Vero |
EC50 |
= |
64000.0 |
nM |
concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cells |
CHEMBL1131121 |
| Vero |
EC50 |
= |
64000.0 |
nM |
concentration required to inhibit Sindbis virus -induced cytopathicity by 50% in Vero cells |
CHEMBL1131121 |
| Vero |
EC50 |
= |
64000.0 |
nM |
concentration required to inhibit reovirus-1-induced cytopathicity by 50% in Vero cells |
CHEMBL1131121 |
| Vero |
EC50 |
= |
64000.0 |
nM |
concentration required to inhibit Punta Toro virus-induced cytopathicity by 50% in Vero cells |
CHEMBL1131121 |
| E6SM |
CC50 |
> |
400.0 |
ug.mL-1 |
Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells |
CHEMBL1129240 |
| Vero |
CC50 |
> |
400.0 |
ug.mL-1 |
Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells |
CHEMBL1129240 |
| HeLa |
CC50 |
> |
200.0 |
ug.mL-1 |
Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells |
CHEMBL1129240 |
| Adrenergic receptor beta |
Activity |
= |
-4.88 |
|
Beta-blocking activity measured by applying the stepwise linear discriminate analysis; Inactive |
CHEMBL1129855 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology |
CHEMBL1134545 |
| E6SM |
MIC |
= |
240.0 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 KOS (HSV-1) in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-2 G (HSV-2) in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
16.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against vesicular simplex virus-1 in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
240.0 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 TK-KOS ACV (HSV-1) in E6SM cell cultures |
CHEMBL1134545 |
| E6SM |
MIC |
= |
240.0 |
ug.mL-1 |
Antiviral activity against herpes simplex virus-1 TK-VMW 1837 (HSV-1) in E6SM cell cultures |
CHEMBL1134545 |
| Human herpesvirus 1 |
MIC |
> |
400.0 |
ug.mL-1 |
Evaluated for minimum inhibitory concentration against KOS, F, McIntyre strains of Herpes simplex virus (HSV-1) in primary rabbit kidney cells |
CHEMBL1125081 |
| Human herpesvirus 2 |
MIC |
> |
400.0 |
ug.mL-1 |
Evaluated for minimum inhibitory concentration against G,196, Lyons strains of Herpes simplex virus (HSV-2) in primary rabbit kidney cells |
CHEMBL1125081 |
| Human herpesvirus 1 |
MIC |
> |
400.0 |
ug.mL-1 |
Evaluated for minimum inhibitory concentration against TK-B2006 strain of Herpes simplex virus (HSV-1) in primary rabbit kidney cells |
CHEMBL1125081 |
| Vaccinia virus |
MIC |
= |
10.0 |
ug.mL-1 |
Evaluated for minimum inhibitory concentration against Vaccinia virus (VV) in primary rabbit kidney cells |
CHEMBL1125081 |
| Vesicular stomatitis virus |
MIC |
= |
300.0 |
ug.mL-1 |
Evaluated for minimum inhibitory concentration against Vesicular stomatitis virus (VSV) in primary rabbit kidney cells |
CHEMBL1125081 |
| Vero |
MIC |
= |
150.0 |
ug.mL-1 |
Evaluated for minimum inhibitory concentration against Vero cells (African green monkey) infected with PV-3, RV-1, SV, Coxs B4, SFV virus |
CHEMBL1125081 |
| HeLa |
MIC |
= |
20.0 |
ug.mL-1 |
Evaluated for minimum inhibitory concentration against HeLa cells (human carcinoma) infected with VSV, Coxs, B4, polio-1 virus |
CHEMBL1125081 |
| ATH-8 cell line |
MIC |
> |
400000.0 |
nM |
Minimum inhibitory concentration of the compound, achieving a complete protection of ATH8 cells against the cytopathic effect of HTLV-III / LAV reverse transcriptase |
CHEMBL1123357 |
| ATH-8 cell line |
SI |
< |
0.3 |
|
Selectivity index expressed as ratio of compound concentration required to reduce the growth of normal uninfected ATH8 cells by 50% to the compound concentration (MIC) |
CHEMBL1123357 |
| HeLa |
MCC |
> |
400.0 |
ug.mL-1 |
Concentration required to cause a microscopically detectable alteration in cell morphology in HeLa cell cultures. |
CHEMBL1122581 |
| Vesicular stomatitis virus |
MIC |
= |
4.0 |
ug.mL-1 |
Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cell cultures. |
CHEMBL1122581 |
| Human coxsackievirus B4 |
MIC |
= |
20.0 |
ug.mL-1 |
Concentration required to reduce coxsackie virus 4 induced cytopathogenicity by 50% in HeLa cell cultures. |
CHEMBL1122581 |
| Human poliovirus 1 |
MIC |
= |
7.0 |
ug.mL-1 |
Concentration required to reduce polio virus type 1 induced cytopathogenicity by 50% in HeLa cell cultures. |
CHEMBL1122581 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Concentration required to cause a microscopically detectable alteration in cell morphology in vero cell cultures. |
CHEMBL1122581 |
| Mammalian orthoreovirus 1 |
MIC |
= |
20.0 |
ug.mL-1 |
Concentration required to reduce reovirus type 1 induced cytopathogenicity by 50% in vero cell cultures. |
CHEMBL1122581 |
| Human parainfluenza virus 3 |
MIC |
= |
20.0 |
ug.mL-1 |
Concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity by 50% in vero cell cultures. |
CHEMBL1122581 |
| Sindbis virus |
MIC |
= |
150.0 |
ug.mL-1 |
Concentration required to reduce sindbis virus induced cytopathogenicity by 50% in vero cell cultures. |
CHEMBL1122581 |
| Human coxsackievirus B4 |
MIC |
> |
400.0 |
ug.mL-1 |
Concentration required to reduce coxsackie virus B4 induced cytopathogenicity by 50% in vero cell cultures. |
CHEMBL1122581 |
| Oryctolagus cuniculus |
MCC |
> |
400.0 |
ug.mL-1 |
Concentration required to cause a microscopically detectable alteration in cell morphology in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| Human herpesvirus 1 |
MIC |
> |
400.0 |
ug.mL-1 |
Concentration required to reduce HSV-1 (KOS) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| Human herpesvirus 2 |
MIC |
> |
400.0 |
ug.mL-1 |
Concentration required to reduce HSV-2 (G) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| Vaccinia virus |
MIC |
= |
10.0 |
ug.mL-1 |
Concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| Vesicular stomatitis virus |
MIC |
= |
70.0 |
ug.mL-1 |
Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures. |
CHEMBL1122581 |
| L1210 |
ID50 |
= |
3.18 |
ug ml-1 |
Dose required to inhibit proliferation of L-1210 Cells by 50% |
CHEMBL1122581 |
| NON-PROTEIN TARGET |
MIC |
= |
46.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured against Herpes simplex virus type 1 (KOS strain) on E6SM cells |
CHEMBL1127471 |
| Human herpesvirus 1 |
MIC |
= |
23.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (F strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
16.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (McIntyre strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
250.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (G strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
120.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (196 strain) |
CHEMBL1127471 |
| NON-PROTEIN TARGET |
MIC |
= |
103.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (Lyons strain) |
CHEMBL1127471 |
| Human herpesvirus 1 |
MIC |
= |
115.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against TK+/TK-Herpes simplex virus type 1 (VMW1837 strain) |
CHEMBL1127471 |
| Human herpesvirus 1 |
MIC |
= |
53.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against TK-Herpes simplex virus type 1 (B2006 strain) |
CHEMBL1127471 |
| Human herpesvirus 3 |
MIC |
= |
43.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Vesicular stomatitis virus |
CHEMBL1127471 |
| Vaccinia virus |
MIC |
= |
28.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells against Vaccinia virus |
CHEMBL1127471 |
| E6SM |
MIC |
= |
400.0 |
ug.mL-1 |
The minimum inhibitory concentration was measured on E6SM cells for morphological alteration |
CHEMBL1127471 |
| Oryctolagus cuniculus |
MTC |
> |
400.0 |
ug ml-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in primary rabbit kidney cells |
CHEMBL1123899 |
| Human herpesvirus 1 |
MIC50 |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Herpes simplex virus type 1 (HSV-1, strain KOS) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human herpesvirus 2 |
MIC50 |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Herpes simplex virus type 2 (HSV-2 strain G) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Vaccinia virus |
MIC50 |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Vesicular stomatitis virus |
MIC50 |
= |
300.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vesicular stomatitis virus (VSV) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| HeLa |
MTC |
> |
400.0 |
ug ml-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Hela cells |
CHEMBL1123899 |
| Vesicular stomatitis virus |
MIC50 |
= |
4.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Vesicular stomatitis virus (VSV) induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human coxsackievirus B4 |
MIC50 |
= |
40.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human poliovirus 1 |
MIC50 |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Polio virus type 1 induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Vero |
MTC |
> |
400.0 |
ug ml-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Vero cells |
CHEMBL1123899 |
| Mammalian orthoreovirus 1 |
MIC50 |
= |
75.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce reo virus type 1 induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human parainfluenza virus 3 |
MIC50 |
= |
50.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce parainfluenza type 3 induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Sindbis virus |
MIC50 |
= |
65.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce sindbis virus induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Human coxsackievirus B4 |
MIC50 |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50% |
CHEMBL1123899 |
| Measles virus |
MIC50 |
= |
30.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce measles virus induced cytopathogenicity by 50% |
CHEMBL1123899 |
| E6SM |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-1 virus in E6SM cells |
CHEMBL1126305 |
| E6SM |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against TK- HSV-1 virus in E6SM cells |
CHEMBL1126305 |
| E6SM |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-2 virus in E6SM cells |
CHEMBL1126305 |
| E6SM |
MIC |
= |
40.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vaccinia virus in E6SM cells |
CHEMBL1126305 |
| E6SM |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in E6SM cells |
CHEMBL1126305 |
| HeLa |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in HeLa cells |
CHEMBL1126305 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in HeLa cells |
CHEMBL1126305 |
| Vero |
MIC |
= |
100.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in Vero cells |
CHEMBL1126305 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against polio 1 virus in HeLa cells |
CHEMBL1126305 |
| Vero |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against parainfluenza 3 virus in Vero cells |
CHEMBL1126305 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against reo type 1 virus in Vero cells |
CHEMBL1126305 |
| Vero |
MIC |
= |
40.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against sindbis virus in Vero cells |
CHEMBL1126305 |
| Vero |
MIC |
= |
40.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against semliki forest virus in Vero cells |
CHEMBL1126305 |
| L1210 |
ID50 |
= |
36.0 |
uM |
Evaluated for cell growth inhibition and induction of cellular differentiation of Murine leukemia cell line (L-1210) |
CHEMBL1124952 |
| Unchecked |
ID50 |
= |
42.0 |
uM |
Evaluated for cell growth inhibition and induction of cellular differentiation of human B-lymphoblast cell line (WI-L2) |
CHEMBL1124952 |
| K562 |
ID50 |
= |
50.0 |
uM |
Evaluated for cell growth inhibition and induction of cellular differentiation of human myeloid leukemia cell line (K562) |
CHEMBL1124952 |
| HL-60 |
ID50 |
= |
67.0 |
uM |
Evaluated for cell growth inhibition and induction of cellular differentiation of human myeloid leukemia cell line (HL-60) |
CHEMBL1124952 |
| ADMET |
MIC |
> |
300.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce HSV-1 (KOS) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| ADMET |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce HSV-2 (G) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| Human herpesvirus 1 |
MIC |
> |
300.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce TK-HSV-1 (B2006) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| Vaccinia virus |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce Vaccinia virus (VV) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| Vesicular stomatitis virus |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required for antiviral activity to reduce Vesicular stomatitis virus (VSV) induced cytopathicity in human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| ESM |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human embryonic skin-muscle cells (ESM) |
CHEMBL1127647 |
| HeLa |
MIC |
= |
4.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of vesicular stomatitis virus induced cytopathicity in HeLa cells |
CHEMBL1130007 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of coxsackie B4 virus induced cytopathicity in HeLa cells |
CHEMBL1130007 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of Polio-1 virus induced cytopathicity in HeLa cells |
CHEMBL1130007 |
| HeLa |
MIC |
> |
200.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of morphology virus induced cytopathicity in HeLa cells |
CHEMBL1130007 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of Parainfluenza-3 virus induced cytopathicity in Vero cells |
CHEMBL1130007 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of Reo-1 virus induced cytopathicity in Vero cells |
CHEMBL1130007 |
| Vero |
MIC |
= |
150.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of Sindbis virus induced cytopathicity in Vero cells |
CHEMBL1130007 |
| Vero |
MIC |
= |
300.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of forest virus induced cytopathicity in Vero cells |
CHEMBL1130007 |
| Vero |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory conc. for 50% inhibition of alteration of morphology in Vero cells |
CHEMBL1130007 |
| Oryctolagus cuniculus |
MCC |
> |
400.0 |
ug.mL-1 |
Evaluation for antiviral activity in primary rabbit kidney cell culture |
CHEMBL1123547 |
| Human herpesvirus 1 |
MIC |
> |
400.0 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus type 1 (strain KOS) in primary rabbit kidney cell culture |
CHEMBL1123547 |
| Human herpesvirus 2 |
MIC |
> |
400.0 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus type 2 (strain G) in primary rabbit kidney cell culture |
CHEMBL1123547 |
| Vaccinia virus |
MIC |
= |
30.0 |
ug.mL-1 |
Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell culture |
CHEMBL1123547 |
| Vesicular stomatitis virus |
MIC |
= |
200.0 |
ug.mL-1 |
Evaluation for antiviral activity against vesion stomatitis virus in primary rabbit kidney cell culture |
CHEMBL1123547 |
| MDCK |
MIC50 |
= |
614800.0 |
nM |
Minimum inhibitory concentration required to reduce influenza A H2N2 virus induced cytopathogenicity by 50% in madin-Darby canine kidney cells (MDCK) |
CHEMBL1133908 |
| MDCK |
MIC50 |
= |
122900.0 |
nM |
Minimum inhibitory concentration required to reduce influenza A H3N2 (X31) virus induced cytopathogenicity by 50% in madin-Darby canine kidney cells (MDCK) |
CHEMBL1133908 |
| MDCK |
MCC50 |
> |
1024.6 |
uM |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in madin-Darby canine kidney cells (MDCK) |
CHEMBL1133908 |
| MDCK |
MIC50 |
= |
19.0 |
ug.mL-1 |
Antiviral activity tested against influenza A,H1N1 virus infected MDCK cell lines. |
CHEMBL1129609 |
| NON-PROTEIN TARGET |
MIC50 |
= |
48.7 |
ug.mL-1 |
Antiviral activity against influenza A,H2N2 virus infected MDCK cell lines. |
CHEMBL1129609 |
| NON-PROTEIN TARGET |
MIC50 |
= |
5.6 |
ug.mL-1 |
Antiviral activity against influenza A,H3N2 virus infected MDCK cell lines. |
CHEMBL1129609 |
| Influenza B virus |
MIC50 |
= |
2.4 |
ug.mL-1 |
Antiviral activity against influenza B virus infected MDCK cell lines. |
CHEMBL1129609 |
| Human parainfluenza virus 3 |
MIC50 |
= |
150.0 |
ug.mL-1 |
Antiviral activity against parainfluenza 3 virus infected Vero cell lines. |
CHEMBL1129609 |
| Human herpesvirus 1 |
MIC50 |
> |
200.0 |
ug.mL-1 |
Antiviral activity against HSV-1 virus infected HEF cell lines. |
CHEMBL1129609 |
| Human herpesvirus 1 |
MIC50 |
> |
200.0 |
ug.mL-1 |
Antiviral activity against TK-HSV-1 virus infected HEF cell lines. |
CHEMBL1129609 |
| Human herpesvirus 2 |
MIC50 |
> |
200.0 |
ug.mL-1 |
Antiviral activity against HSV-2 virus infected HEF cell lines. |
CHEMBL1129609 |
| Vaccinia virus |
MIC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against vaccinia virus infected HEF cell lines. |
CHEMBL1129609 |
| Vesicular stomatitis virus |
MIC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against vesicular stomatitis virus infected HEF cell lines. |
CHEMBL1129609 |
| Vesicular stomatitis virus |
MIC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against vesicular stomatitis virus infected HeLa cell lines. |
CHEMBL1129609 |
| Poliovirus |
MIC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against polio 1 virus infected HeLa cell lines. |
CHEMBL1129609 |
| Human coxsackievirus B4 |
MIC50 |
= |
10.0 |
ug.mL-1 |
Antiviral activity against Coxsackie B4 virus infected HeLa cell lines. |
CHEMBL1129609 |
| Human coxsackievirus B4 |
MIC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Coxsackie B4 virus infected vero cell lines. |
CHEMBL1129609 |
| Sindbis virus |
MIC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against sindbis virus infected Vero cell lines. |
CHEMBL1129609 |
| Semliki forest virus |
MIC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Semliki forest virus infected Vero cell lines. |
CHEMBL1129609 |
| Mammalian orthoreovirus 1 |
MIC50 |
= |
70.0 |
ug.mL-1 |
Antiviral activity against Reo 1 virus infected vero cell lines. |
CHEMBL1129609 |
| MDCK |
MIC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity of compound was tested against morphology virus infec+ted MDCK cell lines. |
CHEMBL1129609 |
| Vero |
MIC50 |
> |
400.0 |
ug.mL-1 |
Effects on cell morphology of Vero cell lines. |
CHEMBL1129609 |
| HEF |
MIC50 |
= |
400.0 |
ug.mL-1 |
Effects on cell morphology of HEF cell lines. |
CHEMBL1129609 |
| HeLa |
MIC50 |
> |
400.0 |
ug.mL-1 |
Effects on cell morphology of HeLa cell lines. |
CHEMBL1129609 |
| MDCK |
Virus rating |
= |
3.4 |
|
In vitro antiviral activity against influenza virus (type A0/PR/8/34) in Madin-Darby canine kidney (MDCK) host cell cultures |
CHEMBL1125060 |
| MDCK |
ID50 |
= |
3.1 |
ug ml-1 |
In vitro minimum drug concentration that inhibited the influenza virus-induced cytopathogenic effects by 50% in Madin-Darby canine kidney (MDCK) host cell cultures |
CHEMBL1125060 |
| MDCK |
MTC |
= |
32.0 |
ug ml-1 |
Minimum concentration (ug/mL) for in vitro antiviral activity against influenza virus (type A0/PR/8/34) in Madin-Darby canine kidney (MDCK) host cell cultures |
CHEMBL1125060 |
| MDCK |
Therapeutic index |
= |
10.3 |
|
In vitro antiviral activity against influenza virus (type A0/PR/8/34) in Madin-Darby canine kidney (MDCK) host cell cultures (MTC/ID50) |
CHEMBL1125060 |
| ADMET |
Permeability coefficient |
= |
4.1 |
|
Permeability coefficient reported (Expressed as Permeability coefficient x 10 e 4 cm/s) |
CHEMBL1129412 |
| Oryctolagus cuniculus |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in primary rabbit kidney (PRK) cells |
CHEMBL1124462 |
| HeLa |
MCC |
> |
200.0 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in HeLa cells |
CHEMBL1124462 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in african green monkey (Vero B) cells |
CHEMBL1124462 |
| ADMET |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce herpes simplex virus-1 (KOS)induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK) |
CHEMBL1124462 |
| ADMET |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce herpes simplex virus-2 (G)induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK) |
CHEMBL1124462 |
| Vaccinia virus |
MIC |
= |
2.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK) |
CHEMBL1124462 |
| ADMET |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK) |
CHEMBL1124462 |
| HeLa |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cells |
CHEMBL1124462 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce polio virus -1 induced cytopathogenicity by 50% in HeLa cells |
CHEMBL1124462 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Coxsackie virus B4 induced cytopathogenicity by 50% in HeLa cells |
CHEMBL1124462 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Coxsackie virus B4 induced cytopathogenicity by 50% in african green monkey (VeroB) cells |
CHEMBL1124462 |
| Sindbis virus |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce Sindbis virus induced cytopathogenicity by 50% in african green monkey (VeroB) cells |
CHEMBL1124462 |
| Vero |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce parainfluenza virus-3 induced cytopathogenicity by 50% in african green monkey (VeroB) cells |
CHEMBL1124462 |
| Mammalian orthoreovirus 1 |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce reovirus-1 induced cytopathogenicity by 50% in african green monkey (VeroB)cells |
CHEMBL1124462 |
| Semliki forest virus |
MIC |
= |
150.0 |
ug.mL-1 |
Minimum inhibitory concentration required to reduce semliki forest virus induced cytopathogenicity by 50% in african green monkey (VeroB) cells |
CHEMBL1124462 |
| NON-PROTEIN TARGET |
Virus rating |
= |
2.8 |
|
Virus rating is measurement of degree of inhibition of virus-induced cytopathogenic effects and the degree of cytotoxicity produced by the test compound for influenza type A2 |
CHEMBL1123751 |
| Human parainfluenza virus 3 |
ED50 |
= |
0.00016 |
M |
In vitro antiviral activity was tested against, parainfluenza type 3 (Para 3) virus |
CHEMBL1122818 |
| Measles virus |
ED50 |
= |
3e-05 |
M |
In vitro antiviral activity was tested against, measles virus |
CHEMBL1122818 |
| Vaccinia virus |
ED50 |
= |
8.499999999999999e-05 |
M |
In vitro antiviral activity was tested against, vaccinia virus (VV) |
CHEMBL1122818 |
| Human herpesvirus 2 |
ED50 |
= |
0.00019 |
M |
In vitro antiviral activity was tested against, herpes simplex type 2 virus (HSV-2) |
CHEMBL1122818 |
| ADMET |
Toxic level |
|
|
|
Toxic level was evaluated; None |
CHEMBL1122818 |
| NON-PROTEIN TARGET |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration which causes microscopically detectable alteration of normal cell morphology after 2 days of incubation. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
60.0 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (KOS) strain of HSV-1 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
80.0 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (F) strain of HSV-1 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
90.0 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Mc Intyre) strain of HSV-1 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
50.0 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (G) strain of HSV-2 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
150.0 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (196) strain of HSV-2 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
100.0 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Lyons) strain of HSV-2 virus on human E6SM cells. |
CHEMBL1130413 |
| E6SM |
MIC |
= |
150.0 |
ug.mL-1 |
50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by TK-(B2006) strain of HSV-1 virus on human E6SM cells. |
CHEMBL1130413 |
| Human herpesvirus 1 |
VR |
= |
1.2 |
|
In vitro antiviral activity against herpes simplex virus/1(HSV/1) expressed as viral rating (VR) |
CHEMBL1121727 |
| Human herpesvirus 1 |
MIC |
> |
400.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce HSV-1(KOS) induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Human herpesvirus 2 |
MIC |
> |
400.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce HSV-2 (G) induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Vaccinia virus |
MIC |
= |
40.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce vaccinia virus induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Vesicular stomatitis virus |
MIC |
= |
40.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce VSV induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Measles virus |
MIC |
= |
20.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce measles virus induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Reovirus sp. |
MIC |
= |
40.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce reovirus type I induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Human parainfluenza virus 3 |
MIC |
= |
10.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Sindbis virus |
MIC |
= |
40.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce Sindbis virus induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Coxsackievirus |
MIC |
= |
200.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce Coxsackie virus type B4 induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Vesicular stomatitis virus |
MIC |
= |
4.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce VSV induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Coxsackievirus |
MIC |
= |
40.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce Coxsackie virus type B4 induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Poliovirus |
MIC |
= |
20.0 |
ug.mL-1 |
The minimum inhibitory concentration required to reduce polio virus type I induced cytopathogenicity in primary rabbit kidney cells by 50% |
CHEMBL1122552 |
| Japanese encephalitis virus |
Virus rating |
= |
2.4 |
|
Tested for inhibition of virus-induced cytopathogenic effect and cytotoxicity of compound against Japanese encephalitis virus with najayama strain in vero cell |
CHEMBL1124192 |
| Punta Toro virus |
Virus rating |
= |
1.8 |
|
Tested for inhibition of virus-induced cytopathogenic effect and cytotoxicity of compound against Punta toro virus with adames strain in vero cell |
CHEMBL1124192 |
| unidentified influenza virus |
Virus rating |
= |
3.6 |
|
Tested for inhibition of virus-induced cytopathogenic effect and cytotoxicity of compound against influenza virus with A2/Aichi/2/68 strain in MDCK cell |
CHEMBL1124192 |
| Japanese encephalitis virus |
ID50 |
= |
3.0 |
ug ml-1 |
Inhibitory dose of compound required to inhibit cytopathogenic effects of Japanese encephalitis virus with najayama strain in vero cells |
CHEMBL1124192 |
| Punta Toro virus |
ID50 |
= |
20.1 |
ug ml-1 |
Inhibitory dose of compound required to inhibit cytopathogenic effects of Punta toro virus with adames strain in vero cells |
CHEMBL1124192 |
| unidentified influenza virus |
ID50 |
= |
18.7 |
ug ml-1 |
Inhibitory dose of compound required to inhibit cytopathogenic effects of influenza virus with A2/Aichi/2/68 strain in MDCK cells |
CHEMBL1124192 |
| ADMET |
Therapeutic index |
= |
1.1 |
|
Ratio of minimum drug concentration to ID50 of the compound (Najayama strain) |
CHEMBL1124192 |
| ADMET |
Therapeutic index |
= |
5.0 |
|
Ratio of minimum drug concentration to ID50 of the compound(Adems strain) |
CHEMBL1124192 |
| HeLa |
EC50 |
= |
20.94 |
ug.mL-1 |
Compound was evaluated for its inhibitory effect on the replication of encephalomyocarditis virus (EMCV) in HeLa cells |
CHEMBL1136289 |
| HeLa |
EC50 |
= |
181.36 |
ug.mL-1 |
Compound was evaluated for its inhibitory effect on the replication of Coxsackie virus B3 (Cox. B3) in HeLa cells |
CHEMBL1136289 |
| HeLa |
EC50 |
= |
14.41 |
ug.mL-1 |
Compound was evaluated for its inhibitory effect on the replication of vesicular stomatitis virus (VSV) in HeLa cells |
CHEMBL1136289 |
| HeLa |
CC50 |
= |
300.0 |
ug.mL-1 |
Cytotoxicity against HeLa cells |
CHEMBL1136289 |
| Vero |
Virus rating |
= |
0.6 |
|
In vitro antiviral activity against HSV-1 virus in (vero) V cells of african green monkey kidney |
CHEMBL1121681 |
| Laryngeal epithelioma cell line |
Virus rating |
= |
1.2 |
|
In vitro antiviral activity against HSV-1 virus in human laryngeal epithelioma cell line |
CHEMBL1121681 |
| Vero |
Virus rating |
= |
1.2 |
|
In vitro antiviral activity against V V virus in (vero) V cells of african green monkey kidney |
CHEMBL1121681 |
| Laryngeal epithelioma cell line |
Virus rating |
= |
1.2 |
|
In vitro antiviral activity against V V virus in human laryngeal epithelioma cell line |
CHEMBL1121681 |
| Vero |
Virus rating |
= |
1.3 |
|
In vitro antiviral activity against Para 3 virus in (vero) V cells of african green monkey kidney |
CHEMBL1121681 |
| Laryngeal epithelioma cell line |
Virus rating |
= |
1.4 |
|
In vitro antiviral activity against Para 3 virus in human laryngeal epithelioma cell line |
CHEMBL1121681 |
| Vero |
Virus rating |
= |
0.8 |
|
In vitro antiviral activity against VSV virus in (vero) V cells |
CHEMBL1121681 |
| Laryngeal epithelioma cell line |
Virus rating |
= |
1.6 |
|
In vitro antiviral activity against VSV virus in human laryngeal epithelioma cell line |
CHEMBL1121681 |
| Vero |
Virus rating |
= |
0.6 |
|
In vitro antiviral activity against COXB1 virus in (vero) V cells |
CHEMBL1121681 |
| Laryngeal epithelioma cell line |
Virus rating |
= |
1.1 |
|
In vitro antiviral activity against COXB1 virus in human laryngeal epithelioma cell line |
CHEMBL1121681 |
| Rift Valley fever virus |
ILS |
= |
70.0 |
% |
Percent increase in survival rate of Rift Valley fever virus infected mice on day 21, by administering 100 (mg/kg)/day of compound |
CHEMBL1121681 |
| Human parainfluenza virus 3 |
Activity |
|
|
|
Antiviral activity at 10-30 uM determined in a culture of Parainfluenza virus type 3; IA = inactive |
CHEMBL1124600 |
| Human herpesvirus 2 |
Activity |
|
|
|
Antiviral activity at 1-3 uM determined in a culture of Herpes simplex virus type 2; IA = inactive |
CHEMBL1124600 |
| unidentified adenovirus |
Activity |
|
|
|
Antiviral activity at 100 uM determined in a culture of Adenovirus type 2; IA = inactive |
CHEMBL1124600 |
| Enterovirus |
Activity |
|
|
|
Antiviral activity at 100 uM determined in a culture of Rhinovirus type 1-A; IA = inactive |
CHEMBL1124600 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity at 10-30 uM determined in a culture of Influenza A; IA = inactive |
CHEMBL1124600 |
| Visna virus |
Activity |
|
|
|
Antiviral activity at 1-3 uM determined in a culture of Visna virus; IA = inactive |
CHEMBL1124600 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Tested for minimum cytotoxic concentration on virus-induced cytopathicity in E6SM cells |
CHEMBL1126836 |
| E6SM |
MIC |
> |
300.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration against HSV-1 (KOS strain) in E6SM cells |
CHEMBL1126836 |
| E6SM |
MIC |
= |
70.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration against Vaccinia virus in E6SM cells |
CHEMBL1126836 |
| E6SM |
MIC |
= |
20.0 |
ug.mL-1 |
Tested for minimum inhibitor concentration against vesicular stomatitis virus (VSV) in E6SM cells |
CHEMBL1126836 |
| unidentified influenza virus |
VR |
= |
2.6 |
|
Antiviral activity is expressed as virus rating (VR) against the influenza Ao/PR/8/34 virus strain |
CHEMBL1123762 |
| unidentified influenza virus |
VR |
= |
2.9 |
|
Antiviral activity is expressed as virus rating (VR) against the influenza Ao/PR/8/34 virus strain |
CHEMBL1123762 |
| unidentified influenza virus |
MIC50 |
= |
54.0 |
ug.mL-1 |
Antiviral activity against the influenza Ao/PR/8/34 virus strain |
CHEMBL1123762 |
| unidentified influenza virus |
MIC50 |
= |
14.0 |
ug.mL-1 |
Antiviral activity against the influenza Ao/PR/8/34 virus strain |
CHEMBL1123762 |
| Unchecked |
Ratio |
= |
0.19 |
|
Ratio measured as the VR of C-3''-deoxyribofuranoside to the VR at a MIC of 54 ug/mL |
CHEMBL1123762 |
| Unchecked |
Ratio |
= |
0.45 |
|
Ratio measured as the VR of C-3''-deoxyribofuranoside to the VR at a MIC of 14 ug/mL |
CHEMBL1123762 |
| E6SM |
MIC |
> |
1600000.0 |
nM |
Minimum inhibitory concentration required to elicit microscopically visible cell morphology in E6SM cell lines |
CHEMBL1134563 |
| HeLa |
MIC |
> |
1600000.0 |
nM |
Minimum inhibitory concentration required to elicit microscopically visible cell morphology in HeLa cell lines |
CHEMBL1134563 |
| Vero |
MIC |
> |
1600000.0 |
nM |
Minimum inhibitory concentration required to elicit microscopically visible cell morphology in Vero cell lines |
CHEMBL1134563 |
| E6SM |
EC50 |
= |
320000.0 |
nM |
Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines |
CHEMBL1134563 |
| E6SM |
EC50 |
= |
320000.0 |
nM |
Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines |
CHEMBL1134563 |
| E6SM |
EC50 |
= |
5.0 |
nM |
Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines |
CHEMBL1134563 |
| E6SM |
EC50 |
= |
65000.0 |
nM |
Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines |
CHEMBL1134563 |
| E6SM |
EC50 |
= |
40000.0 |
nM |
Effective concentration required to inhibit vesicular stomatitis virus(VSV) -induced cytopathicity by 50% in E6SM cell lines |
CHEMBL1134563 |
| HeLa |
EC50 |
= |
1000000.0 |
nM |
Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines |
CHEMBL1134563 |
| HeLa |
EC50 |
> |
320000.0 |
nM |
Effective concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cell lines |
CHEMBL1134563 |
| Vero |
EC50 |
> |
1600000.0 |
nM |
Effective concentration required to inhibit respiratory synaptial (RSV) virus-induced cytopathicity by 50% in Vero cell lines |
CHEMBL1134563 |
| HeLa |
EC50 |
= |
1500.0 |
nM |
Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines |
CHEMBL1134563 |
| Vero |
EC50 |
= |
196000.0 |
nM |
Effective concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cell lines |
CHEMBL1134563 |
| Vero |
EC50 |
= |
40000.0 |
nM |
Effective concentration required to inhibit reovirus-induced cytopathicity by 50% in Vero cell lines |
CHEMBL1134563 |
| Vero |
EC50 |
= |
40000.0 |
nM |
Effective concentration required to inhibit PuntaToro virus-induced cytopathicity by 50% in Vero cell lines |
CHEMBL1134563 |
| Vero |
MIC |
> |
500000.0 |
nM |
Minimum inhibitory concentration required to elicit microscopically visible cell morphology in Vero cell lines |
CHEMBL1134563 |
| MDCK |
EC50 |
= |
8.3 |
ug.mL-1 |
The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 PR8/34 strain in MDCK cells |
CHEMBL1129818 |
| Unchecked |
Ratio |
> |
12.0 |
|
Selectivity index ratio of CC50 / EC50 was determined |
CHEMBL1129818 |
| MDCK |
EC50 |
= |
34.2 |
ug.mL-1 |
The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 Bangkok/10/83 strain in MDCK cells |
CHEMBL1129818 |
| Unchecked |
Ratio |
> |
2.9 |
|
Selectivity index ratio of CC50 / EC50 was determined |
CHEMBL1129818 |
| MDCK |
EC50 |
= |
11.7 |
ug.mL-1 |
The compound was evaluated for inhibitory effect on the replication of influenza A subtype H1N1 yamagata/120/86 strain in MDCK cells |
CHEMBL1129818 |
| Unchecked |
Ratio |
> |
8.5 |
|
Selectivity index ratio of CC50 / EC50 was determined |
CHEMBL1129818 |
| MDCK |
EC50 |
= |
2.1 |
ug.mL-1 |
The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 murakami/4/64 strain in MDCK cells |
CHEMBL1129818 |
| Unchecked |
Ratio |
> |
47.6 |
|
Selectivity index ratio of CC50 / EC50 was determined |
CHEMBL1129818 |
| MDCK |
EC50 |
= |
2.2 |
ug.mL-1 |
The compound was evaluated for inhibitory effect on the replication of influenza A subtype H2N2 Adachi/2/57 in MDCK cells |
CHEMBL1129818 |
| Unchecked |
Ratio |
> |
45.5 |
|
Selectivity index ratio of CC50 / EC50 was determined |
CHEMBL1129818 |
| MDCK |
EC50 |
= |
7.9 |
ug.mL-1 |
The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 ishikawa/7/82 in MDCK cells |
CHEMBL1129818 |
| Unchecked |
Ratio |
> |
12.7 |
|
Selectivity index ratio of CC50 / EC50 was determined |
CHEMBL1129818 |
| MDCK |
EC50 |
= |
6.1 |
ug.mL-1 |
The compound was evaluated for inhibitory effect on the replication of influenza A subtype H3N2 Philippine/2/82 in MDCK cells |
CHEMBL1129818 |
| Unchecked |
Ratio |
> |
16.4 |
|
Selectivity index ratio of CC50 / EC50 was determined |
CHEMBL1129818 |
| MDCK |
EC50 |
= |
5.5 |
ug.mL-1 |
The compound was evaluated for inhibitory effect on the replication of influenza B norway/1/80 strain in MDCK cells |
CHEMBL1129818 |
| Unchecked |
Ratio |
> |
18.2 |
|
Selectivity index ratio of CC50 / EC50 was determined |
CHEMBL1129818 |
| MDCK |
EC50 |
= |
8.5 |
ug.mL-1 |
The compound was evaluated for inhibitory effect on the replication of influenza B Singapore/222/79 strain in MDCK cells |
CHEMBL1129818 |
| Unchecked |
Ratio |
> |
11.8 |
|
Selectivity index ratio of CC50 / EC50 was determined |
CHEMBL1129818 |
| MDCK |
CC50 |
> |
100.0 |
ug.mL-1 |
The compound was evaluated for cytotoxicity by MTT assay in MDCK cells |
CHEMBL1129818 |
| MDCK |
MIC50 |
= |
31100.0 |
nM |
Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza A H2N2 strain (A2 Japan/305/57) |
CHEMBL1131911 |
| MDCK |
MIC50 |
= |
41000.0 |
nM |
Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza A H3N2 (X31) |
CHEMBL1131911 |
| MDCK |
MIC50 |
= |
41000.0 |
nM |
Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza B (Hong Kong/5/72) |
CHEMBL1131911 |
| MDCK |
MTC50 |
> |
1025.0 |
uM |
Concentration required to reduce the viability of MDCK cells |
CHEMBL1131911 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Inhibition of virus-induced cytopathicity in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| ADMET |
EC50 |
= |
48.0 |
ug.mL-1 |
Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Human herpesvirus 1 |
EC50 |
= |
48.0 |
ug.mL-1 |
Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Human herpesvirus 1 |
EC50 |
= |
240.0 |
ug.mL-1 |
Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| ADMET |
EC50 |
= |
80.0 |
ug.mL-1 |
Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Unchecked |
EC50 |
= |
240.0 |
ug.mL-1 |
Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Unchecked |
EC50 |
= |
240.0 |
ug.mL-1 |
Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Vaccinia virus |
EC50 |
= |
240.0 |
ug.mL-1 |
Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Vesicular stomatitis virus |
EC50 |
> |
400.0 |
ug.mL-1 |
Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| ADMET |
EC50 |
= |
240.0 |
ug.mL-1 |
Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle |
CHEMBL1135597 |
| Vero |
ED50 |
= |
0.00016 |
M |
In vitro antiviral activity against Parainfluenza type 3 was evaluated. |
CHEMBL1123095 |
| Vero |
ED50 |
= |
3.3e-05 |
M |
In vitro antiviral activity against measles virus was evaluated. |
CHEMBL1123095 |
| Vero |
ED50 |
= |
8.499999999999999e-05 |
M |
In vitro antiviral activity against vaccinia virus was evaluated. |
CHEMBL1123095 |
| Vero |
ED50 |
= |
0.00019 |
M |
In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated. |
CHEMBL1123095 |
| Vero |
Toxic level |
|
|
|
Toxicity level was reported; none |
CHEMBL1123095 |
| E6SM |
MIC |
= |
240.0 |
ug.mL-1 |
Tested for antiviral activity against vaccinia virus in human embryonic skin muscle fibroblast |
CHEMBL1135216 |
| HeLa |
MIC |
= |
240.0 |
ug.mL-1 |
The compound was tested for antiviral activity against VSV-virus in human epithelial cells |
CHEMBL1135216 |
| E6SM |
MIC |
= |
400.0 |
ug.mL-1 |
Tested for antiviral activity against VSV-virus in human embryonic skin muscle fibroblasts |
CHEMBL1135216 |
| HeLa |
MIC |
= |
48.0 |
ug.mL-1 |
Tested for antiviral activity against coxsackie-B4 virus in human epithelial cell line |
CHEMBL1135216 |
| Vero |
MIC |
= |
240.0 |
ug.mL-1 |
Tested for antiviral activity against coxsackie B-4 virus in African green monkey kidney cell (Vero) |
CHEMBL1135216 |
| Vero |
MIC |
= |
80.0 |
ug.mL-1 |
Tested for antiviral activity against Sindbis virus in African green monkey kidney cell (Vero) |
CHEMBL1135216 |
| Vero |
MIC |
= |
80.0 |
ug.mL-1 |
Tested for antiviral activity against Reo-1 virus in African green monkey kidney cell (Vero) |
CHEMBL1135216 |
| Vero |
MCC |
= |
48.0 |
ug.mL-1 |
Tested for antiviral activity against parainfluenza virus in african green monkey kidney cell (Vero) |
CHEMBL1135216 |
| Vero |
MIC |
= |
16.0 |
ug.mL-1 |
Tested for antiviral activity against Punta toro virus in African green monkey kidney cell (Vero) |
CHEMBL1135216 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Tested for cytotoxic activity in human embryonic skin muscle fibroblast (E6SM) |
CHEMBL1135216 |
| HeLa |
MCC |
> |
400.0 |
ug.mL-1 |
Tested for cytotoxic activity in human epithelial cell line (HeLa) |
CHEMBL1135216 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Tested for cytotoxic activity in African green monkey kidney cells (Vero) |
CHEMBL1135216 |
| Staphylococcus hominis |
MIC |
> |
400.0 |
ug.mL-1 |
Tested for the antimicrobial activity minimum inhibitory concentration) against Staphylococcus hominis |
CHEMBL1135216 |
| Klebsiella pneumoniae |
MIC |
> |
400.0 |
ug.mL-1 |
Tested for the antimicrobial activity minimum inhibitory concentration) against Klebsiella pneumoniae |
CHEMBL1135216 |
| Escherichia coli |
MIC |
> |
400.0 |
ug.mL-1 |
Tested for the antimicrobial activity minimum inhibitory concentration) against Escherichia coli |
CHEMBL1135216 |
| HeLa |
MCC |
> |
400.0 |
ug.mL-1 |
Evaluation in HeLa cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology |
CHEMBL1125540 |
| HeLa |
MIC |
= |
3.0 |
ug.mL-1 |
Compound was evaluated for antiviral activity against respiratory syncitial virus (long) in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| HeLa |
MIC |
= |
20.0 |
ug.mL-1 |
Evaluation for antiviral activity against vesicular stomatitis virus in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Evaluation for antiviral activity against Coxsackie virus B4 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Evaluation for antiviral activity against polio virus-1 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| Vero |
MIC |
= |
20.0 |
ug.mL-1 |
Evaluation for antiviral activity against parainfluenza-3 virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Evaluation for antiviral activity against reo virus-1 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| Vero |
MIC |
= |
40.0 |
ug.mL-1 |
Evaluation for antiviral activity against Sindbis virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Evaluation for antiviral activity against Coxsackie virus B4 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| Vero |
MIC |
= |
40.0 |
ug.mL-1 |
Evaluation for antiviral activity against forest virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| ADMET |
MIC |
> |
200.0 |
ug.mL-1 |
Evaluated for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| ADMET |
MIC |
> |
200.0 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus-1(F) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| ADMET |
MIC |
> |
200.0 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus-1 (McIntyre) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| ADMET |
MIC |
> |
200.0 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| ADMET |
MIC |
> |
200.0 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus-2(196) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| ADMET |
MIC |
> |
200.0 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus-2(Lyons) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| ADMET |
MIC |
= |
20.0 |
ug.mL-1 |
Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| ADMET |
MIC |
> |
400.0 |
ug.mL-1 |
Evaluation for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| ADMET |
MIC |
> |
200.0 |
ug.mL-1 |
Evaluation for antiviral activity against herpes simplex virus-1(TK-) (B2006) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%) |
CHEMBL1125540 |
| MDCK |
MCC |
> |
200.0 |
ug.mL-1 |
Compound was evaluated in MDCK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology |
CHEMBL1125540 |
| Influenza A virus |
MIC |
= |
15.0 |
ug.mL-1 |
Concentration required to reduce influenza virus A (ishikawa) induced cytopathogenicity by 50% |
CHEMBL1125540 |
| Influenza B virus |
MIC |
= |
15.0 |
ug.mL-1 |
Concentration required to reduce influenza virus B (singapore) induced cytopathogenicity by 50% |
CHEMBL1125540 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Evaluation in Vero cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology |
CHEMBL1125540 |
| ADMET |
MCC |
> |
400.0 |
ug.mL-1 |
Evaluation in PRK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology |
CHEMBL1125540 |
| MDCK |
EC50 |
= |
3700.0 |
nM |
Antiviral activity against influenza A H2N2(A2 japan/305/57) in MDCK cells |
CHEMBL1136382 |
| Epithelial cells |
EC50 |
> |
1024600.0 |
nM |
Antiviral activity against influenza B (Hong kong/5/72) in human epithelial cells |
CHEMBL1136382 |
| MDCK |
MCC50 |
> |
276.9 |
uM |
Minimum cytotoxic concentration required to cause a microscopically detectable alteration of MDCK, Madin-Darby canine kidney cell morphology. |
CHEMBL1136382 |
| Unchecked |
SI |
> |
276.9 |
|
Selectivity ratio of MCC50 to that of EC50 of influenza A H2N2(A2 japan/305/57) |
CHEMBL1136382 |
| Human herpesvirus 1 |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against HSV-1(KOS) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines |
CHEMBL1126104 |
| Human herpesvirus 2 |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against HSV-2(G) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines |
CHEMBL1126104 |
| Vaccinia virus |
MIC |
= |
30.0 |
ug.mL-1 |
Antiviral activity against vaccinia virus (VV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines |
CHEMBL1126104 |
| Vesicular stomatitis virus |
MIC |
= |
50.0 |
ug.mL-1 |
Antiviral activity against vesicular stomatitis virus (VSV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines |
CHEMBL1126104 |
| Vesicular stomatitis virus |
MIC |
= |
20.0 |
ug.mL-1 |
Antiviral activity against vesicular stomatitis virus (VSV) in HeLa cell culture lines, |
CHEMBL1126104 |
| Human poliovirus 1 |
MIC |
= |
70.0 |
ug.mL-1 |
Antiviral activity against polio virus type 1 in HeLa cell culture lines |
CHEMBL1126104 |
| Human coxsackievirus B4 |
MIC |
= |
40.0 |
ug.mL-1 |
Antiviral activity against coxsackie B4 virus in HeLa cell culture lines |
CHEMBL1126104 |
| Human coxsackievirus B4 |
MIC |
> |
70.0 |
ug.mL-1 |
Antiviral activity against coxsackie B4 in Vero cell culture lines |
CHEMBL1126104 |
| Human parainfluenza virus 3 |
MIC |
= |
70.0 |
ug.mL-1 |
Antiviral activity against parainfluenza virus type 3 in Vero cell culture lines |
CHEMBL1126104 |
| Mammalian orthoreovirus 1 |
MIC |
= |
40.0 |
ug.mL-1 |
Antiviral activity against reovirus type 1 in Vero cell culture lines |
CHEMBL1126104 |
| Sindbis virus |
MIC |
= |
200.0 |
ug.mL-1 |
Antiviral activity against sindbis virus in Vero cell culture lines |
CHEMBL1126104 |
| Semliki forest virus |
MIC |
= |
200.0 |
ug.mL-1 |
Antiviral activity against semliki forest virus (SFV) in Vero cell culture lines |
CHEMBL1126104 |
| Human immunodeficiency virus 1 |
MIC |
> |
20.0 |
ug.mL-1 |
Antiviral activity against (HIV-1) in MT-4 cells Value in parentheses is inhibitory concentration for cell growth (MT-4) |
CHEMBL1126104 |
| NON-PROTEIN TARGET |
MIC |
> |
400.0 |
ug.mL-1 |
Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures. |
CHEMBL1126074 |
| NON-PROTEIN TARGET |
MIC |
> |
400.0 |
ug.mL-1 |
Concentration required to reduce HSV-2(G) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures. |
CHEMBL1126074 |
| NON-PROTEIN TARGET |
MIC |
= |
70.0 |
ug.mL-1 |
Concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures. |
CHEMBL1126074 |
| NON-PROTEIN TARGET |
MIC |
= |
150.0 |
ug.mL-1 |
Concentration required to reduce vesicular stomatitis virus(VSV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures. |
CHEMBL1126074 |
| NON-PROTEIN TARGET |
MIC |
= |
300.0 |
ug.mL-1 |
Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(B2006) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures. |
CHEMBL1126074 |
| NON-PROTEIN TARGET |
MIC |
= |
40.0 |
ug.mL-1 |
Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(VMW 1837) induced cytopathogenicity in by 50% ESM(embryonic skin muscle) cell cultures. |
CHEMBL1126074 |
| NON-PROTEIN TARGET |
MCC |
> |
400.0 |
ug.mL-1 |
Concentration required to cause a microscopically detectable alteration of normal ESM cell morphology. |
CHEMBL1126074 |
| Homo sapiens |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| Oryctolagus cuniculus |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration against Herpes simplex virus 1(KOS) in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| Oryctolagus cuniculus |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration against Herpes simplex virus 2 (G) in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| Oryctolagus cuniculus |
MIC |
= |
10.0 |
ug.mL-1 |
Minimum inhibitory concentration against Vaccinia virus in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| Oryctolagus cuniculus |
MIC |
= |
300.0 |
ug.mL-1 |
Minimum inhibitory concentration against Vesicular stomatitis virus in primary rabbit kidney cell cultures |
CHEMBL1124622 |
| HeLa |
MCC |
> |
200.0 |
ug.mL-1 |
Minimum cytotoxic concentration in HeLa cell cultures |
CHEMBL1124622 |
| HeLa |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration against Vesicular stomatitis virus in HeLa cell cultures |
CHEMBL1124622 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration against Coxsackie virus B4 in HeLa cell cultures |
CHEMBL1124622 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration against polio virus 1 in HeLa cell cultures |
CHEMBL1124622 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration in Vero cell cultures |
CHEMBL1124622 |
| Human parainfluenza virus 3 |
MIC |
= |
40.0 |
ug.mL-1 |
Minimum inhibitory concentration against parainfluenza 3 virus in Vero cell cultures |
CHEMBL1124622 |
| Mammalian orthoreovirus 1 |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration against reovirus in Vero cell cultures |
CHEMBL1124622 |
| Sindbis virus |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration against Sindbis virus in Vero cell cultures |
CHEMBL1124622 |
| Human coxsackievirus B4 |
MIC |
= |
100.0 |
ug.mL-1 |
Minimum inhibitory concentration against Coxsackie virus B4 in Vero cell cultures |
CHEMBL1124622 |
| Semliki forest virus |
MIC |
= |
300.0 |
ug.mL-1 |
Minimum inhibitory concentration against forest virus in Vero cell cultures |
CHEMBL1124622 |
| ADMET |
MCC |
> |
400.0 |
ug.mL-1 |
Concentration required for microscopically detectable alteration of the normal cell morphology in PRK cells. |
CHEMBL1123394 |
| HeLa |
MCC |
>= |
400.0 |
ug.mL-1 |
Concentration required for microscopically detectable alteration of the normal cell morphology in HeLa cells. |
CHEMBL1123394 |
| Vero |
MCC |
>= |
400.0 |
ug.mL-1 |
Concentration required for microscopically detectable alteration of the normal cell morphology in Vero B cells. |
CHEMBL1123394 |
| WI-38 |
MCC |
> |
400.0 |
ug.mL-1 |
Concentration required for microscopically detectable alteration of the normal cell morphology in Wi-38 cells. |
CHEMBL1123394 |
| ADMET |
MCC |
> |
400.0 |
ug.mL-1 |
Antiviral activity was measured against Herpes simplex virus (HSV-1 KOS) in rabbit kidney cells. |
CHEMBL1123394 |
| ADMET |
MCC |
> |
400.0 |
ug.mL-1 |
Antiviral activity was measured against Herpes simplex virus (HSV-2 G) in rabbit kidney cells. |
CHEMBL1123394 |
| ADMET |
MCC |
= |
7.0 |
ug.mL-1 |
Antiviral activity was measured against Vaccinia virus in rabbit kidney cells. |
CHEMBL1123394 |
| ADMET |
MCC |
= |
100.0 |
ug.mL-1 |
Antiviral activity was measured against Vesicular stomatitis virus in rabbit kidney cells. |
CHEMBL1123394 |
| HeLa |
MCC |
= |
20.0 |
ug.mL-1 |
Antiviral activity was measured against Vesicular stomatitis virus in HeLa cells. |
CHEMBL1123394 |
| HeLa |
MCC |
= |
70.0 |
ug.mL-1 |
Antiviral activity was measured against Polio virus-1 in HeLa cells. |
CHEMBL1123394 |
| HeLa |
MCC |
= |
70.0 |
ug.mL-1 |
Antiviral activity was measured against Coxsackie virus B4 in HeLa cells. |
CHEMBL1123394 |
| Vero |
MCC |
= |
70.0 |
ug.mL-1 |
Antiviral activity was measured against Coxsackie virus B4 in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| Vero |
MCC |
= |
20.0 |
ug.mL-1 |
Antiviral activity was measured against Parainfluenza virus-3 in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| Vero |
MCC |
= |
7.0 |
ug.mL-1 |
Antiviral activity was measured against Reo virus-1 in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| Vero |
MCC |
= |
70.0 |
ug.mL-1 |
Antiviral activity was measured against Sindbis virus in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| Vero |
MCC |
= |
70.0 |
ug.mL-1 |
Antiviral activity was measured against forest virus in african green monkey kidney (Vero B) cells. |
CHEMBL1123394 |
| WI-38 |
MCC |
= |
150.0 |
ug.mL-1 |
Antiviral activity was measured against Rhino virus-1A in human diploid (WI-38) cells. |
CHEMBL1123394 |
| WI-38 |
MCC |
= |
70.0 |
ug.mL-1 |
Antiviral activity was measured against Rhino virus-9 in human diploid (WI-38) cells. |
CHEMBL1123394 |
| MDCK |
IC50 |
= |
4900.0 |
nM |
Inhibitory concentration against influenza virus A in MDCK cells |
CHEMBL1128542 |
| MDCK |
IC50 |
= |
16300.0 |
nM |
Inhibitory concentration against influenza virus B in MDCK cells |
CHEMBL1128542 |
| HeLa |
IC50 |
= |
11400.0 |
nM |
Inhibitory concentration against respiratory syncytial virus in HeLa cells |
CHEMBL1128542 |
| Vero |
IC50 |
= |
286800.0 |
nM |
Inhibitory concentration against parainfluenza-3 virus in vero cells |
CHEMBL1128542 |
| MDCK |
MTC |
> |
819.6 |
uM |
Minimum toxic concentration required to cause a microscopically detectable alteration of normal MDCK cell morphology |
CHEMBL1128542 |
| HeLa |
MTC |
> |
819.6 |
uM |
Minimum toxic concentration required to cause a microscopically detectable alteration of normal HeLa cell morphology |
CHEMBL1128542 |
| Vero |
MTC |
> |
1639.2 |
uM |
Minimum toxic concentration required to cause a microscopically detectable alteration of normal vero cell morphology |
CHEMBL1128542 |
| Vero |
MTC |
> |
0.005 |
M |
Maximum tolerated concentration against Vero cells. |
CHEMBL1123400 |
| Human parainfluenza virus 3 |
ED50 |
= |
0.00016 |
M |
In vitro antiviral activity against parainfluenza type 3 virus in Vero cells. |
CHEMBL1123400 |
| Measles virus |
ED50 |
= |
9.9e-05 |
M |
In vitro antiviral activity against measles virus in Vero cells |
CHEMBL1123400 |
| Vaccinia virus |
ED50 |
= |
9e-05 |
M |
In vitro antiviral activity against vaccinia virus in Vero cells. |
CHEMBL1123400 |
| Human herpesvirus 2 |
ED50 |
= |
0.00019 |
M |
In vitro antiviral activity against herpes simplex virus type 2 (HSV-2) in Vero cells. |
CHEMBL1123400 |
| Human herpesvirus 1 |
CPE50 |
= |
75.0 |
ug ml-1 |
Compound was tested for antiviral activity in HeLa Cell cultures, against herpes simplex virus type 1 (HSV-1), cytopathic effect induced by the virus (CPE) |
CHEMBL1123091 |
| Human herpesvirus 1 |
Tox50 |
= |
400.0 |
ug ml-1 |
Compound was tested for antiviral activity in HeLa Cell cultures, against herpes simplex virus type 1 (HSV-1) |
CHEMBL1123091 |
| Vesicular stomatitis virus |
CPE50 |
= |
15.0 |
ug ml-1 |
Compound was tested for antiviral activity in HeLa Cell cultures, against vesicular stomatitis virus (VSV), cytopathic effect induced by the virus (CPE) |
CHEMBL1123091 |
| Vesicular stomatitis virus |
Tox50 |
= |
400.0 |
ug ml-1 |
Compound was tested for antiviral activity in HeLa Cell cultures, against vesicular stomatitis virus (VSV) |
CHEMBL1123091 |
| Vero |
Virus rating |
= |
0.6 |
|
In vitro antiviral activity against herpes simplex type 1 (HSV-1) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(>1000 ug/mL) |
CHEMBL1122187 |
| Vero |
Virus rating |
= |
1.2 |
|
In vitro antiviral activity against vaccinia(VV) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(>1000 ug/mL) |
CHEMBL1122187 |
| Vero |
Virus rating |
= |
1.3 |
|
In vitro antiviral activity against parainfluenza type 3(para 3) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(>1000 ug/mL) |
CHEMBL1122187 |
| HEp-2 |
Virus rating |
= |
1.2 |
|
In vitro antiviral activity against herpes simplex type 1 (HSV-1) virus was determined in human laryngeal epithelioma (HEp-2,H)expressed as virus rating. Toxic level(>1000 ug/mL) |
CHEMBL1122187 |
| HEp-2 |
Virus rating |
= |
1.7 |
|
In vitro antiviral activity against vaccinia(VV) virus was determined in human laryngeal epithelioma (HEp-2,H)expressed as virus rating. Toxic level(>1000 ug/mL) |
CHEMBL1122187 |
| HEp-2 |
Virus rating |
= |
1.7 |
|
In vitro antiviral activity against parainfluenza type 3 (para 3) type 1 (HSV-1) virus was determined in human laryngeal epithelioma (HEp-2,H)expressed as virus rating. Toxic level(>1000 ug/mL) |
CHEMBL1122187 |
| Vero |
Plaque reduction |
= |
31.0 |
% |
Percentage plaque reduction was determined against rift valley fever(RVF) virus in african green monkey kidney (vero,V) at a conc of 100-250 ug/mL. Toxic level(>1000 ug/mL); 31-60 |
CHEMBL1122187 |
| Vero |
Plaque reduction |
= |
10.0 |
% |
Percentage plaque reduction was determined against venezuelan equine encephalitis (VEE) virus in african green monkey kidney (vero,V) at a conc of 250-500 ug/mL. Toxic level(>1000 ug/mL); 10-30 |
CHEMBL1122187 |
| Vero |
Plaque reduction |
= |
61.0 |
% |
Percentage plaque reduction was determined against pichinde(PICH) virus in african green monkey kidney (vero,V). Toxic level(>1000 ug/mL); 61-90 |
CHEMBL1122187 |
| Vero |
Plaque reduction |
= |
61.0 |
% |
Percentage plaque reduction was determined against yellow fever(YF) virus in african green monkey kidney (vero,V).Toxic level(>1000 ug/mL); 61-90 |
CHEMBL1122187 |
| Vero |
Plaque reduction |
= |
61.0 |
% |
Percentage plaque reduction was determined against Sandfly fever (SF) virus in african green monkey kidney (vero,V) at a conc of 25-100 ug/mL. Toxic level(>1000 ug/mL); 61-90 |
CHEMBL1122187 |
| Unchecked |
Activity |
= |
155.0 |
% |
Percent purine synthesized in human B lymphoblast WI-L2 cells was determined |
CHEMBL1124027 |
| Unchecked |
Activity |
= |
74.0 |
% |
Percent purine accumulated in human B lymphoblast WI-L2 cells cultured medium was determined |
CHEMBL1124027 |
| Unchecked |
Ratio |
= |
3.0 |
|
Adenylate to guanylate ratio for the cell fraction was determined |
CHEMBL1124027 |
| Purine nucleoside phosphorylase |
Ki |
|
|
nM |
Inhibitory activity against purine nucleoside phosphorylase (PNPase); E means not determined |
CHEMBL1124027 |
| MDCK |
MIC50 |
= |
1.2 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on MDCK cell line infected with influenza A virus |
CHEMBL1127450 |
| MDCK |
MIC50 |
= |
4.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on MDCK cell line infected with influenza B virus |
CHEMBL1127450 |
| Vero |
MIC50 |
= |
70.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with parainfluenza 3 virus |
CHEMBL1127450 |
| HeLa |
MIC50 |
= |
2.8 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HeLa cell line infected with RSV virus |
CHEMBL1127450 |
| HEF |
MIC50 |
= |
200.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with HSV-1 virus |
CHEMBL1127450 |
| HEF |
MIC50 |
>= |
200.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with thymidine kinase-deficient herpes simplex virus type 1 (TK-HSV-1) |
CHEMBL1127450 |
| HEF |
MIC50 |
> |
400.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with HSV-2 virus |
CHEMBL1127450 |
| HEF |
MIC50 |
= |
70.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with vaccinia virus |
CHEMBL1127450 |
| HEF |
MIC50 |
= |
20.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with vesicular stomatitis virus |
CHEMBL1127450 |
| HeLa |
MIC50 |
= |
70.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HeLa cell line infected with polio 1 virus |
CHEMBL1127450 |
| Vero |
MIC50 |
= |
300.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with coxsackie B4 virus |
CHEMBL1127450 |
| Vero |
MIC50 |
= |
70.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with sindbis virus |
CHEMBL1127450 |
| Vero |
MIC50 |
= |
20.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with semliki forest virus |
CHEMBL1127450 |
| Vero |
MIC50 |
= |
20.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with Reo 1 virus |
CHEMBL1127450 |
| MDCK |
MIC50 |
> |
200.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on MDCK cell line |
CHEMBL1127450 |
| Vero |
MIC50 |
> |
400.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on vero cell line |
CHEMBL1127450 |
| HeLa |
MIC50 |
> |
200.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on HeLa cell line |
CHEMBL1127450 |
| HEF |
MIC50 |
> |
400.0 |
ug.mL-1 |
Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on HEF cell line |
CHEMBL1127450 |
| ADMET |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration in primary rabbit kidney (PRK) cell cultures |
CHEMBL1124666 |
| Human herpesvirus 1 |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration against Herpes simplex virus 1(KOS) |
CHEMBL1124666 |
| Human herpesvirus 2 |
MIC |
= |
300.0 |
ug.mL-1 |
Minimum inhibitory concentration against Herpes simplex virus 2(G) |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration against Vaccinia virus |
CHEMBL1124666 |
| Vesicular stomatitis virus |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration against Vesicular stomatitis virus |
CHEMBL1124666 |
| Vaccinia virus |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration against vaccinia virus in primary rabbit kidney cell cultures |
CHEMBL1124666 |
| Vaccinia virus |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration against vaccinia virus in HeLa cell cultures |
CHEMBL1124666 |
| Vaccinia virus |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration against vaccinia virus in Vero cell cultures |
CHEMBL1124666 |
| Vaccinia virus |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration against vaccinia virus embryonic skin muscle cell cultures |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 1 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
7.0 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 2 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 2 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
7.0 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in Vero cell cultures of experiment 1 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus in Vero cell cultures of experiment 2 |
CHEMBL1124666 |
| Vaccinia virus |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration against vaccinia virus embryonic skin muscle cell cultures |
CHEMBL1124666 |
| Human parainfluenza virus 3 |
VR |
= |
2.5 |
|
Viral rating activity against Parainfluenza type 3 viral strain Huebner C243 in H.Ep-2 cell line |
CHEMBL1124512 |
| Human parainfluenza virus 3 |
ID50 |
= |
17.5 |
ug ml-1 |
Inhibitory dose against Parainfluenza type 3 viral strain Huebner C243 in H.Ep-2 cell line |
CHEMBL1124512 |
| NON-PROTEIN TARGET |
Selectivity index |
= |
5.7 |
|
Ratio of minimum toxic compound concentration to inhibitory dose against Parainfluenza type 3 viral strain Huebner C243 in H.Ep-2 cell line |
CHEMBL1124512 |
| Human parainfluenza virus 3 |
Rating |
= |
1.3 |
|
Virus rating against parainfluenza virus type 3 |
CHEMBL1124438 |
| Human rhinovirus 1A |
Rating |
= |
0.7 |
|
Virus rating against rhinovirus type 1A |
CHEMBL1124438 |
| Human herpesvirus 2 |
Rating |
= |
1.4 |
|
Virus rating of against herpes simplex virus type 2 |
CHEMBL1124438 |
| Human adenovirus type 2 |
Rating |
= |
0.3 |
|
Virus rating against adenovirus type 2 |
CHEMBL1124438 |
| Human coxsackievirus B3 |
EC50 |
= |
92.45 |
ug.mL-1 |
Tested for its anti-polio activity against Coxsackie B virus type-3 |
CHEMBL1135116 |
| Vesicular stomatitis virus |
EC50 |
= |
15.62 |
ug.mL-1 |
Tested for its anti-polio activity against Vesicular stomatitis virus |
CHEMBL1135116 |
| Human coxsackievirus B3 |
Selectivity index |
= |
5.58 |
|
Selectivity index as the ratio of CC50/EC50 against Coxsackie B virus type-3 |
CHEMBL1135116 |
| Vesicular stomatitis virus |
Selectivity index |
= |
27.26 |
|
Selectivity index as the ratio of CC50/EC50 against Vesicular stomatitis virus |
CHEMBL1135116 |
| ADMET |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with PRK cells |
CHEMBL1123770 |
| HeLa |
MCC |
> |
200.0 |
ug.mL-1 |
Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with HeLa cells |
CHEMBL1123770 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with Vero B cells |
CHEMBL1123770 |
| WI-38 |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with WI-38 cells |
CHEMBL1123770 |
| Oryctolagus cuniculus |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against KOS strain of Herpes simplex virus-1 in primary rabbit kidney cells |
CHEMBL1123770 |
| Oryctolagus cuniculus |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against G strain of Herpes simplex virus-2 in primary rabbit kidney cells |
CHEMBL1123770 |
| Oryctolagus cuniculus |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vaccinia virus in primary rabbit kidney cells |
CHEMBL1123770 |
| Oryctolagus cuniculus |
MIC |
= |
150.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vesicular stomatitis virus in primary rabbit kidney cells |
CHEMBL1123770 |
| HeLa |
MIC |
= |
20.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vesicular stomatitis virus in HeLa cells |
CHEMBL1123770 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Polio virus-1 in HeLa cells |
CHEMBL1123770 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Coxsackie virus B4 in HeLa cells |
CHEMBL1123770 |
| Vero |
MIC |
= |
10.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Coxsackie virus B4 in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Parainfluenza virus-3 in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Reo virus-1 in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Sindbis virus in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| Vero |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against forest virus in African green monkey kidney (Vero B)cells |
CHEMBL1123770 |
| WI-38 |
MIC |
= |
150.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Rhinovirus-1A in human diploid (WI-38)cells |
CHEMBL1123770 |
| WI-38 |
MIC |
> |
400.0 |
ug.mL-1 |
Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Rhinovirus 9 in human diploid (WI-38)cells |
CHEMBL1123770 |
| Influenza A virus |
Activity |
= |
29.2 |
mM |
Antiviral activity against influenza virus A strain H7N7 (FPV) was determined as zone of plaque inhibition |
CHEMBL1128032 |
| Influenza A virus |
Activity |
= |
9.5 |
mM |
Antiviral activity against influenza virus A strain H7N7 (FPV) was determined as zone of cytotoxicity |
CHEMBL1128032 |
| Influenza A virus |
Activity |
= |
12.0 |
mM |
Antiviral effect against influenza virus A strain H7N7 (FPV) by the difference between zone of plaque inhibition and zone of cytotoxicity; (11-12 mm) |
CHEMBL1128032 |
| Newcastle disease virus |
Activity |
= |
52.0 |
mM |
Antiviral activity against newcastle disease virus strain Russeff (NDV) was determined as zone of plaque inhibition |
CHEMBL1128032 |
| Newcastle disease virus |
Activity |
= |
15.0 |
mM |
Antiviral activity against newcastle disease virus strain Russeff (NDV) was determined as zone of cytotoxicity |
CHEMBL1128032 |
| Newcastle disease virus |
Activity |
= |
40.0 |
mM |
Antiviral effect against newcastle disease virus strain Russeff (NDV) by the difference between zone of plaque inhibition and zone of cytotoxicity; (21-40 mm) |
CHEMBL1128032 |
| Suid herpesvirus 1 |
Activity |
= |
47.0 |
mM |
Antiviral activity against pseudorabies virus strain Anjeszky A2 was determined as zone of plaque inhibition |
CHEMBL1128032 |
| Suid herpesvirus 1 |
Activity |
= |
16.0 |
mM |
Antiviral activity against pseudorabies virus strain Anjeszky A2 was determined as zone of cytotoxicity |
CHEMBL1128032 |
| Suid herpesvirus 1 |
Activity |
= |
40.0 |
mM |
Antiviral effect against pseudorabies virus strain Anjeszky A2 by the difference between zone of plaque inhibition and zone of cytotoxicity; (21-40 mm) |
CHEMBL1128032 |
| ESM |
IC50 |
>= |
350.0 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus HSV-1(KOS) in ESM cell line |
CHEMBL1127059 |
| ESM |
IC50 |
> |
300.0 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus HSV-2 (G) in ESM cell line |
CHEMBL1127059 |
| ESM |
IC50 |
> |
135.0 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus TK-HSV-1 (B2006) in ESM cell line |
CHEMBL1127059 |
| ESM |
IC50 |
= |
110.0 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus TK-HSV-1(VMW 1837) in ESM cell line |
CHEMBL1127059 |
| ESM |
IC50 |
= |
45.0 |
ug.mL-1 |
Tested for inhibitory effect on DNA virus VV in ESM cell line |
CHEMBL1127059 |
| MDCK |
IC50 |
= |
4.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus Influenza A in MDCK cell line |
CHEMBL1127059 |
| MDCK |
IC50 |
= |
4.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus Influenza B in MDCK cell line |
CHEMBL1127059 |
| HeLa |
IC50 |
= |
4.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus RSV in HeLa cell line |
CHEMBL1127059 |
| Vero |
IC50 |
= |
20.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus PV-3 in Vero cell line |
CHEMBL1127059 |
| Vero |
IC50 |
>= |
250.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus SV in Vero cell line |
CHEMBL1127059 |
| Vero |
IC50 |
>= |
235.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus SFV in Vero cell line |
CHEMBL1127059 |
| Vero |
IC50 |
= |
20.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus Coxsackie B4 in Vero cell line |
CHEMBL1127059 |
| HeLa |
IC50 |
= |
70.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus Polio-1 in HeLa cell line |
CHEMBL1127059 |
| HeLa |
IC50 |
= |
14.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus VSV in HeLa cell line |
CHEMBL1127059 |
| Vero |
IC50 |
= |
160.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus Reo-1 in Vero cell line |
CHEMBL1127059 |
| Vero |
IC50 |
= |
5.2 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus JV in Vero cell line |
CHEMBL1127059 |
| Vero |
IC50 |
= |
6.4 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus TV in Vero cell line |
CHEMBL1127059 |
| MT4 |
IC50 |
> |
5.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus HIV-1 in MT-4 cell line |
CHEMBL1127059 |
| MT4 |
IC50 |
> |
5.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus HIV-2 in MT-4 cell line |
CHEMBL1127059 |
| ESM |
IC50 |
>= |
400.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell morphology in ESM cell line |
CHEMBL1127059 |
| HeLa |
IC50 |
>= |
400.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell morphology in HeLa cell line |
CHEMBL1127059 |
| MDCK |
IC50 |
> |
200.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell morphology in MDCK cell line |
CHEMBL1127059 |
| Vero |
IC50 |
> |
400.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell morphology in Vero cell line |
CHEMBL1127059 |
| MT4 |
IC50 |
= |
6.5 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line |
CHEMBL1127059 |
| L1210 |
IC50 |
= |
7.1 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell growth in L1210 cell line |
CHEMBL1127059 |
| FM3A |
IC50 |
= |
3.9 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell growth in FM3A cell line |
CHEMBL1127059 |
| CCRF-CEM |
IC50 |
= |
19.0 |
ug.mL-1 |
Tested for inhibitory effect on RNA virus cell growth in CEM cell line |
CHEMBL1127059 |
| L1210 |
IC50 |
= |
16600.0 |
nM |
Compound was tested for its effect on the proliferation of L1210 murine leukemia cell line. |
CHEMBL1151497 |
| Raji |
IC50 |
= |
56000.0 |
nM |
Compound was tested for its effect on the proliferation of RAJI burkitt lymphoma cell line. |
CHEMBL1151497 |
| CCRF-SB |
IC50 |
> |
100000.0 |
nM |
Compound was tested for its effect on the proliferation of CCRF-SB human lymphoblastic B-leukemia cell line. |
CHEMBL1151497 |
| WIL2-NS |
IC50 |
> |
100000.0 |
nM |
Compound was tested for its effect on the proliferation of WIL-2-NS cell line. |
CHEMBL1151497 |
| CCRF-CEM |
IC50 |
= |
19000.0 |
nM |
Compound was tested for its effect on the proliferation of CCRF-CEM human lymphoblastic T-leukemia cell line |
CHEMBL1151497 |
| MOLT-4 |
IC50 |
= |
5700.0 |
nM |
Compound was tested for its effect on the proliferation of MOLT-4 human lymphoblastic T-leukemia cell line. |
CHEMBL1151497 |
| MT4 |
IC50 |
= |
23000.0 |
nM |
Compound was tested for its effect on the proliferation of MT-4 cells expressing the TAT gene of HTLV-1. |
CHEMBL1151497 |
| C8166 |
IC50 |
> |
100000.0 |
nM |
Compound was tested for its effect on the proliferation of C8166 cells expressing the TAT gene of HTLV-1. |
CHEMBL1151497 |
| HT-29 |
IC50 |
|
|
nM |
Compound was tested for its effect on the proliferation of HT-29 human colon adenocarcinoma; Not determined |
CHEMBL1151497 |
| ACHN |
IC50 |
> |
100000.0 |
nM |
Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma |
CHEMBL1151497 |
| CHO-K1 |
IC50 |
= |
50000.0 |
nM |
Compound was tested for its effect on the proliferation of CHO-K1 hamster ovarian cancer cell line. |
CHEMBL1151497 |
| HEL 299 |
IC50 |
= |
45000.0 |
nM |
Compound was tested for its effect on the proliferation of HELL-299 human diploid embryonal lung cell line. |
CHEMBL1151497 |
| Vero |
MTC |
> |
5.0 |
M |
Maximum tolerated concentration (MTC) was evaluated in vero cells. |
CHEMBL1123027 |
| Human herpesvirus 2 |
ED50 |
= |
1.9 |
M |
In vitro antiviral activity was tested against herpes simplex type 2 (HSV-2) |
CHEMBL1123027 |
| Vaccinia virus |
ED50 |
= |
9.0 |
M |
In vitro antiviral activity was tested against vaccinia virus(VV) |
CHEMBL1123027 |
| Human parainfluenza virus 3 |
ED50 |
= |
1.6 |
M |
In vitro antiviral activity was tested against parainfluenza type 3 (para3) |
CHEMBL1123027 |
| Rift Valley fever virus |
ED50 |
= |
1.1 |
M |
In vitro antiviral activity was tested against rift valley fever virus(RVF) |
CHEMBL1123027 |
| Venezuelan equine encephalitis virus |
ED50 |
= |
2.5 |
M |
In vitro antiviral activity was tested against venezuelan equine encephalomyelitis (VEE) |
CHEMBL1123027 |
| Mus musculus |
MTC |
> |
100.0 |
mg kg-1 |
The maximum tolerated dose was evaluated in mice (mg/kg of body weight). |
CHEMBL1123027 |
| ADMET |
Therapeutic index |
= |
4.0 |
|
Therapeutic index against Rift valley fever virus. |
CHEMBL1123027 |
| ADMET |
Therapeutic index |
= |
1.5 |
|
Therapeutic index against Venezuelan equine encephalomyelitis virus. |
CHEMBL1123027 |
| Mus musculus |
EC50 |
= |
8300.0 |
nM |
Concentration that reduces Friend murine leukemia virus titer by 50% |
CHEMBL1125745 |
| Unchecked |
SI |
= |
6.3 |
|
Selectivity index is the ratio of IC50 to EC50 of F-MuLV. |
CHEMBL1125745 |
| Mus musculus |
EC50 |
= |
32100.0 |
nM |
Concentration that reduces Rauscher murine leukemia virus titer by 50% |
CHEMBL1125745 |
| Unchecked |
SI |
= |
1.6 |
|
Selectivity index which is the ratio of IC50 to EC50 of R-MuLV. |
CHEMBL1125745 |
| Mus musculus |
IC50 |
= |
52000.0 |
nM |
Cytotoxicity was evaluated |
CHEMBL1125745 |
| Human herpesvirus 1 |
MIC |
> |
400.0 |
ug.mL-1 |
Compound was tested for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cells |
CHEMBL1122693 |
| Human herpesvirus 2 |
MIC |
> |
400.0 |
ug.mL-1 |
Compound was tested for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cells |
CHEMBL1122693 |
| Vaccinia virus |
MIC |
= |
20.0 |
ug.mL-1 |
Compound was tested for antiviral activity against vaccinia virus in primary rabbit kidney cells |
CHEMBL1122693 |
| Vesicular stomatitis virus |
MIC |
= |
20.0 |
ug.mL-1 |
Compound was tested for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cells |
CHEMBL1122693 |
| Measles virus |
MIC |
= |
20.0 |
ug.mL-1 |
Compound was tested for antiviral activity against measles virus in vero cells |
CHEMBL1122693 |
| Mammalian orthoreovirus 1 |
MIC |
= |
100.0 |
ug.mL-1 |
Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells reovirus type 1 |
CHEMBL1122693 |
| Human parainfluenza virus 3 |
MIC |
= |
10.0 |
ug.mL-1 |
Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells parainfluenza virus type 3 |
CHEMBL1122693 |
| Sindbis virus |
MIC |
= |
40.0 |
ug.mL-1 |
Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells sindbis virus |
CHEMBL1122693 |
| Human coxsackievirus B4 |
MIC |
= |
200.0 |
ug.mL-1 |
Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells coxsackie virus type B4 |
CHEMBL1122693 |
| Vesicular stomatitis virus |
MIC |
= |
20.0 |
ug.mL-1 |
Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells vesicular stomatitis virus (VSV) |
CHEMBL1122693 |
| Human coxsackievirus B4 |
MIC |
= |
20.0 |
ug.mL-1 |
Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells coxsackie virus type 4 |
CHEMBL1122693 |
| Human poliovirus 1 |
MIC |
= |
10.0 |
ug.mL-1 |
Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells polio virus type 1 |
CHEMBL1122693 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxic concentration (to alter cell morphology) against vero cells |
CHEMBL1153258 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Parainfluenza-3 virus in vero cells |
CHEMBL1153258 |
| Vero |
MIC |
= |
100.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Reovirus-1 in vero cells |
CHEMBL1153258 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Sindbis virus in vero cells |
CHEMBL1153258 |
| Vero |
MIC |
= |
300.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Coxsackie virus in vero cells |
CHEMBL1153258 |
| Vero |
MIC |
= |
70.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against forest virus in vero cells |
CHEMBL1153258 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity (to alter cell morphology) against E6SM cell cultures |
CHEMBL1153258 |
| E6SM |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-1(KOS) in E6SM cell cultures |
CHEMBL1153258 |
| E6SM |
MIC |
= |
150.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-2 (G) in E6SM cell cultures |
CHEMBL1153258 |
| E6SM |
MIC |
= |
70.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Vaccinia virus in E6SM cell cultures |
CHEMBL1153258 |
| E6SM |
MIC |
= |
150.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Vesicular stomatitis virus in E6SM cell cultures |
CHEMBL1153258 |
| E6SM |
MIC |
= |
300.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-1 TK-B2006 in E6SM cell cultures |
CHEMBL1153258 |
| E6SM |
MIC |
= |
300.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Herpes simplex virus-1 TK-VMW1837 in E6SM cell cultures |
CHEMBL1153258 |
| HeLa |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity (to alter cell morphology) against HeLa cells |
CHEMBL1153258 |
| HeLa |
MIC |
= |
20.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Vesicular stomatitis virus in HeLa cells |
CHEMBL1153258 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Coxsackie virus B4 in HeLa cells |
CHEMBL1153258 |
| HeLa |
MIC |
= |
70.0 |
ug.mL-1 |
Antiviral activity (to reduce virus-induced cytopathogenicity) against Polio virus-I in HeLa cells |
CHEMBL1153258 |
| Vesicular stomatitis virus |
EC50 |
> |
10.0 |
ug.mL-1 |
Effective dose required for plaque reduction in vesicular stomatitis virus (VSV) was determined |
CHEMBL1128782 |
| Human herpesvirus 5 |
EC50 |
> |
10.0 |
ug.mL-1 |
Effective dose required for plaque reduction in human cytomegalovirus (HCMV) was determined |
CHEMBL1128782 |
| Influenza A virus |
EC50 |
= |
19.6 |
ug.mL-1 |
Effective dose required to reduce virus induced cytopathogenicity by Influenza A(H1N1,Fu 88) was determined |
CHEMBL1128782 |
| Influenza B virus |
EC50 |
= |
36.9 |
ug.mL-1 |
Effective dose required to reduce virus induced cytopathogenicity by Influenza B(Fu 207) was determined |
CHEMBL1128782 |
| Influenza B virus |
EC50 |
= |
6.7 |
ug.mL-1 |
Effective dose required to reduce virus induced cytopathogenicity by Influenza B(singapore) was determined |
CHEMBL1128782 |
| ADMET |
Toxic level |
|
|
|
Toxic level was evaluated; None |
CHEMBL1122625 |
| Human herpesvirus 1 |
Virus rating |
= |
0.6 |
|
In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and HSV-1 virus control cells |
CHEMBL1122625 |
| Vaccinia virus |
Virus rating |
= |
1.2 |
|
In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and Vaccinia virus control cells |
CHEMBL1122625 |
| Human parainfluenza virus 3 |
Virus rating |
= |
1.3 |
|
In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and Parainfluenza type 3 virus control cells. |
CHEMBL1122625 |
| Vesicular stomatitis virus |
Virus rating |
= |
0.8 |
|
In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and Vesicular stomatitis virus control cells |
CHEMBL1122625 |
| HeLa |
MIC50 |
= |
16.0 |
ug.mL-1 |
Minimum inhibitory concentration against vesicular stomatitis virus was determined |
CHEMBL1144367 |
| HeLa |
MIC50 |
= |
48.0 |
ug.mL-1 |
Minimum inhibitory concentration against coxsackie virus B4 was determined |
CHEMBL1144367 |
| HeLa |
MIC50 |
= |
1.92 |
ug.mL-1 |
Minimum inhibitory concentration against respiratory syncytial virus was determined |
CHEMBL1144367 |
| HeLa |
MCC |
> |
400.0 |
ug.mL-1 |
Minimum cytotoxicity concentration to HeLa cell line was determined |
CHEMBL1144367 |
| Vero |
TC50 |
> |
1000.0 |
ug ml-1 |
Cytotoxic concentration required to inhibit Vero cell growth by 50% |
CHEMBL1142825 |
| Vero |
IC50 |
= |
447.8 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B3 growth by 50% in Vero cells |
CHEMBL1142825 |
| Vero |
SI |
> |
2.23 |
|
Selectivity index (TC50/IC50) against Coxsackie virus B3 in Vero cells |
CHEMBL1142825 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity in MDBK (Madin-darby bovine kidney) cells |
CHEMBL1138786 |
| ADMET |
CC50/EC50 |
< |
150.0 |
|
Ratio of cytotoxicity to anti BVDV activity of the compound |
CHEMBL1138786 |
| ADMET |
EC50 |
= |
1500.0 |
nM |
Anti BVDV activity in MDBK (Madin-darby bovine kidney) cells |
CHEMBL1138786 |
| ADMET |
EC50rel |
= |
1.0 |
uM |
Anti BVDV activity relative to ribavirin |
CHEMBL1138786 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity in MDBK (Madin-darby bovine kidney) cells |
CHEMBL1138786 |
| ADMET |
CC50/EC50 |
> |
67.0 |
|
Ratio of cytotoxicity to anti BVDV activity of the compound |
CHEMBL1138786 |
| ADMET |
EC50 |
= |
670.0 |
nM |
Anti BVDV activity in MDBK (Madin-darby bovine kidney) cells |
CHEMBL1138786 |
| ADMET |
EC50rel |
= |
1.0 |
uM |
Anti-bovine viral diarrhoea virus activity relative to ribavirin |
CHEMBL1138786 |
| ADMET |
CC50 |
= |
71000.0 |
nM |
Cytotoxic concentration against HCV replication in AVA5 cell culture |
CHEMBL1140348 |
| Hepatitis C virus |
EC50 |
> |
100000.0 |
nM |
Effective concentrations at which 2-fold depression of HCV RNA was observed in AVA5 cells (Huh 7 cells with subgenomic HCV replicon BB7) |
CHEMBL1140348 |
| Hepatitis C virus |
EC90 |
> |
100.0 |
uM |
Effective concentrations at which 10-fold depression of HCV RNA was observed in AVA5 cells (Huh 7 cells with subgenomic HCV replicon BB7I |
CHEMBL1140348 |
| Influenza A virus |
IC50 |
= |
3.73 |
ug.mL-1 |
Antiviral activity against influenza A H3N2 virus in MDCK cells |
CHEMBL1141874 |
| Influenza A virus |
CC50 |
> |
2000.0 |
ug.mL-1 |
Cytotoxicity in MDCK cells infected with influenza A H3N2 virus |
CHEMBL1141874 |
| Hepatitis C virus |
Activity |
= |
89.0 |
% |
Antiviral activity against HCV in Huh7 ETcell line at 10 uM assessed by measuring HCV-RNA-derived LUC activity relative to control |
CHEMBL1141861 |
| Huh-7 |
Activity |
= |
12.0 |
% |
Cytotoxicity against Huh7ET cell line containg HCV replicon at 10 uM assessed by measuring the beta-actin RNA level relative to control |
CHEMBL1141861 |
| Huh-7 |
Selectivity index |
= |
0.42 |
|
Selectivity index (toxicity/antiviral activity) |
CHEMBL1141861 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against HEL cells |
CHEMBL1147740 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against vero cells |
CHEMBL1147740 |
| HeLa |
MCC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against HeLa cells |
CHEMBL1147740 |
| Human herpesvirus 1 |
MIC50 |
= |
240.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 1 KOS strain in HEL cells |
CHEMBL1147740 |
| Human herpesvirus 2 |
MIC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 2 G strain in HEL cells |
CHEMBL1147740 |
| Vaccinia virus |
MIC50 |
= |
80.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in HEL cells |
CHEMBL1147740 |
| Vesicular stomatitis virus |
MIC50 |
= |
240.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus in HEL cells |
CHEMBL1147740 |
| Human herpesvirus 1 |
MIC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against herpes simplex virus 1 TK- KOS ACVr strain in HEL cells |
CHEMBL1147740 |
| Human parainfluenza virus 3 |
MIC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against Parainfluenza-3 virus in vero cells |
CHEMBL1147740 |
| Mammalian orthoreovirus 1 |
MIC50 |
= |
16.0 |
ug.mL-1 |
Antiviral activity against Reovirus 1 in vero cells |
CHEMBL1147740 |
| Sindbis virus |
MIC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus in vero cells |
CHEMBL1147740 |
| Human coxsackievirus B4 |
MIC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 in vero cells |
CHEMBL1147740 |
| Punta Toro virus |
MIC50 |
= |
80.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus in vero cells |
CHEMBL1147740 |
| Respiratory syncytial virus |
MIC50 |
= |
9.6 |
ug.mL-1 |
Antiviral activity against Respiratory syncytial virus in HeLa cells |
CHEMBL1147740 |
| Human coxsackievirus B4 |
MIC50 |
= |
9.6 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 in HeLa cells |
CHEMBL1147740 |
| Vesicular stomatitis virus |
MIC50 |
= |
16.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus in HeLa cells |
CHEMBL1147740 |
| Cotton rat |
Efficacy |
= |
2.5 |
|
Efficacy in cotton rat measured as reduction in log TCID50 of RSV per gram of lung at 90 mg/kg, ip |
CHEMBL1138147 |
| Mus musculus |
Efficacy |
= |
1.86 |
|
Efficacy in BALB/c mouse measured as reduction in log TCID50 of RSV per gram of lung at 90 mg/kg, sc |
CHEMBL1138147 |
| West Nile virus |
EC50 |
= |
18000.0 |
nM |
Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line |
CHEMBL1138199 |
| West Nile virus |
EC50 |
= |
30000.0 |
nM |
Inhibition of Rluc-FL-WNV replicon in Vero cells |
CHEMBL1138199 |
| BHK-21 |
EC50 |
= |
1100.0 |
nM |
Inhibition of West Nile virus VLP replicon in BHK21 cell line |
CHEMBL1138199 |
| Vero |
EC50 |
= |
119000.0 |
nM |
Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells |
CHEMBL1138199 |
| Tobacco mosaic virus |
Activity |
= |
49.0 |
% |
Antiviral activity against TMV |
CHEMBL1147696 |
| HeLa |
Activity |
= |
70.0 |
% |
Viability of human HeLa S3 cells |
CHEMBL1137395 |
| Poliovirus |
Activity |
|
|
|
Antiviral activity against poliovirus in HeLa S3 cells assessed as reduction in viral titer |
CHEMBL1137395 |
| Human coxsackievirus B3 |
Activity |
|
|
|
Antiviral activity against coxsackievirus B3 in HeLa S3 cells assessed as reduction in viral titer |
CHEMBL1137395 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
300000.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells |
CHEMBL1138863 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
500000.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells |
CHEMBL1138863 |
| Human herpesvirus 2 |
EC50 |
> |
500000.0 |
nM |
Antiviral activity against HSV2 in HEL cells |
CHEMBL1138863 |
| Vaccinia virus |
EC50 |
= |
100000.0 |
nM |
Antiviral activity against vaccinia virus in HEL cells |
CHEMBL1138863 |
| Vesicular stomatitis virus |
EC50 |
> |
500000.0 |
nM |
Antiviral activity against vesicular somatitis virus in HEL cells |
CHEMBL1138863 |
| HEL |
CC50 |
> |
500000.0 |
nM |
Cytotoxicity against HEL cells |
CHEMBL1138863 |
| Human coxsackievirus B4 |
EC50 |
> |
500000.0 |
nM |
Antiviral activity against Coxsackie B4 virus in HeLa cells |
CHEMBL1138863 |
| Respiratory syncytial virus |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against RSV in HeLa cells |
CHEMBL1138863 |
| HeLa |
CC50 |
> |
500000.0 |
nM |
Cytotoxicity against HeLa cells |
CHEMBL1138863 |
| Sindbis virus |
EC50 |
> |
500000.0 |
nM |
Antiviral activity against Sindbis virus in Vero cells |
CHEMBL1138863 |
| Human parainfluenza virus 3 |
EC50 |
= |
300000.0 |
nM |
Antiviral activity against para influenza 3 virus in Vero cells |
CHEMBL1138863 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
100000.0 |
nM |
Antiviral activity against reovirus 1 in Vero cells |
CHEMBL1138863 |
| Punta Toro virus |
EC50 |
= |
100000.0 |
nM |
Antiviral activity against Punta Toro virus in Vero cells |
CHEMBL1138863 |
| Vero |
CC50 |
> |
500000.0 |
nM |
Cytotoxicity against Vero cells |
CHEMBL1138863 |
| HeLa |
MIC |
> |
500000.0 |
nM |
Cytotoxicity against HeLa cells |
CHEMBL1141413 |
| Human coxsackievirus B4 |
MIC |
> |
500000.0 |
nM |
Antiviral activity against CV B4 |
CHEMBL1141413 |
| Vesicular stomatitis virus |
MIC |
= |
300000.0 |
nM |
Antiviral activity against VSV |
CHEMBL1141413 |
| Respiratory syncytial virus |
MIC |
= |
60000.0 |
nM |
Antiviral activity against RSV |
CHEMBL1141413 |
| Respiratory syncytial virus |
IC50 |
= |
180.0 |
ug.mL-1 |
Antiviral activity against RSV A2 in MA104 cells by CPE assay |
CHEMBL1142060 |
| Respiratory syncytial virus |
EC50 |
= |
3.6 |
ug.mL-1 |
Antiviral activity against RSV A2 in MA104 cells by CPE assay |
CHEMBL1142060 |
| Respiratory syncytial virus |
IC50 |
= |
460.0 |
ug.mL-1 |
Antiviral activity against RSV A2 in MA104 cells by plaque reduction assay |
CHEMBL1142060 |
| Respiratory syncytial virus |
EC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against RSV A2 in MA104 cells by plaque reduction assay |
CHEMBL1142060 |
| Vesicular stomatitis virus |
EC50 |
= |
240.0 |
ug.mL-1 |
Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Vesicular stomatitis virus |
EC50 |
= |
80.0 |
ug.mL-1 |
Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human coxsackievirus B4 |
EC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human coxsackievirus B4 |
EC50 |
= |
240.0 |
ug.mL-1 |
Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Respiratory syncytial virus |
EC50 |
= |
16.0 |
ug.mL-1 |
Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Human parainfluenza virus 3 |
EC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Sindbis virus |
EC50 |
= |
240.0 |
ug.mL-1 |
Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| Punta Toro virus |
EC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1142867 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against E6SM cells assessed as alteration in cell morphology |
CHEMBL1142867 |
| HeLa |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against HeLa cells assessed as alteration in cell morphology |
CHEMBL1142867 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against Vero cells assessed as alteration in cell morphology |
CHEMBL1142867 |
| Unchecked |
Inhibition |
= |
90.0 |
% |
Inhibition of viral RNA levels in HTNV 76-118-infected Vero E6 cells at 2 ug/ml after 3 days |
CHEMBL1142140 |
| Unchecked |
Inhibition |
= |
99.9 |
% |
Inhibition of viral RNA levels in HTNV 76-118-infected Vero E6 cells at 40 ug/ml after 3 days |
CHEMBL1142140 |
| Unchecked |
Inhibition |
= |
-80.0 |
% |
Inhibition of viral RNA levels in HTNV76-118-infected Vero E6 cells at 0.5 ug/ml |
CHEMBL1142140 |
| Vero |
Activity |
= |
40.0 |
% |
Decrease in GTP level in Vero E6 cells at 10 ug/ml |
CHEMBL1142140 |
| Vero |
Activity |
= |
1.1 |
pmol |
RBV metabolism in Vero E6 cells assessed as RBV-MP concentration at 10 ug/ml after 24 h |
CHEMBL1142140 |
| Vero |
Activity |
= |
6.5 |
pmol |
RBV metabolism in Vero E6 cells assessed as RBV-TP concentration at 10 ug/ml after 24 h |
CHEMBL1142140 |
| Vero |
Activity |
= |
3.2 |
pmol |
RBV metabolism in Vero E6 cells assessed as RBV-MP concentration at 40 ug/ml after 24 h |
CHEMBL1142140 |
| Vero |
Activity |
= |
22.0 |
pmol |
RBV metabolism in Vero E6 cells assessed as RBV-TP concentration at 40 ug/ml after 24 h |
CHEMBL1142140 |
| Vero |
Activity |
|
|
|
Decrease in GTP level in Vero E6 cells at 40 ug/ml after 4 h |
CHEMBL1142140 |
| Vero |
Activity |
= |
50.0 |
% |
Decrease in GTP level in Vero E6 cells at 40 ug/ml after 24 h |
CHEMBL1142140 |
| Influenza A virus |
EC50 |
= |
43000.0 |
nM |
Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay |
CHEMBL1142087 |
| Influenza A virus |
EC90 |
= |
20.1 |
uM |
Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay |
CHEMBL1142087 |
| Influenza A virus |
EC50 |
= |
38100.0 |
nM |
Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay |
CHEMBL1142087 |
| Influenza A virus |
EC90 |
= |
32.0 |
uM |
Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay |
CHEMBL1142087 |
| Influenza A virus |
EC50 |
= |
14300.0 |
nM |
Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay |
CHEMBL1142087 |
| Influenza A virus |
EC90 |
= |
33.2 |
uM |
Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay |
CHEMBL1142087 |
| Influenza A virus |
EC50 |
= |
35700.0 |
nM |
Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay |
CHEMBL1142087 |
| Influenza A virus |
EC90 |
= |
18.4 |
uM |
Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay |
CHEMBL1142087 |
| MDCK |
CC50 |
= |
2336000.0 |
nM |
Cytotoxicity against MDCK cells |
CHEMBL1142087 |
| HeLa |
CC50 |
> |
300.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells |
CHEMBL1144496 |
| Encephalomyocarditis virus |
EC50 |
= |
23.45 |
ug.mL-1 |
Antiviral activity against encephalomyocarditis virus by CPE assay |
CHEMBL1144496 |
| Human coxsackievirus B3 |
EC50 |
= |
64.09 |
ug.mL-1 |
Antiviral activity against coxsackie B virus type 3 by CPE assay |
CHEMBL1144496 |
| Vesicular stomatitis virus |
EC50 |
= |
10.32 |
ug.mL-1 |
Antiviral activity against vesicular stomatitis virus by CPE assay |
CHEMBL1144496 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
500000.0 |
nM |
Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Human herpesvirus 2 |
MIC |
= |
300000.0 |
nM |
Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Vaccinia virus |
MIC |
= |
100000.0 |
nM |
Antiviral activity against Vaccinia virus-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Vesicular stomatitis virus |
MIC |
> |
500000.0 |
nM |
Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
500000.0 |
nM |
Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells |
CHEMBL1144557 |
| E6SM |
MIC |
> |
500000.0 |
nM |
Cytotoxicity against E6SM cells |
CHEMBL1144557 |
| Sindbis virus |
MIC |
= |
100000.0 |
nM |
Antiviral activity against Sindbis virus-induced cytopathogenicity in Vero cells |
CHEMBL1144557 |
| Human coxsackievirus B4 |
MIC |
> |
500000.0 |
nM |
Antiviral activity against Coxsackie virus B4-induced cytopathogenicity in Vero cells |
CHEMBL1144557 |
| Punta Toro virus |
MIC |
= |
300000.0 |
nM |
Antiviral activity against Punta Toro virus-induced cytopathogenicity in Vero cells |
CHEMBL1144557 |
| Vesicular stomatitis virus |
MIC |
= |
100000.0 |
nM |
Antiviral activity against in Vesicular stomatitis virus- induced cytopathogenicity in HeLa cells |
CHEMBL1144557 |
| E6SM |
MCC |
= |
400.0 |
ug.mL-1 |
Cytotoxicity against E6SM cells assessed as alteration in cell morphology |
CHEMBL1143708 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
70.0 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 2 |
EC50 |
= |
150.0 |
ug.mL-1 |
Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Vaccinia virus |
EC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 1 |
EC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Human herpesvirus 1 |
EC50 |
= |
70.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1143708 |
| Vesicular stomatitis virus |
IC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against VSV in HeLa cells |
CHEMBL1143708 |
| Human coxsackievirus B4 |
IC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 in HeLa cells |
CHEMBL1143708 |
| Respiratory syncytial virus |
IC50 |
= |
2.0 |
ug.mL-1 |
Antiviral activity against Respiratory syncytial virus in HeLa cells |
CHEMBL1143708 |
| Mammalian orthoreovirus 1 |
IC50 |
= |
0.7 |
ug.mL-1 |
Antiviral activity against Reovirus1 in vero cells |
CHEMBL1143708 |
| Punta Toro virus |
IC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus in vero cells |
CHEMBL1143708 |
| SARS coronavirus |
IC50 |
= |
82000.0 |
nM |
Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay |
CHEMBL1144631 |
| Vero |
CC50 |
> |
850000.0 |
nM |
Cytotoxicity against Vero E6 cells |
CHEMBL1144631 |
| Unchecked |
Ratio CC50/IC50 |
> |
10.0 |
|
Selectivity index, ratio of CC50 for Vero E6 cells to IC50 for SARS-CoV Frankfurt1 |
CHEMBL1144631 |
| Human parainfluenza virus 3 |
EC50 |
= |
150000.0 |
nM |
Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days |
CHEMBL1145384 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
250000.0 |
nM |
Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days |
CHEMBL1145384 |
| Sindbis virus |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days |
CHEMBL1145384 |
| Punta Toro virus |
EC50 |
= |
150000.0 |
nM |
Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days |
CHEMBL1145384 |
| Human coxsackievirus B4 |
EC50 |
= |
150000.0 |
nM |
Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days |
CHEMBL1145384 |
| Vesicular stomatitis virus |
MIC |
> |
250000.0 |
nM |
Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Human parainfluenza virus 3 |
MIC |
= |
150000.0 |
nM |
Antiviral activity against Parainfluenza 3 virus in Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
250000.0 |
nM |
Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Human herpesvirus 2 |
MIC |
= |
250000.0 |
nM |
Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Vaccinia virus |
MIC |
= |
150000.0 |
nM |
Antiviral activity against Vaccinia virus in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Respiratory syncytial virus |
MIC |
= |
150000.0 |
nM |
Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Mammalian orthoreovirus 1 |
MIC |
= |
150000.0 |
nM |
Antiviral activity against Reovirus 1 in Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Sindbis virus |
MIC |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus in Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Human coxsackievirus B4 |
MIC |
> |
250000.0 |
nM |
Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Punta Toro virus |
MIC |
= |
250000.0 |
nM |
Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1148744 |
| Hepatitis C virus |
Activity |
= |
89.0 |
% |
Antiviral activity against HCV in Huh7 ET cells assessed as HCV RNA derived luciferase activity at 10 uM by replicon assay relative to control |
CHEMBL1147191 |
| ADMET |
Activity |
= |
12.0 |
% |
Cytotoxicity against Huh7 ET cells assessed as beta actin level relative to control |
CHEMBL1147191 |
| Unchecked |
Selectivity index |
= |
0.42 |
|
Selectivity index, ratio of toxicity against Huh7 ET cells to viral activity against HCV |
CHEMBL1147191 |
| Influenza A virus |
IC50 |
= |
5850.0 |
nM |
Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay |
CHEMBL1149649 |
| Influenza A virus |
IC50 |
= |
5040.0 |
nM |
Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay |
CHEMBL1149649 |
| Influenza A virus |
IC50 |
= |
176000.0 |
nM |
Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay |
CHEMBL1149649 |
| Influenza A virus |
IC50 |
= |
7010.0 |
nM |
Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay |
CHEMBL1149649 |
| Influenza B virus |
IC50 |
= |
96200.0 |
nM |
Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay |
CHEMBL1149649 |
| Influenza B virus |
IC50 |
= |
15200.0 |
nM |
Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay |
CHEMBL1149649 |
| Influenza B virus |
IC50 |
= |
164000.0 |
nM |
Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay |
CHEMBL1149649 |
| Influenza A virus |
Survival |
= |
100.0 |
% |
Antiviral activity against influenza A/Jingfang/Fm1 (H1N1) infected in mouse assessed as survival of mouse at 100 mg/kg, ip bid after 2 hrs of viral infection for 5 days |
CHEMBL1149649 |
| Mus musculus |
Activity |
|
|
|
Survival of mouse at 100 mg/kg, ip bid after 5 days |
CHEMBL1149649 |
| Mus musculus |
Activity |
= |
11.5 |
g |
Weight change in mouse at 100 mg/kg, ip bid after 14 days |
CHEMBL1149649 |
| Influenza A virus |
Activity |
= |
14.0 |
day |
Antiviral activity against influenza A/Jingfang/Fm1 (H1N1) infected in mouse assessed as mean survival time of mouse at 100 mg/kg, ip bid after 2 hrs of viral infection for 5 days |
CHEMBL1149649 |
| Hepatitis C virus |
EC50 |
= |
54800.0 |
nM |
Inhibition of HCV replication in Huh7 cells after 48 hrs by luciferase assay |
CHEMBL1137457 |
| ADMET |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against Huh7 cells by XTT assay |
CHEMBL1137457 |
| NON-PROTEIN TARGET |
Ratio CC50/EC50 |
> |
3.7 |
|
Antiviral index, ratio of CC50 for Huh7 cells to EC50 for HCV replication |
CHEMBL1137457 |
| Unchecked |
Activity |
|
|
|
Inactivation of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 at 100 uM |
CHEMBL1137494 |
| Adenosylhomocysteinase |
Activity |
|
|
|
Inactivation of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 at 100 uM |
CHEMBL1137494 |
| Adenosylhomocysteinase |
Fluorescence intensity |
= |
182369.0 |
|
Inactivation of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 assessed as increase in fluorescence at 200 uM |
CHEMBL1137494 |
| Unchecked |
Fluorescence intensity |
= |
226933.0 |
|
Inactivation of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 assessed as increase in fluorescence at 200 uM |
CHEMBL1137494 |
| Adenosylhomocysteinase |
Activity |
= |
2.2 |
10^10/M |
Inactivation of human recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109 assessed by measuring fluorescence |
CHEMBL1137494 |
| Unchecked |
Activity |
= |
3.13 |
10^10/M |
Inactivation of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109 assessed by measuring fluorescence |
CHEMBL1137494 |
| Adenosylhomocysteinase |
KR |
= |
407.0 |
uM |
Binding to human recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109 |
CHEMBL1137494 |
| Unchecked |
KR |
= |
586.0 |
uM |
Binding to Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109 |
CHEMBL1137494 |
| Adenosylhomocysteinase |
Kinact |
= |
266.0 |
uM |
Inhibition of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 |
CHEMBL1137494 |
| Adenosylhomocysteinase |
Kinact |
= |
1.5 |
10^-4/s |
Inhibition of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 |
CHEMBL1137494 |
| Adenosylhomocysteinase |
Ratio |
= |
0.56 |
/M/s |
Ratio of kinact for human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form to KI for human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ |
CHEMBL1137494 |
| Unchecked |
Kinact |
= |
194.0 |
uM |
Inhibition of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form expressed in Escherichia coli JM109 |
CHEMBL1137494 |
| Unchecked |
Kinact |
= |
7.6 |
10^-4/s |
Inhibition of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form expressed in Escherichia coli JM109 |
CHEMBL1137494 |
| Unchecked |
Ratio |
= |
3.92 |
/M/s |
Ratio of kinact for Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form to KI for Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form |
CHEMBL1137494 |
| Vesicular stomatitis virus |
EC50 |
= |
120.0 |
ug.mL-1 |
Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Vesicular stomatitis virus |
EC50 |
= |
24.0 |
ug.mL-1 |
Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human coxsackievirus B4 |
EC50 |
= |
90.0 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human coxsackievirus B4 |
EC50 |
> |
200.0 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Respiratory syncytial virus |
EC50 |
= |
24.0 |
ug.mL-1 |
Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1138246 |
| Human parainfluenza virus 3 |
EC50 |
= |
120.0 |
ug.mL-1 |
Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days |
CHEMBL1138246 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
200.0 |
ug.mL-1 |
Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days |
CHEMBL1138246 |
| Sindbis virus |
EC50 |
= |
120.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days |
CHEMBL1138246 |
| Punta Toro virus |
EC50 |
= |
40.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days |
CHEMBL1138246 |
| HeLa |
MCC |
> |
200.0 |
ug.mL-1 |
Cytotoxicity against HeLa cells assessed as alteration in morphology after 3 days |
CHEMBL1138246 |
| Vero |
MCC |
> |
200.0 |
ug.mL-1 |
Cytotoxicity against Vero cells assessed as alteration in morphology after 3 days |
CHEMBL1138246 |
| HEL |
MCC |
> |
200.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days |
CHEMBL1138246 |
| Adenosine kinase |
Activity |
= |
203.0 |
nmol/mg.hr |
Specific activity of human adenosine kinase |
CHEMBL1139898 |
| Influenza A virus |
EC50 |
= |
8680.0 |
nM |
Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay |
CHEMBL1140674 |
| MDCK |
MCC |
= |
20000.0 |
nM |
Cytotoxicity against MDCK cells assessed as changes in cell morphology |
CHEMBL1140674 |
| Unchecked |
Ratio |
= |
2.0 |
|
Selectivity index, ratio of EC50 for influenza A/Hong Kong/7/87 (H3N2) to MCC for MDCK cells |
CHEMBL1140674 |
| Tobacco mosaic virus |
IC50 |
= |
2989600.0 |
nM |
Antiviral activity against Tobacco mosaic virus U1 after 72 hrs by half leaf method |
CHEMBL1141279 |
| Homo sapiens |
F |
= |
64.0 |
% |
Oral bioavailability in human |
CHEMBL1141299 |
| Poliovirus |
Activity |
= |
40.0 |
% |
Antiviral activity against poliovirus infected HeLa S3 cells assessed as plaque formation at 0.5 mM relative to control |
CHEMBL1140696 |
| Poliovirus |
Activity |
= |
4.0 |
% |
Antiviral activity against poliovirus infected HeLa S3 cells assessed as plaque formation at 2 mM |
CHEMBL1140696 |
| Unchecked |
Kcat/Km |
= |
8.4 |
10^-6 microM/s |
Ratio of kcat/Km of Poliovirus RNA dependent RNA polymerase incorporation into sym/sub-C primer relative to control |
CHEMBL1140696 |
| MDCK |
CC50 |
> |
500000.0 |
ug.mL-1 |
Cytotoxicity against dog MDCK cells |
CHEMBL1143112 |
| Influenza A virus |
IC50 |
= |
2060.0 |
ug.mL-1 |
Antiviral activity against influenza A virus H3N2 (A3 China/15/90) expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect |
CHEMBL1143112 |
| Influenza B virus |
IC50 |
= |
4270.0 |
ug.mL-1 |
Antiviral activity against influenza B virus expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect |
CHEMBL1143112 |
| Yellow fever virus |
Activity |
= |
1.3 |
g |
Antiviral activity against YFV Jimenez infected in Syrian golden hamster assessed as weight change at 50 mg/kg, po bid for 7 days |
CHEMBL1145477 |
| Yellow fever virus |
Activity |
= |
120.0 |
IU/L |
Antiviral activity against YFV Jimenez infected in Syrian golden hamster assessed as serum alanine aminotransferase at 50 mg/kg, ip bid for 7 days |
CHEMBL1145477 |
| Yellow fever virus |
Activity |
= |
6.0 |
day |
Antiviral activity against YFV Jimenez infected in Syrian golden hamster assessed as mean day to death after 21 days post-infection at 50 mg/kg, ip bid for 7 days |
CHEMBL1145477 |
| Yellow fever virus |
Activity |
= |
6.0 |
day |
Antiviral activity against YFV Jimenez infected in Syrian golden hamster liver treated 4 hrs before viral challenge assessed as mean day to death at 50 mg/kg/day, ip bid for 8 days |
CHEMBL1145477 |
| Yellow fever virus |
Activity |
= |
120.0 |
IU/L |
Antiviral activity against YFV Jimenez infected in Syrian golden hamster liver treated 4 hrs before viral challenge assessed as alanine aminotransferase at 50 mg/kg/day, ip bid for 8 days |
CHEMBL1145477 |
| Yellow fever virus |
Activity |
= |
1.3 |
IU/L |
Antiviral activity against YFV Jimenez infected in Syrian golden hamster liver treated 4 hrs before viral challenge assessed as weight change at 50 mg/kg/day, ip bid for 8 days |
CHEMBL1145477 |
| Murine hepatitis virus |
Activity |
|
|
|
Antiviral activity against mouse coronavirus at 10 ug |
CHEMBL1151115 |
| Hepatitis C virus |
IC50 |
= |
58000.0 |
nM |
Antiviral activity against wild type HCV 1b Con1 in human Huh7 cells after 48 hrs by replicon cell assay |
CHEMBL1156474 |
| Hepatitis C virus |
IC50 |
= |
37000.0 |
nM |
Antiviral activity against HCV 1b Con1 with NS3-4A R155K mutation in human Huh7 cells after 48 hrs by replicon cell assay |
CHEMBL1156474 |
| Hepatitis C virus |
IC50 |
= |
32000.0 |
nM |
Antiviral activity against HCV 1b with NS3-4A R155T mutation in human Huh7 cells after 48 hrs by replicon cell assay |
CHEMBL1156474 |
| Hepatitis C virus |
IC50 |
= |
39000.0 |
nM |
Antiviral activity against HCV 1b with NS3-4A R155M mutation in human Huh7 cells after 48 hrs by replicon cell assay |
CHEMBL1156474 |
| Hepatitis C virus |
FC |
= |
0.6 |
|
Ratio of IC50 for HCV 1b with NS3-4 R155K mutation to IC50 for wild type HCV 1b |
CHEMBL1156474 |
| Hepatitis C virus |
FC |
= |
0.6 |
|
Ratio of IC50 for HCV 1b with NS3-4A R155T mutation to IC50 for wild type HCV 1b |
CHEMBL1156474 |
| Hepatitis C virus |
FC |
= |
0.7 |
|
Ratio of IC50 for HCV 1b with NS3-4A R155G mutation to IC50 for wild type HCV 1b |
CHEMBL1156474 |
| HeLa |
CC50 |
= |
300.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells after 2 days by MTT assay |
CHEMBL1150133 |
| Human coxsackievirus B3 |
EC50 |
= |
236.4 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B3 Nancy infected in human HeLa assessed as inhibition of virus-induced cytopathic effect after 2 days by MTT assay |
CHEMBL1150133 |
| Encephalomyocarditis virus |
EC50 |
= |
27.2 |
ug.mL-1 |
Antiviral activity against Encephalomyocarditis virus EMC infected in human HeLa assessed as inhibition of virus-induced cytopathic effect after 2 days by MTT assay |
CHEMBL1150133 |
| Vesicular stomatitis Indiana virus |
EC50 |
= |
13.7 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis Indiana virus infected in human HeLa assessed as inhibition of virus-induced cytopathic effect after 2 days by MTT assay |
CHEMBL1150133 |
| Human parainfluenza virus 3 |
IC50 |
= |
2.6 |
ug.mL-1 |
Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect |
CHEMBL1156352 |
| ADMET |
LC50 |
= |
62.5 |
ug.mL-1 |
Cytotoxicity against human Hep2 cells |
CHEMBL1156352 |
| ADMET |
TI |
= |
24.0 |
|
Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Parainfluenza virus type 3 |
CHEMBL1156352 |
| HeLa |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells |
CHEMBL1149790 |
| Vesicular stomatitis virus |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against vesicular stomatitis virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human coxsackievirus B4 |
MIC |
= |
240.0 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Spermidine synthase |
Activity |
|
|
|
Binding affinity to Plasmodium falciparum spermidine synthase by saturation transfer difference-NMR experiment |
CHEMBL1150259 |
| Respiratory syncytial virus |
MIC |
= |
9.6 |
ug.mL-1 |
Antiviral activity against respiratory syncytial virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL1149790 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against human E6SM cells |
CHEMBL1149790 |
| HEL |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against human HEL cells assessed as alteration of cell morphology |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
9.6 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
9.6 |
ug.mL-1 |
Antiviral activity against HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 2 |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against HSV2 G in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 2 |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against HSV2 G in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vaccinia virus |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vaccinia virus |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vesicular stomatitis virus |
MIC |
= |
240.0 |
ug.mL-1 |
Antiviral activity against in Vesicular stomatitis virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vesicular stomatitis virus |
MIC |
= |
240.0 |
ug.mL-1 |
Antiviral activity against in Vesicular stomatitis virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human herpesvirus 1 |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Vero |
Activity |
> |
400.0 |
ug ml-1 |
Cytotoxicity against african green monkey Vero cells |
CHEMBL1149790 |
| Human coxsackievirus B4 |
MIC |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Punta Toro virus |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Human parainfluenza virus 3 |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against Parainfluenza 3 virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Mammalian orthoreovirus 1 |
MIC |
= |
48.0 |
ug.mL-1 |
Antiviral activity against Reo virus 1 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Sindbis virus |
MIC |
= |
240.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL1149790 |
| Rift Valley fever virus |
Activity |
|
|
|
Antiviral activity against Rift Valley fever virus infected in african green monkey Vero cells assessed as plaque reduction at 250 ug/mL |
CHEMBL1137794 |
| Venezuelan equine encephalitis virus |
Activity |
|
|
|
Antiviral activity against Venezuelan equine encephalomyelitis virus infected in african green monkey Vero cells assessed as plaque reduction at 250 ug/mL |
CHEMBL1137794 |
| Yellow fever virus |
Activity |
|
|
|
Antiviral activity against Yellow fever virus infected in rhesus monkey MK2 cells assessed as plaque reduction at 250 ug/mL |
CHEMBL1137794 |
| Sandfly fever sicilian virus |
Activity |
|
|
|
Antiviral activity against Sandfly fever virus assessed as plaque reduction at 250 ug/mL |
CHEMBL1137794 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against VSV assessed as reduction in plaque formation at 100 ug |
CHEMBL1137795 |
| Respiratory syncytial virus |
EC50 |
= |
2.3 |
ug.mL-1 |
Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection |
CHEMBL1150874 |
| ADMET |
IC50 |
= |
25.0 |
ug.mL-1 |
Cytotoxicity against human Hep2 cells administered 3 hrs postinfection |
CHEMBL1150874 |
| Unchecked |
Ratio IC50/EC50 |
= |
10.8 |
|
Selectivity index, ratio of EC50 for RSV administered 3 hrs postinfection over IC50 for human Hep2 cells administered 3 hrs after infection |
CHEMBL1150874 |
| ADMET |
IC50 |
= |
25.0 |
ug.mL-1 |
Cytotoxicity against RSV A-2 infected human Hep2 cells after 3 days |
CHEMBL1150874 |
| Respiratory syncytial virus |
EC50 |
= |
1.8 |
ug.mL-1 |
Antiviral activity against respiratory syncytial virus assessed as effect on virus-induced cytopathic effect |
CHEMBL1158236 |
| Unchecked |
Ratio IC50/EC50 |
> |
59.0 |
|
Selectivity index, ratio of IC50 for MDCK cells to EC50 for influenza A virus NWS33 |
CHEMBL1145712 |
| MDCK |
IC50 |
> |
200.0 |
ug.mL-1 |
Cytotoxicity against MDCK cells by neutral red assay |
CHEMBL1145712 |
| Influenza A virus |
EC50 |
= |
3.7 |
ug.mL-1 |
Antiviral activity against influenza A virus NWS33 in MDCK cells assessed as inhibition of viral cytopathic effect by neutral red assay |
CHEMBL1145712 |
| Respiratory syncytial virus |
EC50 |
= |
1.8 |
ug.mL-1 |
Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1150966 |
| Respiratory syncytial virus |
IC50 |
= |
2.6 |
ug.mL-1 |
Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1151177 |
| MDCK |
IC50 |
= |
62.5 |
ug.mL-1 |
Cytotoxicity against MDCK cells |
CHEMBL1151177 |
| Unchecked |
Ratio CC50/IC50 |
= |
24.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to IC50 for RSV Long |
CHEMBL1151177 |
| Human parainfluenza virus 3 |
IC50 |
= |
2.6 |
ug.mL-1 |
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1151177 |
| Unchecked |
Ratio CC50/IC50 |
= |
24.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to IC50 for PIV3 |
CHEMBL1151177 |
| Influenza A virus |
IC50 |
= |
62.5 |
ug.mL-1 |
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1151177 |
| Unchecked |
Ratio CC50/IC50 |
< |
2.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to IC50 for influenza virus type A H1N1 |
CHEMBL1151177 |
| Human parainfluenza virus 3 |
CC50 |
= |
62.5 |
ug.mL-1 |
Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1151177 |
| Influenza A virus |
CC50 |
> |
125.0 |
ug.mL-1 |
Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1151177 |
| Respiratory syncytial virus |
EC50 |
= |
1.8 |
ug.mL-1 |
Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days |
CHEMBL1150874 |
| ADMET |
IC50 |
= |
35.0 |
ug.mL-1 |
Cytotoxicity against RSV long infected human Hep2 cells after 3 days |
CHEMBL1150874 |
| Respiratory syncytial virus |
EC50 |
= |
2.2 |
ug.mL-1 |
Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay |
CHEMBL1150874 |
| Unchecked |
Ratio IC50/EC50 |
= |
19.0 |
|
Selectivity index, ratio of EC50 for RSV long by cytopathic effect over IC50 for human Hep2 cells |
CHEMBL1150874 |
| Unchecked |
Ratio IC50/EC50 |
= |
11.0 |
|
Selectivity index, ratio of EC50 for RSV A-2 by plaque neutralization over IC50 for human Hep2 cells |
CHEMBL1150874 |
| Hepatitis C virus |
EC50 |
= |
7.0 |
ug.mL-1 |
Antiviral activity against Hepatitis C virus infected human Huh-5-2 cells assessed as inhibition of luciferase activity after 4 days by RNA replicon assay |
CHEMBL1150316 |
| Huh-5-2 |
CC50 |
= |
21.0 |
ug.mL-1 |
Cytotoxicity against human Huh-5-2 cells |
CHEMBL1150316 |
| Hepatitis C virus |
EC50 |
= |
28700.0 |
nM |
Antiviral activity against HCV in human HuH5.2 cells assessed as inhibition of replicon replication |
CHEMBL1140901 |
| ADMET |
CC50 |
= |
86000.0 |
nM |
Cytotoxicity against human HuH5.2 cells |
CHEMBL1140901 |
| Hepatitis C virus |
EC50 |
= |
84000.0 |
nM |
Antiviral activity against HCV in human Huh9.13 cells assessed as inhibition of replicon replication |
CHEMBL1140901 |
| ADMET |
CC50 |
= |
229000.0 |
nM |
Cytotoxicity against human Huh-9-13 cells |
CHEMBL1140901 |
| Hepatitis C virus |
EC50 |
= |
33000.0 |
nM |
Antiviral activity against HCV in human HuH6 cells assessed as inhibition of replicon replication |
CHEMBL1140901 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HuH6 cells |
CHEMBL1140901 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days |
CHEMBL1153955 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against african green monkey Vero cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days |
CHEMBL1153955 |
| Vesicular stomatitis virus |
EC50 |
= |
22000.0 |
nM |
Antiviral activity against VSV in human HeLa cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Respiratory syncytial virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against RSV Long in human HeLa cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Human coxsackievirus B4 |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against Coxsackievirus B4 in human HeLa cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Human coxsackievirus B4 |
EC50 |
>= |
250000.0 |
nM |
Antiviral activity against Coxsackievirus B4 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Human parainfluenza virus 3 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Parainfluenza virus type 3 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Reovirus 1 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Sindbis virus |
EC50 |
= |
250000.0 |
nM |
Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Punta Toro virus |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days |
CHEMBL1153955 |
| Human herpesvirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Human herpesvirus 2 |
EC50 |
= |
250000.0 |
nM |
Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Vaccinia virus |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Vesicular stomatitis virus |
EC50 |
= |
125000.0 |
nM |
Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| Human herpesvirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1153955 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as drug level causing microscopically detectable alteration of normal cell morphology |
CHEMBL1153955 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells by MTS assay |
CHEMBL1153955 |
| Influenza A virus |
EC50 |
= |
900000.0 |
nM |
Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method |
CHEMBL1153955 |
| Influenza A virus |
EC50 |
= |
8400000.0 |
nM |
Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method |
CHEMBL1153955 |
| Influenza A virus H3N2 |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method |
CHEMBL1153955 |
| Influenza A virus H3N2 |
EC50 |
= |
8100.0 |
nM |
Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method |
CHEMBL1153955 |
| Influenza B virus |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method |
CHEMBL1153955 |
| Influenza B virus |
EC50 |
= |
4800.0 |
nM |
Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method |
CHEMBL1153955 |
| Unchecked |
Ratio CC50/EC50 |
= |
14.4 |
|
Selectivity index, ratio of CC50 for Vero cells to EC50 for Measles virus Leningrad 16 |
CHEMBL1157461 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against african green monkey Vero cells assessed as alteration in cell morphology by MTS assay |
CHEMBL1144203 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as alteration in cell morphology by MTS assay |
CHEMBL1144203 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as alteration in cell morphology by MTS assay |
CHEMBL1144203 |
| MDCK |
MCC |
= |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as alteration in cell morphology by MTS assay |
CHEMBL1144203 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay |
CHEMBL1144203 |
| La Crosse virus |
EC50 |
= |
70000.0 |
nM |
Antiviral activity against La Crosse virus assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days |
CHEMBL1154414 |
| Punta Toro virus |
EC50 |
= |
172000.0 |
nM |
Antiviral activity against Punta Toro virus Adames assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days |
CHEMBL1154414 |
| Rift Valley fever virus |
EC50 |
= |
53000.0 |
nM |
Antiviral activity against Rift Valley fever virus MP-12 assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days |
CHEMBL1154414 |
| Sandfly fever Naples virus |
EC50 |
= |
90000.0 |
nM |
Antiviral activity against Sandfly fever Naples virus assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days |
CHEMBL1154414 |
| Unchecked |
Ratio CC50/EC50 |
= |
51.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for La Crosse virus |
CHEMBL1154414 |
| Unchecked |
Ratio CC50/EC50 |
= |
21.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Punta Toro virus Adames |
CHEMBL1154414 |
| Unchecked |
Ratio CC50/EC50 |
> |
70.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Rift Valley fever virus MP-12 |
CHEMBL1154414 |
| Unchecked |
Ratio CC50/EC50 |
> |
33.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Sandfly fever Naples virus |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
100.0 |
% |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as protection against viral infection at 75 mg/kg, po twice daily for 5 to 7 days |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
5.0 |
day |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
|
|
|
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
2.9 |
|
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
2.8 |
|
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
20.0 |
% |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
0.0 |
% |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
4.2 |
|
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
= |
5.9 |
|
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
60.0 |
% |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
100.0 |
% |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
1491.0 |
IU/L |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
1515.0 |
IU/L |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
13.3 |
day |
Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean day of death at 30 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
2.8 |
|
Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
0.0 |
% |
Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
2.8 |
|
Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
0.0 |
% |
Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
13.0 |
IU/L |
Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
|
|
|
Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as inhibition of liver damage at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Survival |
= |
70.0 |
% |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 30 mg/kg, po twice daily for 5 days 24 hrs post viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
Survival |
= |
10.0 |
% |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
70.0 |
% |
Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as survival at 30 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge |
CHEMBL1154414 |
| Vero |
CC50 |
= |
156000.0 |
nM |
Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay |
CHEMBL1154414 |
| Unchecked |
Ratio CC50/EC50 |
= |
28.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Tacaribe virus TRVL11573 |
CHEMBL1154414 |
| Unchecked |
Ratio CC50/EC50 |
= |
12.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Pichinde virus An 4763 |
CHEMBL1154414 |
| Unchecked |
Ratio CC50/EC50 |
= |
19.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Junin virus Candid-1 |
CHEMBL1154414 |
| Tacaribe virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days |
CHEMBL1154414 |
| Pichinde mammarenavirus |
EC50 |
= |
13000.0 |
nM |
Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days |
CHEMBL1154414 |
| Junin virus |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
11.0 |
day |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
< |
3.2 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
20.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
< |
3.0 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
40.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
30.0 |
IU/L |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
|
|
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as inhibition of liver damage at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
|
|
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
> |
21.0 |
day |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
18.0 |
day |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
= |
4.2 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
= |
6.0 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
< |
3.5 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
< |
5.1 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
100.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
100.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
40.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
80.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
26.0 |
IU/L |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
24.0 |
IU/L |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
18.5 |
day |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
18.3 |
day |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
= |
6.5 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
= |
6.8 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
= |
6.0 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
|
|
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as inhibition of liver damage at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
log10CCID50 |
= |
6.8 |
|
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
100.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
100.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
15.0 |
IU/L |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
67.0 |
IU/L |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
2150.0 |
IU/L |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
450.0 |
IU/L |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
100.0 |
% |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
80.0 |
% |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
20.0 |
% |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
60.0 |
% |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
= |
6.7 |
|
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
5.0 |
|
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
2.9 |
|
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
3.1 |
|
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
5.0 |
day |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
5.3 |
day |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
5.3 |
day |
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
2.8 |
|
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
3.3 |
|
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
= |
6.1 |
|
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
log10CCID50 |
< |
4.9 |
|
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
20.0 |
% |
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
40.0 |
% |
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
100.0 |
% |
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
60.0 |
% |
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
131.0 |
IU/L |
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
846.0 |
IU/L |
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Efficacy |
= |
60.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Efficacy |
= |
60.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge |
CHEMBL1154414 |
| Syrian golden hamster |
LD50 |
= |
217.0 |
mg/kg/day |
Toxicity in Pichinde virus An 4763 infected po dosed Syrian golden hamster administered twice daily 72 hrs post viral-challenge |
CHEMBL1154414 |
| Mus musculus |
LD50 |
= |
730.0 |
mg/kg/day |
Toxicity in po dosed C57BL/6 mouse administered twice daily for 5 days administered 4 hrs before viral challenge |
CHEMBL1154414 |
| Mus musculus |
LD50 |
= |
220.0 |
mg/kg/day |
Toxicity in BALB/c mouse |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
38.0 |
IU/L |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 75 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
100.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Pichinde mammarenavirus |
Activity |
= |
100.0 |
% |
Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
> |
21.0 |
day |
Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
4.0 |
day |
Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge |
CHEMBL1154414 |
| Punta Toro virus |
Activity |
= |
20.0 |
% |
Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 75 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection |
CHEMBL1154414 |
| Respiratory syncytial virus |
EC50 |
= |
11500.0 |
nM |
Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay |
CHEMBL1143412 |
| Respiratory syncytial virus |
EC50 |
= |
25300.0 |
nM |
Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA |
CHEMBL1143412 |
| Respiratory syncytial virus |
EC50 |
= |
13300.0 |
nM |
Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay |
CHEMBL1143412 |
| Respiratory syncytial virus |
EC50 |
= |
16800.0 |
nM |
Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay |
CHEMBL1143412 |
| Respiratory syncytial virus |
EC50 |
= |
19000.0 |
nM |
Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay |
CHEMBL1143412 |
| Respiratory syncytial virus |
EC50 |
= |
29000.0 |
nM |
Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay |
CHEMBL1143412 |
| ADMET |
CC50 |
|
|
|
Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay |
CHEMBL1143412 |
| ADMET |
Ratio CC50/EC50 |
|
|
|
Therapeutic index, CC50 for human Hep2 cells to EC50 for RSV RSS |
CHEMBL1143412 |
| Respiratory syncytial virus |
EC50 |
= |
20700.0 |
nM |
Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay |
CHEMBL1143412 |
| Respiratory syncytial virus |
EC50 |
= |
17600.0 |
nM |
Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay |
CHEMBL1143412 |
| Respiratory syncytial virus |
FC |
= |
0.85 |
|
Drug resistance, ratio of EC50 for plaque picked RSV604-resistant RSV RSS from passage 2 to EC50 for DMSO-passaged wild type RSV RSS |
CHEMBL1143412 |
| Respiratory syncytial virus |
EC50 |
|
|
|
Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay |
CHEMBL1143412 |
| Respiratory syncytial virus |
FC |
|
|
|
Drug resistance, ratio of EC50 for plaque picked A-33903-resistant RSV RSS from passage 2 to EC50 for DMSO-passaged wild type RSV RSS |
CHEMBL1143412 |
| ADMET |
CC50 |
= |
54000.0 |
nM |
Cytotoxicity against MDBK cells after 3 days by MTS/PMS assay |
CHEMBL1140965 |
| Bovine viral diarrhea virus |
EC50 |
= |
4620.0 |
nM |
Antiviral activity against bovine viral diarrhoea virus type-1 NADL in MDBK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1140965 |
| Unchecked |
Ratio CC50/EC50 |
= |
11.64 |
|
Selectivity index, ratio of CC50 for MDBK cells to EC50 for bovine viral diarrhoea virus type-1 NADL |
CHEMBL1140965 |
| Potato virus X |
Inhibition |
= |
94.0 |
% |
Antiviral activity against Potato virus X in half leaf of Chenopodium quinoa at 9.3 mg/mL after 10 days |
CHEMBL1150650 |
| ADMET |
CC50 |
= |
62.5 |
ug.mL-1 |
Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| ADMET |
MNCC |
|
|
|
Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| Respiratory syncytial virus |
IC50 |
= |
3.0 |
ug.mL-1 |
Antiviral activity against RSV Long in human Hep2 cells assessed as reduction of virus induced cytopathic effect |
CHEMBL1157953 |
| Unchecked |
Ratio CC50/IC50 |
= |
20.8 |
|
Selectivity index, CC50 for human Hep2 cells to IC50 for RSV Long |
CHEMBL1157953 |
| Vero |
CC50 |
|
|
|
Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| Vero |
MNCC |
|
|
|
Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| Human herpesvirus 1 |
IC50 |
|
|
|
Antiviral activity against HSV1 15577 in african green monkey Vero cells assessed as reduction of virus induced cytopathic effect |
CHEMBL1157953 |
| Unchecked |
Ratio CC50/IC50 |
|
|
|
Selectivity index, CC50 for african green monkey Vero cells to IC50 for HSV1 15577 |
CHEMBL1157953 |
| MDCK |
CC50 |
|
|
|
Cytotoxicity against MDCK cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| MDCK |
MNCC |
|
|
|
Cytotoxicity against MDCK cells after 3 days by MTT reduction assay |
CHEMBL1157953 |
| Influenza A virus |
IC50 |
|
|
|
Antiviral activity against influenza A virus H1N1 A/NWS/33 in human MDCK cells assessed as reduction of virus induced cytopathic effect |
CHEMBL1157953 |
| Unchecked |
Ratio CC50/IC50 |
|
|
|
Selectivity index, CC50 for MDCK cells to IC50 for influenza A virus H1N1 A/NWS/33 |
CHEMBL1157953 |
| Human coxsackievirus B3 |
IC50 |
|
|
|
Antiviral activity against Cox B3 virus in human Hep2 cells assessed as reduction of virus induced cytopathic effect |
CHEMBL1157953 |
| Unchecked |
Ratio CC50/IC50 |
|
|
|
Selectivity index, CC50 for human Hep2 cells to IC50 for Cox B3 virus |
CHEMBL1157953 |
| MDCK |
CC50 |
> |
512000.0 |
nM |
Cytotoxicity against MDCK cells by MTT assay |
CHEMBL1155907 |
| Influenza A virus |
IC50 |
= |
25620.0 |
nM |
Antiviral activity against Influenza A virus Jinan/15/90 H3N2 assessed as reduction of virus-induced cytopathic effect |
CHEMBL1155907 |
| Unchecked |
Ratio CC50/IC50 |
> |
19.98 |
|
Selectivity index, ratio of CC50 to MDCK cells to IC50 to Influenza A Jinan/15/90 H3N2 virus |
CHEMBL1155907 |
| MDCK |
MNCC |
|
|
|
Cytotoxicity against MDCK cells assessed as maximal non-cytotoxic concentration by MTT assay |
CHEMBL1155907 |
| Influenza A virus H3N2 |
IC50 |
= |
20000.0 |
nM |
Antiviral activity against influenza H3N2 virus |
CHEMBL1136837 |
| Cowpox virus |
IC50 |
= |
410000.0 |
nM |
Antiviral activity against Cowpox virus |
CHEMBL1136837 |
| Camelpox virus |
IC50 |
= |
215000.0 |
nM |
Antiviral activity against Camelpox virus |
CHEMBL1136837 |
| Influenza B virus |
IC50 |
= |
19000.0 |
nM |
Antiviral activity against influenza B virus |
CHEMBL1136837 |
| Human adenovirus type 2 |
IC50 |
= |
100000.0 |
nM |
Antiviral activity against Human adenovirus 2 |
CHEMBL1136837 |
| Monkeypox virus |
IC50 |
= |
145000.0 |
nM |
Antiviral activity against Monkeypox virus |
CHEMBL1136837 |
| Influenza A virus |
IC50 |
= |
7700.0 |
nM |
Antiviral activity against influenza H1N1 virus |
CHEMBL1136837 |
| Vaccinia virus |
IC50 |
= |
281000.0 |
nM |
Antiviral activity against Vaccinia virus |
CHEMBL1136837 |
| H2N2 subtype |
IC50 |
= |
13800.0 |
nM |
Antiviral activity against influenza H2N2 virus |
CHEMBL1136837 |
| Encephalomyocarditis virus |
EC50 |
= |
0.02 |
ug.mL-1 |
Antiviral activity against EMCV assessed as inhibition of virus-induced cytopathicity |
CHEMBL1136856 |
| Human coxsackievirus B3 |
EC50 |
= |
0.04 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B3 assessed as inhibition of virus-induced cytopathicity |
CHEMBL1136856 |
| Vesicular stomatitis virus |
EC50 |
= |
0.08 |
ug.mL-1 |
Antiviral activity against VSV assessed as inhibition of virus-induced cytopathicity |
CHEMBL1136856 |
| Influenza A virus |
EC50 |
= |
8700.0 |
nM |
Antiviral activity against influenza A virus H3N2 assessed as inhibition of virus-induced cytopathic effect after 72 hrs by MTS assay |
CHEMBL1152743 |
| MDCK |
MCC |
= |
20000.0 |
nM |
Cytotoxicity against MDCK cells assessed as changes in cell morphology after 72 hrs by MTS assay |
CHEMBL1152743 |
| Unchecked |
Ratio |
= |
2.0 |
|
Selectivity index, ratio of MCC for MDCK cells to EC50 for influenza A virus H3N2 |
CHEMBL1152743 |
| Influenza B virus |
Activity |
|
|
|
Antiviral activity against influenza B virus |
CHEMBL1152743 |
| HEL |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against human HEL cells assessed as alteration in cell morphology |
CHEMBL1158343 |
| Human herpesvirus 1 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Human herpesvirus 2 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Vaccinia virus |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Vesicular stomatitis virus |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Human herpesvirus 1 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| HeLa |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells assessed as alteration in cell morphology |
CHEMBL1158343 |
| Vesicular stomatitis virus |
EC50 |
= |
29.0 |
ug.mL-1 |
Antiviral activity against VSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Human coxsackievirus B4 |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Respiratory syncytial virus |
EC50 |
= |
10.0 |
ug.mL-1 |
Antiviral activity against RSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Vero |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells assessed as alteration in cell morphology |
CHEMBL1158343 |
| Human parainfluenza virus 3 |
EC50 |
= |
45.0 |
ug.mL-1 |
Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Sindbis virus |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Human coxsackievirus B4 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Punta Toro virus |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days |
CHEMBL1158343 |
| Respiratory syncytial virus |
IC50 |
= |
10700.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay |
CHEMBL1151977 |
| ADMET |
TC50 |
= |
256.1 |
uM |
Cytotoxicity against human Hep2 cells |
CHEMBL1151977 |
| ADMET |
TI |
= |
23.9 |
|
Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Respiratory syncytial virus infected in human Hep2 cells |
CHEMBL1151977 |
| Human parainfluenza virus 3 |
IC50 |
= |
10700.0 |
nM |
Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay |
CHEMBL1151977 |
| ADMET |
TI |
= |
23.9 |
|
Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Parainfluenza virus type 3 infected in human Hep2 cells |
CHEMBL1151977 |
| Influenza A virus |
IC50 |
= |
42600.0 |
nM |
Antiviral activity against Influenza A virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay |
CHEMBL1151977 |
| MDCK |
TC50 |
> |
256.1 |
uM |
Cytotoxicity against MDCK cells |
CHEMBL1151977 |
| ADMET |
TI |
> |
6.0 |
|
Therapeutic index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus infected in MDCK cells |
CHEMBL1151977 |
| HeLa |
CC50 |
= |
426.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay |
CHEMBL1152344 |
| Coxsackievirus |
IC50 |
= |
20.3 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B3 Nacy infected in human HeLa cells assessed as reduction of virus-induced cytopathic effect by MTT assay |
CHEMBL1152344 |
| ADMET |
Ratio CC50/IC50 |
= |
21.0 |
|
Therapeutic index, CC50 for human HeLa cells to IC50 for Coxsackie virus B3 Nacy |
CHEMBL1152344 |
| Homo sapiens |
CL |
= |
5.2 |
mL.min-1.kg-1 |
Total body clearance in human |
CHEMBL1151930 |
| Homo sapiens |
CL_renal |
= |
1.7 |
mL.min-1.kg-1 |
Renal clearance in human |
CHEMBL1151930 |
| Hepatitis C virus |
FC |
= |
0.7 |
|
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type |
CHEMBL1152460 |
| Hepatitis C virus |
FC |
= |
0.6 |
|
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type |
CHEMBL1152460 |
| Hepatitis C virus |
EC50 |
= |
58000.0 |
nM |
Antiviral activity against wild type Con1-mADE HCV replicon in human HuH7 cells after 48 hrs by RNA replicon assay |
CHEMBL1152460 |
| Hepatitis C virus |
EC50 |
= |
33000.0 |
nM |
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay |
CHEMBL1152460 |
| Hepatitis C virus |
EC50 |
= |
43000.0 |
nM |
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay |
CHEMBL1152460 |
| Hepatitis C virus |
EC50 |
= |
22000.0 |
nM |
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease T54A double mutation in human HuH7 cells after 48 hrs by RNA replicon assay |
CHEMBL1152460 |
| Hepatitis C virus |
EC50 |
= |
41000.0 |
nM |
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay |
CHEMBL1152460 |
| Hepatitis C virus |
EC50 |
= |
36000.0 |
nM |
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay |
CHEMBL1152460 |
| Hepatitis C virus |
EC50 |
= |
36000.0 |
nM |
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay |
CHEMBL1152460 |
| Hepatitis C virus |
EC50 |
= |
42000.0 |
nM |
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay |
CHEMBL1152460 |
| Hepatitis C virus |
FC |
= |
0.6 |
|
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type |
CHEMBL1152460 |
| Hepatitis C virus |
FC |
= |
0.8 |
|
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type |
CHEMBL1152460 |
| Hepatitis C virus |
FC |
= |
0.4 |
|
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36L mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type |
CHEMBL1152460 |
| Hepatitis C virus |
FC |
= |
0.7 |
|
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type |
CHEMBL1152460 |
| Hepatitis C virus |
FC |
= |
0.6 |
|
Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type |
CHEMBL1152460 |
| HEL |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology |
CHEMBL1153616 |
| Human herpesvirus 2 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Vesicular stomatitis virus |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Human herpesvirus 1 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| HeLa |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology |
CHEMBL1153616 |
| Human herpesvirus 1 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Vero |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology |
CHEMBL1153616 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Sindbis virus |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days postinfection |
CHEMBL1153616 |
| Human coxsackievirus B4 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| HeLa |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells assessed as change in cell morphology |
CHEMBL1153581 |
| Human herpesvirus 1 |
MIC50 |
= |
250.0 |
ug.mL-1 |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Human herpesvirus 2 |
MIC50 |
= |
250.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 2 infected in HEL cells assessed as protection against in virus-induced cytopathogenicity |
CHEMBL1153581 |
| Vaccinia virus |
MIC50 |
= |
150.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Vesicular stomatitis virus |
MIC50 |
= |
150.0 |
ug.mL-1 |
Antiviral activity against sVesicular stomatitis virus infected in HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Human herpesvirus 1 |
MIC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against acyclovir-resistant thymidine kinase-deficient HSV1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Vesicular stomatitis virus |
MIC50 |
= |
30.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Human coxsackievirus B4 |
MIC50 |
= |
150.0 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Respiratory syncytial virus |
MIC50 |
= |
50.0 |
ug.mL-1 |
Antiviral activity against RSV infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Human parainfluenza virus 3 |
MIC50 |
= |
150.0 |
ug.mL-1 |
Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Mammalian orthoreovirus 1 |
MIC50 |
= |
150.0 |
ug.mL-1 |
Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Sindbis virus |
MIC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Human coxsackievirus B4 |
MIC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| Punta Toro virus |
MIC50 |
= |
250.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity |
CHEMBL1153581 |
| HEL |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against HEL cells assessed as change in cell morphology |
CHEMBL1153581 |
| Vero |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells assessed as change in cell morphology |
CHEMBL1153581 |
| Respiratory syncytial virus |
EC50 |
= |
10.0 |
ug.mL-1 |
Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Vesicular stomatitis virus |
EC50 |
= |
29.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Human parainfluenza virus 3 |
EC50 |
= |
45.0 |
ug.mL-1 |
Antiviral activity against Parainfluenza virus type 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Vaccinia virus |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Human coxsackievirus B4 |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Punta Toro virus |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days |
CHEMBL1153616 |
| Bovine viral diarrhea virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay |
CHEMBL1154067 |
| Respiratory syncytial virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay |
CHEMBL1154067 |
| MT4 |
CC50 |
= |
31000.0 |
nM |
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay |
CHEMBL1154067 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL1154067 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay |
CHEMBL1154067 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay |
CHEMBL1154067 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining |
CHEMBL1154067 |
| Human coxsackievirus B2 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay |
CHEMBL1154067 |
| Human herpesvirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay |
CHEMBL1154067 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL1154067 |
| NON-PROTEIN TARGET |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Human poliovirus 1 strain Sabin after 2 days by plaque reduction assay |
CHEMBL1154067 |
| Dengue virus |
EC50 |
= |
49.0 |
ug.mL-1 |
Antiviral activity against Dengue virus |
CHEMBL1155220 |
| Unchecked |
IC50 |
= |
1.6 |
ug.mL-1 |
Inhibition of Dengue virus IMPDH |
CHEMBL1155220 |
| Hepatitis C virus |
MIC |
= |
16.15 |
ug.mL-1 |
Antiviral activity HCV in replicon cells assessed as inhibition of NS3-4A protease activity by RT-PCR |
CHEMBL1154704 |
| Hepatitis C virus |
MIC |
= |
77.89 |
ug.mL-1 |
Antiviral activity against HCV infected in hamster brain assessed as subacute sclerosing panencephalitis |
CHEMBL1154704 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay |
CHEMBL1156074 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
9700.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as cell viability by cell-based MTS assay |
CHEMBL1156074 |
| Influenza A virus |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay |
CHEMBL1156074 |
| Influenza A virus |
EC50 |
= |
6000.0 |
nM |
Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as cell viability by cell-based MTS assay |
CHEMBL1156074 |
| NON-PROTEIN TARGET |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as inhibition of virus-induced cytopathic effect by cell-based assay |
CHEMBL1156074 |
| NON-PROTEIN TARGET |
EC50 |
= |
3600.0 |
nM |
Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as cell viability by cell-based MTS assay |
CHEMBL1156074 |
| Hepatitis C virus |
MIC |
= |
16.15 |
ug.mL-1 |
Antiviral activity against HCV by cell based replicon assay |
CHEMBL1152689 |
| Measles virus |
MIC |
= |
77.89 |
ug.mL-1 |
Antiviral activity against Measles virus infected in intracranially dosed hamster assessed as inhibition of subacute sclerosing panencephalitis |
CHEMBL1152689 |
| Sindbis virus |
EC50 |
= |
111000.0 |
nM |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay |
CHEMBL1154855 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay |
CHEMBL1154855 |
| Punta Toro virus |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity by MTT assay |
CHEMBL1154855 |
| Influenza A virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay |
CHEMBL1154855 |
| Influenza A virus |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay |
CHEMBL1154855 |
| Influenza B virus |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay |
CHEMBL1154855 |
| HeLa |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against VSV infected human HeLa cells by trypan blue exclusion method |
CHEMBL1154855 |
| HeLa |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Human coxsackievirus B4 infected human HeLa cells by trypan blue exclusion method |
CHEMBL1154855 |
| HeLa |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Respiratory syncytial virus infected human HeLa cells by trypan blue exclusion method |
CHEMBL1154855 |
| HEL |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| HEL |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| HEL |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| HEL |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| HEL |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method |
CHEMBL1154855 |
| Vero |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against PIV 3 infected african green monkey Vero cells by trypan blue exclusion method |
CHEMBL1154855 |
| Vero |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Reovirus 1 infected african green monkey Vero cells by trypan blue exclusion method |
CHEMBL1154855 |
| Vero |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Sindbis virus infected african green monkey Vero cells by trypan blue exclusion method |
CHEMBL1154855 |
| Vero |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Human coxsackievirus B4 infected african green monkey Vero cells by trypan blue exclusion method |
CHEMBL1154855 |
| Vero |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Punta Toro virus infected african green monkey Vero cells by trypan blue exclusion method |
CHEMBL1154855 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Influenza A virus subtype H1N1 infected MDCK cells by trypan blue exclusion method |
CHEMBL1154855 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Influenza A virus subtype H3N2 infected MDCK cells by trypan blue exclusion method |
CHEMBL1154855 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against Influenza B virus infected MDCK cells by trypan blue exclusion method |
CHEMBL1154855 |
| Vesicular stomatitis virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against VSV infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay |
CHEMBL1154855 |
| Human coxsackievirus B4 |
EC50 |
= |
30000.0 |
nM |
Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay |
CHEMBL1154855 |
| Respiratory syncytial virus |
EC50 |
= |
30000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay |
CHEMBL1154855 |
| Human herpesvirus 1 |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay |
CHEMBL1154855 |
| Human herpesvirus 2 |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay |
CHEMBL1154855 |
| Vaccinia virus |
EC50 |
= |
85000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay |
CHEMBL1154855 |
| Vesicular stomatitis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay |
CHEMBL1154855 |
| Human herpesvirus 1 |
EC50 |
= |
125000.0 |
nM |
Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay |
CHEMBL1154855 |
| Human parainfluenza virus 3 |
EC50 |
= |
95000.0 |
nM |
Antiviral activity against PIV 3 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay |
CHEMBL1154855 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
250000.0 |
nM |
Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay |
CHEMBL1154855 |
| Semliki forest virus |
IC50 |
= |
95100.0 |
nM |
Antiviral activity against SFV infected in BHK cells after 14 hrs by luciferase reporter gene assay |
CHEMBL1154369 |
| Semliki forest virus |
IC50 |
= |
95499.26 |
nM |
Antiviral activity against SFV infected in BHK cells after 14 hrs by luciferase reporter gene assay |
CHEMBL1154369 |
| Semliki forest virus |
Activity |
|
|
|
Antiviral activity against SFV infected in BHK cells assessed as surviving virus fraction at 200 uM after 14 hrs by luciferase reporter gene assay in presence of 50 ug/ml guanosine |
CHEMBL1154369 |
| Human poliovirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay |
CHEMBL1156237 |
| Human coxsackievirus B2 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay |
CHEMBL1156237 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Yellow fever virus 17D infected in BHK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL1156237 |
| Bovine viral diarrhea virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus NADL infected in MDBK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method |
CHEMBL1156237 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero cells |
CHEMBL1156237 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against BHK cells after 48 to 96 hrs by MTT assay |
CHEMBL1156237 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL1156237 |
| MT4 |
CC50 |
= |
31000.0 |
nM |
Cytotoxicity against human MT4 cells after 96 hrs by MTT assay |
CHEMBL1156237 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay |
CHEMBL1156237 |
| Hepatitis C virus |
EC50 |
= |
17600.0 |
nM |
Antiviral activity against HCV 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 4 days by replicon assay |
CHEMBL1156199 |
| ADMET |
CC50 |
= |
1060000.0 |
nM |
Cytotoxicity against human HuH7 cells after3 days by MTT assay |
CHEMBL1156199 |
| ADMET |
Ratio CC50/EC50 |
= |
60.2 |
|
Therapeutic index, ratio of CC50 for human HuH7 cells to EC50 for HCV 1b |
CHEMBL1156199 |
| Influenza A virus (H5N1) |
EC50 |
= |
35400.0 |
nM |
Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC50 |
= |
32500.0 |
nM |
Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC90 |
= |
43.6 |
uM |
Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 3 days by virus yield reduction assay |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC50 |
= |
23600.0 |
nM |
Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC50 |
= |
27400.0 |
nM |
Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC90 |
= |
20.3 |
uM |
Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 3 days by virus yield reduction assay |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC50 |
= |
4300.0 |
nM |
Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC50 |
= |
9400.0 |
nM |
Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC90 |
= |
16.8 |
uM |
Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 3 days by virus yield reduction assay |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC50 |
= |
8400.0 |
nM |
Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC50 |
= |
13900.0 |
nM |
Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay |
CHEMBL1156973 |
| Influenza A virus (H5N1) |
EC90 |
= |
11.6 |
uM |
Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 3 days by virus yield reduction assay |
CHEMBL1156973 |
| MDCK |
IC50 |
> |
1310000.0 |
nM |
Cytotoxicity against MDCK cells after 3 days by neutral red dye uptake assay |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
37.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Duck/MN/1525/81/H5N1 |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
40.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Duck/MN/1525/81/H5N1 by neutral red dye uptake assay |
CHEMBL1156973 |
| ADMET |
Ratio |
> |
30.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Duck/MN/1525/81/H5N1 by virus yield reduction assay |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
55.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Gull/PA/4175/83/H5N1 |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
48.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Gull/PA/4175/83/H5N1 by neutral red dye uptake assay |
CHEMBL1156973 |
| ADMET |
Ratio |
> |
65.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Gull/PA/4175/83/H5N1 by virus yield reduction assay |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
305.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Hong Kong/213/2003/H5N1 |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
139.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Hong Kong/213/2003/H5N1 by neutral red dye uptake assay |
CHEMBL1156973 |
| ADMET |
Ratio |
> |
78.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Hong Kong/213/2003/H5N1 by virus yield reduction assay |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
156.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Vietnam/1203/ 2004H/H5N1 |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
94.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Vietnam/1203/ 2004H/H5N1 by neutral red dye uptake assay |
CHEMBL1156973 |
| ADMET |
Ratio |
> |
113.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Vietnam/1203/ 2004H/H5N1 by virus yield reduction assay |
CHEMBL1156973 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
11200.0 |
nM |
Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days |
CHEMBL1156973 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
19400.0 |
nM |
Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay |
CHEMBL1156973 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC90 |
= |
13.0 |
uM |
Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 3 days by virus yield reduction assay |
CHEMBL1156973 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
23300.0 |
nM |
Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days |
CHEMBL1156973 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
25100.0 |
nM |
Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay |
CHEMBL1156973 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC90 |
= |
27.0 |
uM |
Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 3 days by virus yield reduction assay |
CHEMBL1156973 |
| Influenza A virus |
EC50 |
= |
16400.0 |
nM |
Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days |
CHEMBL1156973 |
| Influenza A virus |
EC50 |
= |
20200.0 |
nM |
Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay |
CHEMBL1156973 |
| Influenza A virus |
EC90 |
= |
21.7 |
uM |
Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 3 days by virus yield reduction assay |
CHEMBL1156973 |
| Influenza B virus |
EC50 |
= |
10200.0 |
nM |
Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days |
CHEMBL1156973 |
| Influenza B virus |
EC50 |
= |
19500.0 |
nM |
Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay |
CHEMBL1156973 |
| Influenza B virus |
EC90 |
= |
22.2 |
uM |
Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 3 days by virus yield reduction assay |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
117.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus California/07/2009 /H1N1 |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
68.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus California/07/2009 /H1N1 by neutral red dye uptake assay |
CHEMBL1156973 |
| ADMET |
Ratio |
> |
101.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus California/07/2009 /H1N1 by virus yield reduction assay |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
56.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Solomon Islands/03/2006/H1N1 |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
52.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Solomon Islands/03/2006/H1N1 by neutral red dye uptake assay |
CHEMBL1156973 |
| ADMET |
Ratio |
> |
49.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Solomon Islands/03/2006/H1N1 by virus yield reduction assay |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
80.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Wisconsin/67/2005/H3N2 |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
65.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Wisconsin/67/2005/H3N2 by neutral red dye uptake assay |
CHEMBL1156973 |
| ADMET |
Ratio |
> |
60.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Wisconsin/67/2005/H3N2 by virus yield reduction assay |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
128.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza B virus Malaysia/2506/2004 |
CHEMBL1156973 |
| ADMET |
Ratio IC50/EC50 |
> |
67.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza B virus Malaysia/2506/2004 by neutral red dye uptake assay |
CHEMBL1156973 |
| ADMET |
Ratio |
> |
59.0 |
|
Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza B virus Malaysia/2506/2004 by virus yield reduction assay |
CHEMBL1156973 |
| Respiratory syncytial virus |
EC50 |
= |
19000.0 |
nM |
Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1156333 |
| Vesicular stomatitis virus |
EC50 |
= |
22000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1156333 |
| Vaccinia virus |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Vaccinia virus lederle infected in human HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1156333 |
| Hepatitis C virus |
EC50 |
= |
87000.0 |
nM |
Antiviral activity against HCV infected in human HuH5.2 cells carrying subgenomic HCV replicon assessed as inhibition of replicon replication by luciferase reporter gene assay |
CHEMBL1156333 |
| Punta Toro virus |
EC50 |
= |
183000.0 |
nM |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1156333 |
| Influenza A virus |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1156333 |
| Influenza B virus |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1156333 |
| HeLa |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HeLa cells |
CHEMBL1156333 |
| HEL |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HEL cells |
CHEMBL1156333 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells |
CHEMBL1156333 |
| ADMET |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against human HuH5.2 cells |
CHEMBL1156333 |
| Respiratory syncytial virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay |
CHEMBL1156237 |
| Human herpesvirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay |
CHEMBL1156237 |
| Homo sapiens |
Activity |
= |
0.33 |
% |
Human intestinal absorption in po dosed human |
CHEMBL1157012 |
| Influenza A virus |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against influenza A virus H1N1 assessed as inhibition of viral induced cytopathic effect |
CHEMBL1158551 |
| Influenza A virus |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against influenza A virus H1N1 assessed as cell viability by cell based MTS assay |
CHEMBL1158551 |
| Influenza A virus |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza A virus H3N2 assessed as inhibition of viral induced cytopathic effect |
CHEMBL1158551 |
| Influenza A virus |
EC50 |
= |
8700.0 |
nM |
Antiviral activity against Influenza A virus H3N2 assessed as cell viability by cell based MTS assay |
CHEMBL1158551 |
| Influenza B virus |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against influenza B virus assessed as inhibition of viral induced cytopathic effect |
CHEMBL1158551 |
| Influenza B virus |
EC50 |
= |
4700.0 |
nM |
Antiviral activity against influenza B virus assessed as cell viability by cell based MTS assay |
CHEMBL1158551 |
| Human herpesvirus 1 |
EC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Human herpesvirus 2 |
EC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Vaccinia virus |
EC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Vesicular stomatitis virus |
EC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Human herpesvirus 1 |
EC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Vesicular stomatitis virus |
EC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Respiratory syncytial virus |
EC50 |
= |
16.0 |
ug.mL-1 |
Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| E6SM |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against human E6SM cells by MTT assay |
CHEMBL1155465 |
| HeLa |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells by MTT assay |
CHEMBL1155465 |
| Human parainfluenza virus 3 |
EC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Reovirus sp. |
EC50 |
= |
80.0 |
ug.mL-1 |
Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Sindbis virus |
EC50 |
> |
400.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Punta Toro virus |
EC50 |
= |
48.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL1155465 |
| Vero |
MCC |
> |
400.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells by MTT assay |
CHEMBL1155465 |
| Respiratory syncytial virus |
EC50 |
= |
6600.0 |
nM |
Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay |
CHEMBL1177846 |
| Human coxsackievirus B4 |
EC50 |
= |
73100.0 |
nM |
Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay |
CHEMBL1177846 |
| Vesicular stomatitis virus |
EC50 |
= |
17200.0 |
nM |
Antiviral activity against VSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay |
CHEMBL1177846 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells after 3 days by MTS assay |
CHEMBL1177846 |
| HeLa |
CC50 |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells after 3 days by MTS assay |
CHEMBL1177846 |
| Hepatitis C virus |
EC50 |
= |
120000.0 |
nM |
Antiviral activity against HCV Con 1 by subgenomic replicon assay |
CHEMBL1250429 |
| ADMET |
CC50 |
= |
177940.0 |
nM |
Cytotoxicity against human HuH7 cells |
CHEMBL1250429 |
| Unchecked |
Ratio CC50/EC50 |
= |
1.5 |
|
Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for |
CHEMBL1250429 |
| Plasmodium falciparum |
IC50 |
= |
12589.25 |
nM |
Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay |
CHEMBL1255382 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay |
CHEMBL1255231 |
| Poliovirus |
PFU |
= |
150.0 |
|
Antiviral activity against Poliovirus infected in human HeLaS3 cells assessed as frequency of viral mutagenesis plaque at 150 uM by guanidine resistance assay |
CHEMBL1269004 |
| Poliovirus |
PFU |
> |
250.0 |
|
Antiviral activity against Poliovirus infected in human HeLaS3 cells assessed as frequency of viral mutagenesis plaque at 300 uM by guanidine resistance assay |
CHEMBL1269004 |
| Hepatitis C virus |
Inhibition |
= |
50.0 |
% |
Antiviral activity against HCV 1a infected in human HuH7 cells assessed as reduction of viral RNA level at 20 ug/ml after 2 days by QRT-PCR analysis |
CHEMBL1268901 |
| ADMET |
CC50 |
|
|
|
Cytotoxicity against human HuH7 cells after 2 days by XTT assay |
CHEMBL1268901 |
| Unchecked |
Selectivity Index |
= |
2.0 |
|
Selectivity index, ratio of MCC for MDCK cells to EC50 for Influenza A virus (A/Hong Kong/7/1987(H3N2)) |
CHEMBL1275292 |
| Influenza A virus |
EC50 |
= |
8700.0 |
nM |
Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay |
CHEMBL1275292 |
| MDCK |
MCC |
= |
20000.0 |
nM |
Cytotoxicity against MDCK cells by MTS assay |
CHEMBL1275292 |
| Hepatitis C virus |
EC50 |
= |
69000.0 |
nM |
Antiviral activity against HCV genotype 1b in RP7 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC50 |
= |
47000.0 |
nM |
Antiviral activity against HCV genotype 1b in NTZ-11 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC50 |
= |
52000.0 |
nM |
Antiviral activity against HCV genotype 1b in TIZ-9 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC90 |
= |
122.0 |
uM |
Antiviral activity against HCV genotype 1b in RP7 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC90 |
= |
107.0 |
uM |
Antiviral activity against HCV genotype 1b in NTZ-11 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| Hepatitis C virus |
EC90 |
= |
123.0 |
uM |
Antiviral activity against HCV genotype 1b in TIZ-9 replicon cell after 4 days by blot hybridization analysis |
CHEMBL1275532 |
| ADMET |
CC50 |
= |
77000.0 |
nM |
Cytotoxicity against human RP7 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay |
CHEMBL1275532 |
| ADMET |
CC50 |
= |
66000.0 |
nM |
Cytotoxicity against human NTZ-11 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay |
CHEMBL1275532 |
| ADMET |
CC50 |
= |
95000.0 |
nM |
Cytotoxicity against human TIZ-9 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay |
CHEMBL1275532 |
| Unchecked |
Ratio CC50/EC50 |
= |
1.1 |
|
Selectivity Index, ratio of CC50 for RP7 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in RP7 replicon cell |
CHEMBL1275532 |
| Unchecked |
Ratio CC50/EC50 |
= |
1.4 |
|
Selectivity Index, ratio of CC50 for NTZ-11 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in NTZ-11 replicon cell |
CHEMBL1275532 |
| Unchecked |
Ratio CC50/EC50 |
= |
1.8 |
|
Selectivity Index, ratio of CC50 for TIZ-9 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in TIZ-9 replicon cell |
CHEMBL1275532 |
| Equilibrative nucleoside transporter 1 |
Activity |
|
|
|
Transport through ENT1 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 2 |
Activity |
|
|
|
Transport through ENT2 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Unchecked |
Activity |
|
|
|
Transport through CNT1 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 2 |
Activity |
|
|
|
Transport through CNT2 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Unchecked |
Activity |
|
|
|
Transport through CNT3 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 1 |
Activity |
|
|
|
Transport through ENT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 2 |
Activity |
|
|
|
Transport through ENT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 1 |
Activity |
|
|
|
Transport through CNT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 2 |
Activity |
|
|
|
Transport through CNT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Unchecked |
Activity |
|
|
|
Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 1 |
Activity |
|
|
|
Transport through ENT1 in rat hepatocytes by oil filtration assay |
CHEMBL1275601 |
| Unchecked |
Activity |
|
|
|
Transport through CNT3 in rat hepatocytes by oil filtration assay |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 1 |
Activity |
|
|
|
Transport through ENT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 2 |
Activity |
|
|
|
Transport through ENT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 1 |
Activity |
|
|
|
Transport through CNT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and thymidine |
CHEMBL1275601 |
| Unchecked |
Activity |
|
|
|
Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and thymidine |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 2 |
Activity |
|
|
|
Transport through CNT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM inosine |
CHEMBL1275601 |
| Unchecked |
Activity |
|
|
|
Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM inosine |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 1 |
Activity |
|
|
|
Transport through ENT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 2 |
Activity |
|
|
|
Transport through ENT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 1 |
Activity |
|
|
|
Transport through CNT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 2 |
Activity |
|
|
|
Transport through CNT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine |
CHEMBL1275601 |
| Unchecked |
Activity |
|
|
|
Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 1 |
Activity |
|
|
|
Transport through ENT1 in mouse hepatocytes by oil filtration assay in presence 100 nM of transporter inhibitor NBMRP |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 1 |
Activity |
|
|
|
Transport through ENT1 in rat hepatocytes by oil filtration assay in presence 100 nM of transporter inhibitor NBMRP |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 1 |
Activity |
|
|
|
Transport through ENT1 in mouse hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 1 |
Activity |
|
|
|
Transport through ENT1 in rat hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 2 |
Activity |
|
|
|
Transport through ENT2 in mouse hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 2 |
Activity |
|
|
|
Transport through ENT2 in rat hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 2 |
Activity |
|
|
|
Transport through CNT2 in mouse hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in presence of sodium ions in Kreb-henseleit buffer containing 100 nM NBMPR |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 2 |
Activity |
|
|
|
Transport through CNT2 in rat hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in presence of sodium ions in Kreb-henseleit buffer containing 100 nM NBMPR |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 2 |
Activity |
|
|
|
Transport through CNT2 in mouse hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in Kreb-henseleit buffer |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 2 |
Activity |
|
|
|
Transport through CNT2 in rat hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in Kreb-henseleit buffer |
CHEMBL1275601 |
| Equilibrative nucleoside transporter 2 |
Activity |
|
|
|
Transport through ENT2 in rat hepatocytes by oil filtration assay |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 1 |
Activity |
|
|
|
Transport through CNT1 in rat hepatocytes by oil filtration assay |
CHEMBL1275601 |
| Sodium/nucleoside cotransporter 2 |
Activity |
|
|
|
Transport through CNT2 in rat hepatocytes by oil filtration assay |
CHEMBL1275601 |
| Influenza B virus |
EC50 |
= |
6.0 |
ug.mL-1 |
Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay |
CHEMBL1287642 |
| Influenza A virus |
EC50 |
= |
7.8 |
ug.mL-1 |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay |
CHEMBL1287642 |
| Influenza A virus |
EC50 |
= |
9.0 |
ug.mL-1 |
Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Influenza A virus |
EC50 |
= |
9.0 |
ug.mL-1 |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Influenza B virus |
EC50 |
= |
9.0 |
ug.mL-1 |
Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Influenza A virus |
EC50 |
= |
12.9 |
ug.mL-1 |
Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay |
CHEMBL1287642 |
| Vesicular stomatitis virus |
EC50 |
= |
22.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Respiratory syncytial virus |
EC50 |
= |
22.0 |
ug.mL-1 |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Vesicular stomatitis virus |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Human parainfluenza virus 3 |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against Para influenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Punta Toro virus |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Human coxsackievirus B4 |
EC50 |
= |
146.0 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Vero |
Activity |
> |
250.0 |
ug ml-1 |
Cytotoxicity against african green monkey Vero cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days |
CHEMBL1287642 |
| MDCK |
CC50 |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against MDCK cells by MTS assay |
CHEMBL1287642 |
| MDCK |
Activity |
> |
100.0 |
ug ml-1 |
Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days |
CHEMBL1287642 |
| HEL |
Activity |
> |
250.0 |
ug ml-1 |
Cytotoxicity against human HEL cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days |
CHEMBL1287642 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Human herpesvirus 2 strain G |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Vaccinia virus |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Sindbis virus |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| Human coxsackievirus B4 |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days |
CHEMBL1287642 |
| HeLa |
Activity |
> |
250.0 |
ug ml-1 |
Cytotoxicity against human HeLa cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days |
CHEMBL1287642 |
| Prelamin-A/C |
Potency |
= |
4.0 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
8912.5 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7. (Class of assay: confirmatory) [Related PubChem assays: 1815 (Assay for Plasmodium falciparum line 7G8), 1816 (Assay for Plasmodium falciparum line GB4), 1828 (Summary assay)] |
CHEMBL1201862 |
| Survival motor neuron protein |
Potency |
= |
22387.2 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Survival motor neuron protein |
Potency |
= |
19952.6 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Thyroid stimulating hormone receptor |
Potency |
= |
15848.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
2818.4 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2. (Class of assay: confirmatory) [Related PubChem assays: 1815 (Assay for Plasmodium falciparum line 7G8), 1877 (Assay for Plasmodium falciparum line D10), 1816 (Assay for Plasmodium falciparum line GB4), 1876 (Assay for Plasmodium falciparum line 7D3), 1828 (Summary assay)] |
CHEMBL1201862 |
| Aldehyde dehydrogenase 1A1 |
Potency |
= |
25118.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
14125.4 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Peripheral myelin protein 22 |
Potency |
= |
23934.1 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
Potency |
= |
15848.9 |
nM |
PUBCHEM_BIOASSAY: qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Lymphoblastoid cells |
Potency |
= |
39810.7 |
nM |
PUBCHEM_BIOASSAY: Cell Viability - LYMP1-003 - Assay at 40 hr. CellTiter-Glo luminescent cell viability assay (Promega), as a homogeneous method to measure the number of viable cells in culture was used. The end point readout of this assay is based on quantitation of intracellular ATP, an indicator of metabolic activity, using the luciferase reaction. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Thyroid stimulating hormone receptor |
Potency |
= |
15848.9 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Muscarinic acetylcholine receptor M1 |
Potency |
= |
50.1 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Thrombopoietin |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 918 ] |
CHEMBL1201862 |
| Alpha-galactosidase A |
Potency |
= |
50118.7 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate. (Class of assay: confirmatory) [Related pubchem assays: 1472, 1467 ] |
CHEMBL1201862 |
| Lymphoblastoid cells |
Potency |
= |
79432.8 |
nM |
PUBCHEM_BIOASSAY: Cell Viability - LYMP2-014. Luminescent cell viability assay, measuring the amount of cellular ATP in the cell line following compound treatment for 24 hours (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
Potency |
= |
794.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Activators of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] |
CHEMBL1201862 |
| Lymphoblastoid cells |
Potency |
= |
31622.8 |
nM |
PUBCHEM_BIOASSAY: Cell Viability - LYMP2-019. CellTiter-Glo luminescent cell viability assay (Promega), as a homogeneous method to measure the number of viable cells in culture was used. The end point readout of this assay is based on quantitation of intracellular ATP, an indicator of metabolic activity, using the luciferase reaction. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cytochrome P450 3A4 |
Potency |
= |
794.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4. (Class of assay: confirmatory) [Related pubchem assays: 410 ] |
CHEMBL1201862 |
| Lymphoblastoid cells |
Potency |
= |
25118.9 |
nM |
PUBCHEM_BIOASSAY: Cell Viability - LYMP2-006. Luminescent cell viability assay, measuring the amount of cellular ATP in the cell line following compound treatment for 24 hours (Class of assay: confirmatory) |
CHEMBL1201862 |
| Thrombopoietin |
Potency |
= |
12589.3 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway. (Class of assay: confirmatory) [Related pubchem assays: 917 ] |
CHEMBL1201862 |
| ADMET |
MRT |
= |
45.0 |
hr |
Mean residence time in human after iv administration |
CHEMBL1614632 |
| ADMET |
T1/2 |
= |
45.0 |
hr |
Half life in human after iv administration |
CHEMBL1614632 |
| NON-PROTEIN TARGET |
Fu |
= |
1.0 |
|
Fraction unbound in human after iv administration |
CHEMBL1614632 |
| ADMET |
CL |
= |
5.2 |
mL.min-1.kg-1 |
Clearance in human after iv administration |
CHEMBL1614632 |
| ADMET |
Vdss |
= |
14.0 |
L.kg-1 |
Volume of distribution at steady state in human after iv administration |
CHEMBL1614632 |
| NON-PROTEIN TARGET |
EC50 |
= |
28000.0 |
nM |
Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis |
CHEMBL1629577 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay |
CHEMBL1629577 |
| NON-PROTEIN TARGET |
EC50 |
|
|
|
Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay |
CHEMBL1629577 |
| Vero |
CC50 |
> |
4100000.0 |
nM |
Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay |
CHEMBL1629577 |
| NON-PROTEIN TARGET |
EC90 |
= |
690.0 |
uM |
Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as reduction in virus yield |
CHEMBL1629577 |
| Unchecked |
Selectivity Index |
> |
6.0 |
|
Selectivity index, ratio of CC50 for African green monkey vero cells to EC90 for Yellow fever virus 17D |
CHEMBL1629577 |
| Yellow fever virus |
Activity |
|
|
|
Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum survival of animal at 50 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection |
CHEMBL1629577 |
| Yellow fever virus |
TIME |
> |
504.0 |
hr |
Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 50 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control |
CHEMBL1629577 |
| Yellow fever virus |
Activity |
= |
103.0 |
IU/L |
Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 10 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection |
CHEMBL1629577 |
| Syrian golden hamster |
Activity |
= |
2.4 |
g |
Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 10 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control |
CHEMBL1629577 |
| Vaccinia virus |
EC50 |
= |
10.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Human herpesvirus 2 strain G |
EC50 |
= |
2.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
1.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| HEL |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against human HEL cells assessed as altered cell morphology |
CHEMBL1629526 |
| Vesicular stomatitis virus |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Human herpesvirus 1 strain KOS |
EC50 |
= |
2.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| HeLa |
CC50 |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells assessed as cell viability by MTS assay |
CHEMBL1629526 |
| HeLa |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells assessed as altered cell morphology |
CHEMBL1629526 |
| Vesicular stomatitis virus |
EC50 |
= |
10.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE |
CHEMBL1629526 |
| Vesicular stomatitis virus |
EC50 |
= |
3.6 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Human coxsackievirus B4 |
EC50 |
= |
50.0 |
ug.mL-1 |
Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE |
CHEMBL1629526 |
| Human coxsackievirus B4 |
EC50 |
= |
14.0 |
ug.mL-1 |
Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Respiratory syncytial virus |
EC50 |
= |
6.0 |
ug.mL-1 |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE |
CHEMBL1629526 |
| Respiratory syncytial virus |
EC50 |
= |
2.8 |
ug.mL-1 |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| MDCK |
CC50 |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against MDCK cells assessed as cell viability by MTS assay |
CHEMBL1629526 |
| MDCK |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against MDCK cells assessed as altered cell morphology |
CHEMBL1629526 |
| Influenza A virus |
EC50 |
= |
9.0 |
ug.mL-1 |
Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE |
CHEMBL1629526 |
| Influenza A virus |
EC50 |
= |
12.0 |
ug.mL-1 |
Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Influenza A virus |
EC50 |
= |
9.0 |
ug.mL-1 |
Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE |
CHEMBL1629526 |
| Influenza A virus |
EC50 |
= |
8.4 |
ug.mL-1 |
Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Influenza B virus |
EC50 |
= |
7.0 |
ug.mL-1 |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE |
CHEMBL1629526 |
| Influenza B virus |
EC50 |
= |
4.3 |
ug.mL-1 |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Vero |
MCC |
> |
250.0 |
ug.mL-1 |
Cytotoxicity against african green monkey Vero cells assessed as altered cell morphology |
CHEMBL1629526 |
| Human parainfluenza virus 3 |
EC50 |
= |
95.0 |
ug.mL-1 |
Antiviral activity against parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
112.0 |
ug.mL-1 |
Antiviral activity against Reovirus 1 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Sindbis virus |
EC50 |
> |
250.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Human coxsackievirus B4 |
EC50 |
= |
250.0 |
ug.mL-1 |
Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Punta Toro virus |
EC50 |
= |
112.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay |
CHEMBL1629526 |
| Glycogen synthase kinase-3 beta |
IC50 |
|
|
|
Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method |
CHEMBL1629446 |
| Glycogen synthase kinase-3 beta |
Inhibition |
= |
33.3 |
% |
Inhibition of recombinant GSK3-beta at 10 uM by Z'-LYTE kinase assay kit method |
CHEMBL1629446 |
| Cyclin-dependent kinase 2 |
Inhibition |
|
|
% |
Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method |
CHEMBL1629446 |
| Tobacco mosaic virus |
Activity |
= |
39.0 |
% |
Antiviral activity against Tobacco mosaic virus after 72 hrs by half-leaf juice rubbing method |
CHEMBL1641422 |
| Hepatitis C virus |
Inhibition |
|
|
% |
Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 2 passages at 30 ug/ml by quantitative RT-PCR |
CHEMBL1649126 |
| Hepatitis C virus |
Inhibition |
|
|
% |
Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 3 passages at 30 ug/ml by quantitative RT-PCR |
CHEMBL1649126 |
| Junin virus |
EC50 |
= |
18500.0 |
nM |
Antiviral activity against Junin virus IV4454 infected in african green monkey Vero cells assessed as reduction in virus yield after 48 hrs by plaque assay |
CHEMBL1649388 |
| Vero |
IC50 |
> |
400000.0 |
nM |
Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay |
CHEMBL1649388 |
| Unchecked |
Selectivity Index |
> |
21.6 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Junin virus IV4454 infected in african green monkey Vero cells |
CHEMBL1649388 |
| Human herpesvirus 5 strain AD169 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Human herpesvirus 5 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Human herpesvirus 2 strain G |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL1667805 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells after 3 days by coulter counter analysis |
CHEMBL1667805 |
| HEL |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells after 3 days by coulter counter analysis |
CHEMBL1667805 |
| Influenza A virus |
EC50 |
= |
19670.0 |
nM |
Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain |
CHEMBL1671691 |
| Influenza A virus |
EC50 |
= |
4920.0 |
nM |
Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain |
CHEMBL1671691 |
| Influenza A virus |
EC50 |
= |
35600.0 |
nM |
Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain |
CHEMBL1671691 |
| Influenza A virus |
EC50 |
= |
46700.0 |
nM |
Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain |
CHEMBL1671691 |
| Influenza A virus |
EC50 |
= |
20920.0 |
nM |
Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain |
CHEMBL1671691 |
| NON-PROTEIN TARGET |
EC50 |
= |
13930.0 |
nM |
Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain |
CHEMBL1671691 |
| NON-PROTEIN TARGET |
EC50 |
= |
25000.0 |
nM |
Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain |
CHEMBL1671691 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset |
CHEMBL1697692 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Human drug-induced liver injury (DILI) modelling dataset from Ekins et al |
CHEMBL1697723 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents |
CHEMBL1697731 |
| Hepatotoxicity |
Hepatotoxicity |
|
|
|
Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents |
CHEMBL1697731 |
| Hepatotoxicity |
Composite Activity - Score |
|
|
|
FDA HLAED, liver enzyme composite activity |
CHEMBL1697781 |
| Hepatotoxicity |
Composite Activity - Active |
= |
0.0 |
|
FDA HLAED, liver enzyme composite activity |
CHEMBL1697781 |
| Hepatotoxicity |
Composite Activity - Marginal |
= |
0.0 |
|
FDA HLAED, liver enzyme composite activity |
CHEMBL1697781 |
| Hepatotoxicity |
Alkaline Phosphatase Increase - Activity Score |
|
|
|
FDA HLAED, alkaline phosphatase increase |
CHEMBL1697781 |
| Hepatotoxicity |
Alkaline Phosphatase Increase - Index Value |
= |
0.0 |
|
FDA HLAED, alkaline phosphatase increase |
CHEMBL1697781 |
| Hepatotoxicity |
Alkaline Phosphatase Increase - Number of Reports |
< |
4.0 |
|
FDA HLAED, alkaline phosphatase increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGOT Increase - Activity Score |
|
|
|
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGOT Increase - Index Value |
= |
0.0 |
|
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGOT Increase - Number of Reports |
< |
4.0 |
|
FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGPT Increase - Activity Score |
|
|
|
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGPT Increase - Index Value |
= |
0.0 |
|
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
SGPT Increase - Number of Reports |
< |
4.0 |
|
FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
LDH Increase - Activity Score |
|
|
|
FDA HLAED, lactate dehydrogenase (LDH) increase |
CHEMBL1697781 |
| Hepatotoxicity |
LDH Increase - Index Value |
= |
0.0 |
|
FDA HLAED, lactate dehydrogenase (LDH) increase |
CHEMBL1697781 |
| Hepatotoxicity |
LDH Increase - Number of Reports |
< |
4.0 |
|
FDA HLAED, lactate dehydrogenase (LDH) increase |
CHEMBL1697781 |
| Hepatotoxicity |
GGT Increase - Activity Score |
|
|
|
FDA HLAED, gamma-glutamyl transferase (GGT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
GGT Increase - Index Value |
= |
0.0 |
|
FDA HLAED, gamma-glutamyl transferase (GGT) increase |
CHEMBL1697781 |
| Hepatotoxicity |
GGT Increase - Number of Reports |
< |
4.0 |
|
FDA HLAED, gamma-glutamyl transferase (GGT) increase |
CHEMBL1697781 |
| Phospholipidosis |
Phospholipidosis |
|
|
|
Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset |
CHEMBL1697821 |
| Nuclear factor erythroid 2-related factor 2 |
Potency |
|
11582.1 |
nM |
PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors: Validation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493163, AID504444, AID504648] |
CHEMBL1201862 |
| Nuclear factor erythroid 2-related factor 2 |
Potency |
|
10322.5 |
nM |
PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
32642.7 |
nM |
PUBCHEM_BIOASSAY: qHTS Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID485345, AID485355] |
CHEMBL1201862 |
| Plasmodium falciparum |
Potency |
|
18526.0 |
nM |
PUBCHEM_BIOASSAY: Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774] |
CHEMBL1201862 |
| Vero |
TC50 |
= |
8190.0 |
uM |
Cytotoxicity against african green monkey Vero cells |
CHEMBL1765049 |
| Human coxsackievirus B3 |
IC50 |
= |
1690000.0 |
nM |
Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method |
CHEMBL1765049 |
| Unchecked |
Selectivity Index |
= |
4.9 |
|
Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B3 |
CHEMBL1765049 |
| Coxsackievirus A16 |
IC50 |
= |
4090000.0 |
nM |
Antiviral activity against Coxsackievirus A16 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method |
CHEMBL1765049 |
| Unchecked |
Selectivity Index |
= |
2.0 |
|
Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus A16 |
CHEMBL1765049 |
| Human coxsackievirus B6 |
IC50 |
= |
910000.0 |
nM |
Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method |
CHEMBL1765049 |
| Unchecked |
Selectivity Index |
= |
9.0 |
|
Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B6 |
CHEMBL1765049 |
| Human enterovirus 71 |
IC50 |
= |
2340000.0 |
nM |
Antiviral activity against Human enterovirus 71 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method |
CHEMBL1765049 |
| Unchecked |
Selectivity Index |
= |
3.9 |
|
Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Human enterovirus 71 |
CHEMBL1765049 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
|
Antiviral activity against HIV 1 3B infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy |
CHEMBL1811861 |
| Human immunodeficiency virus type 2 (ISOLATE ROD) |
EC50 |
|
|
|
Antiviral activity against HIV 2 ROD infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy |
CHEMBL1811861 |
| Vesicular stomatitis virus |
EC50 |
|
|
|
Antiviral activity against VSV infected in HEL cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Vesicular stomatitis virus |
EC50 |
= |
14800.0 |
nM |
Antiviral activity against VSV infected in HeLa cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Respiratory syncytial virus |
EC50 |
= |
3000.0 |
nM |
Antiviral activity against RSV infected in HeLa cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human coxsackievirus B4 |
EC50 |
= |
69000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in HeLa cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Human parainfluenza virus 3 |
EC50 |
= |
121000.0 |
nM |
Antiviral activity against Parainfluenza virus 3 infected in Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Mammalian orthoreovirus 1 |
EC50 |
>= |
174000.0 |
nM |
Antiviral activity against Mammalian orthoreovirus 1 infected in Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Punta Toro virus |
EC50 |
= |
125000.0 |
nM |
Antiviral activity against Punta Toro virus infected in Vero cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Feline coronavirus |
EC50 |
|
|
|
Antiviral activity against Feline coronavirus infected in CRFK cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Influenza A virus |
EC50 |
= |
9800.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Influenza A virus |
EC50 |
= |
12500.0 |
nM |
Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Influenza B virus |
EC50 |
= |
7300.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity |
CHEMBL1811861 |
| Vero |
MCC |
|
|
|
Cytotoxicity against african green monkey Vero cells assessed as alteration of cell morphology after 3 days by microscopy |
CHEMBL1811861 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as alteration of cell morphology after 3 days by microscopy |
CHEMBL1811861 |
| HeLa |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis |
CHEMBL1811861 |
| CCRF-CEM |
CC50 |
|
|
|
Cytotoxicity against human CEM cells assessed as growth inhibition after 3 days by coulter counting analysis |
CHEMBL1811861 |
| Influenza A virus |
IC50 |
= |
100800.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as compound concentration required for inhibiting influenza virus yield at 48 h post-infection by crystal violet staining based CPE inhibition assay |
CHEMBL1821623 |
| Vero |
TC50 |
= |
8190.0 |
uM |
Cytotoxicity against african green monkey Vero cells infected with Coxsackievirus B3 assessed as growth inhibition after 48 hrs by Reed-Muench analysis |
CHEMBL1833964 |
| Vero |
TC50 |
= |
8190.0 |
uM |
Cytotoxicity against african green monkey Vero cells infected with Enterovirus 71 assessed as growth inhibition after 48 hrs by Reed-Muench analysis |
CHEMBL1833964 |
| Human enterovirus 71 |
IC50 |
= |
2119000.0 |
nM |
Antiviral activity against Enterovirus 71 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis |
CHEMBL1833964 |
| Human coxsackievirus B3 |
IC50 |
= |
910000.0 |
nM |
Antiviral activity against Coxsackievirus B3 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis |
CHEMBL1833964 |
| Unchecked |
Selectivity Index |
= |
9.0 |
|
Selectivity index, ratio of TC50 for african green monkey vero cells to IC50 for Coxsackievirus B3 |
CHEMBL1833964 |
| Unchecked |
Selectivity Index |
= |
3.9 |
|
Selectivity index, ratio of TC50 for african green monkey vero cells to IC50 for Enterovirus 71 |
CHEMBL1833964 |
| Ataxin-2 |
Potency |
|
31622.8 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of ATXN expression: Validation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588349, AID588380] |
CHEMBL1201862 |
| Plasmodium falciparum |
Potency |
|
2078.7 |
nM |
PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] |
CHEMBL1201862 |
| Bile acid receptor FXR |
Potency |
|
31622.8 |
nM |
PUBCHEM_BIOASSAY: qHTS assay for small molecule antagonists of farnesoid X receptor signaling. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Chromobox protein homolog 1 |
Potency |
|
89125.1 |
nM |
PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] |
CHEMBL1201862 |
| Peroxisome proliferator-activated receptor gamma |
Potency |
|
50118.7 |
nM |
PUBCHEM_BIOASSAY: qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
7079.5 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of Cell Surface uPA Generation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493178] |
CHEMBL1201862 |
| HEK293 |
Potency |
|
23099.9 |
nM |
PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
1000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
20587.8 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
1000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
20587.8 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
20587.8 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Unchecked |
Potency |
|
1000.0 |
nM |
PUBCHEM_BIOASSAY: qHTS for inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249, AID540278] |
CHEMBL1201862 |
| Acetylcholinesterase |
IC50 |
|
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) |
CHEMBL1909046 |
| Acetylcholinesterase |
Ki |
|
|
|
DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine) |
CHEMBL1909046 |
| Adenosine A1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) |
CHEMBL1909046 |
| Adenosine A1 receptor |
Ki |
|
|
|
DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX) |
CHEMBL1909046 |
| Adenosine A2a receptor |
IC50 |
|
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Adenosine A2a receptor |
Ki |
|
|
|
DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Adenosine A3 receptor |
IC50 |
|
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Adenosine A3 receptor |
Ki |
|
|
|
DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine) |
CHEMBL1909046 |
| Alpha-1a adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1a adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1b adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1b adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1d adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-1d adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin) |
CHEMBL1909046 |
| Alpha-2a adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) |
CHEMBL1909046 |
| Alpha-2a adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912) |
CHEMBL1909046 |
| Alpha-2b adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) |
CHEMBL1909046 |
| Alpha-2b adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine) |
CHEMBL1909046 |
| Alpha-2c adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) |
CHEMBL1909046 |
| Alpha-2c adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912) |
CHEMBL1909046 |
| Beta-1 adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Beta-1 adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Beta-2 adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) |
CHEMBL1909046 |
| Beta-2 adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177) |
CHEMBL1909046 |
| Beta-3 adrenergic receptor |
IC50 |
|
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Beta-3 adrenergic receptor |
Ki |
|
|
|
DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Norepinephrine transporter |
IC50 |
|
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Norepinephrine transporter |
Ki |
|
|
|
DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Aldose reductase |
IC50 |
|
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) |
CHEMBL1909046 |
| Aldose reductase |
Ki |
|
|
|
DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde) |
CHEMBL1909046 |
| Angiotensin II type 2 (AT-2) receptor |
IC50 |
|
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) |
CHEMBL1909046 |
| Angiotensin II type 2 (AT-2) receptor |
Ki |
|
|
|
DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin) |
CHEMBL1909046 |
| Bradykinin B2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) |
CHEMBL1909046 |
| Bradykinin B2 receptor |
Ki |
|
|
|
DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin) |
CHEMBL1909046 |
| Calcitonin receptor |
IC50 |
|
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) |
CHEMBL1909046 |
| Calcitonin receptor |
Ki |
|
|
|
DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888)) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888)) |
CHEMBL1909046 |
| Cannabinoid CB1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) |
CHEMBL1909046 |
| Cannabinoid CB1 receptor |
Ki |
|
|
|
DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A) |
CHEMBL1909046 |
| Carbonic anhydrase II |
IC50 |
|
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) |
CHEMBL1909046 |
| Carbonic anhydrase II |
Ki |
|
|
|
DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)) |
CHEMBL1909046 |
| C-C chemokine receptor type 2 |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) |
CHEMBL1909046 |
| C-C chemokine receptor type 2 |
Ki |
|
|
|
DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1) |
CHEMBL1909046 |
| C-C chemokine receptor type 4 |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) |
CHEMBL1909046 |
| C-C chemokine receptor type 4 |
Ki |
|
|
|
DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC) |
CHEMBL1909046 |
| C-C chemokine receptor type 5 |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) |
CHEMBL1909046 |
| C-C chemokine receptor type 5 |
Ki |
|
|
|
DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha) |
CHEMBL1909046 |
| Interleukin-8 receptor A |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A) |
CHEMBL1909046 |
| Interleukin-8 receptor A |
Ki |
|
|
|
DRUGMATRIX: Chemokine CXCR1 (IL-8A) |
CHEMBL1909046 |
| Interleukin-8 receptor B |
IC50 |
|
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) |
CHEMBL1909046 |
| Interleukin-8 receptor B |
Ki |
|
|
|
DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8) |
CHEMBL1909046 |
| Cholecystokinin A receptor |
IC50 |
|
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) |
CHEMBL1909046 |
| Cholecystokinin A receptor |
Ki |
|
|
|
DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718) |
CHEMBL1909046 |
| Cyclooxygenase-1 |
IC50 |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cyclooxygenase-1 |
Ki |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cyclooxygenase-2 |
IC50 |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cyclooxygenase-2 |
Ki |
|
|
|
DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid) |
CHEMBL1909046 |
| Cytochrome P450 1A2 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 1A2 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2A6 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2A6 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C19 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C19 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C9 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2C9 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2D6 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2D6 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2E1 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 2E1 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin) |
CHEMBL1909046 |
| Cytochrome P450 3A4 |
IC50 |
|
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) |
CHEMBL1909046 |
| Cytochrome P450 3A4 |
Ki |
|
|
|
DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin) |
CHEMBL1909046 |
| Dopamine D1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) |
CHEMBL1909046 |
| Dopamine D1 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390) |
CHEMBL1909046 |
| Dopamine D2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D2 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D3 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D3 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D4 receptor |
IC50 |
|
|
|
DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine D4 receptor |
Ki |
|
|
|
DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone) |
CHEMBL1909046 |
| Dopamine transporter |
IC50 |
|
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Dopamine transporter |
Ki |
|
|
|
DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55) |
CHEMBL1909046 |
| Endothelin receptor ET-A |
IC50 |
|
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) |
CHEMBL1909046 |
| Endothelin receptor ET-A |
Ki |
|
|
|
DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1) |
CHEMBL1909046 |
| Estrogen receptor alpha |
IC50 |
|
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Estrogen receptor alpha |
Ki |
|
|
|
DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Estrogen receptor beta |
IC50 |
|
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Estrogen receptor beta |
Ki |
|
|
|
DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB) |
CHEMBL1909046 |
| Glucocorticoid receptor |
IC50 |
|
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) |
CHEMBL1909046 |
| Glucocorticoid receptor |
Ki |
|
|
|
DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP) |
CHEMBL1909046 |
| Glycine receptor |
IC50 |
|
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) |
CHEMBL1909046 |
| Glycine receptor |
Ki |
|
|
|
DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine) |
CHEMBL1909046 |
| Histamine H1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) |
CHEMBL1909046 |
| Histamine H1 receptor |
Ki |
|
|
|
DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine) |
CHEMBL1909046 |
| Histamine H2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) |
CHEMBL1909046 |
| Histamine H2 receptor |
Ki |
|
|
|
DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine) |
CHEMBL1909046 |
| HMG-CoA reductase |
IC50 |
|
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) |
CHEMBL1909046 |
| HMG-CoA reductase |
Ki |
|
|
|
DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan) |
CHEMBL1909046 |
| Insulin receptor |
IC50 |
|
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) |
CHEMBL1909046 |
| Insulin receptor |
Ki |
|
|
|
DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4) |
CHEMBL1909046 |
| Leukotriene C4 synthase |
IC50 |
|
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) |
CHEMBL1909046 |
| Leukotriene C4 synthase |
Ki |
|
|
|
DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4) |
CHEMBL1909046 |
| Cysteinyl leukotriene receptor 1 |
IC50 |
|
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) |
CHEMBL1909046 |
| Cysteinyl leukotriene receptor 1 |
Ki |
|
|
|
DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4) |
CHEMBL1909046 |
| Arachidonate 15-lipoxygenase |
IC50 |
|
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) |
CHEMBL1909046 |
| Arachidonate 15-lipoxygenase |
Ki |
|
|
|
DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid) |
CHEMBL1909046 |
| Melanocortin receptor 3 |
IC50 |
|
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 3 |
Ki |
|
|
|
DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 4 |
IC50 |
|
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 4 |
Ki |
|
|
|
DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 5 |
IC50 |
|
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Melanocortin receptor 5 |
Ki |
|
|
|
DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH) |
CHEMBL1909046 |
| Monoamine oxidase A |
IC50 |
|
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) |
CHEMBL1909046 |
| Monoamine oxidase A |
Ki |
|
|
|
DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M1 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M1 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M2 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M2 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M3 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M3 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M4 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M4 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M5 |
IC50 |
|
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Muscarinic acetylcholine receptor M5 |
Ki |
|
|
|
DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 1 |
IC50 |
|
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 1 |
Ki |
|
|
|
DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 2 |
IC50 |
|
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Neuropeptide Y receptor type 2 |
Ki |
|
|
|
DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine) |
CHEMBL1909046 |
| Nitric-oxide synthase, brain |
IC50 |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) |
CHEMBL1909046 |
| Nitric-oxide synthase, brain |
Ki |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine) |
CHEMBL1909046 |
| Nitric oxide synthase, inducible |
IC50 |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) |
CHEMBL1909046 |
| Nitric oxide synthase, inducible |
Ki |
|
|
|
DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine) |
CHEMBL1909046 |
| Delta opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) |
CHEMBL1909046 |
| Delta opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole) |
CHEMBL1909046 |
| Kappa opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Kappa opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Mu opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Mu opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP) |
CHEMBL1909046 |
| Phosphodiesterase 5A |
IC50 |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) |
CHEMBL1909046 |
| Phosphodiesterase 5A |
Ki |
|
|
|
DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP) |
CHEMBL1909046 |
| Platelet activating factor receptor |
IC50 |
|
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) |
CHEMBL1909046 |
| Platelet activating factor receptor |
Ki |
|
|
|
DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide) |
CHEMBL1909046 |
| HERG |
IC50 |
|
|
|
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) |
CHEMBL1909046 |
| HERG |
Ki |
|
|
|
DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole) |
CHEMBL1909046 |
| Progesterone receptor |
IC50 |
|
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) |
CHEMBL1909046 |
| Progesterone receptor |
Ki |
|
|
|
DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020) |
CHEMBL1909046 |
| Angiotensin-converting enzyme |
IC50 |
|
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) |
CHEMBL1909046 |
| Angiotensin-converting enzyme |
Ki |
|
|
|
DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG) |
CHEMBL1909046 |
| Caspase-1 |
IC50 |
|
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) |
CHEMBL1909046 |
| Caspase-1 |
Ki |
|
|
|
DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC) |
CHEMBL1909046 |
| Cathepsin G |
IC50 |
|
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) |
CHEMBL1909046 |
| Cathepsin G |
Ki |
|
|
|
DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC) |
CHEMBL1909046 |
| Leukocyte elastase |
IC50 |
|
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) |
CHEMBL1909046 |
| Leukocyte elastase |
Ki |
|
|
|
DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA) |
CHEMBL1909046 |
| Matrix metalloproteinase-1 |
IC50 |
|
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Matrix metalloproteinase-1 |
Ki |
|
|
|
DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Matrix metalloproteinase 9 |
IC50 |
|
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Matrix metalloproteinase 9 |
Ki |
|
|
|
DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2) |
CHEMBL1909046 |
| Protein kinase C alpha |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) |
CHEMBL1909046 |
| Protein kinase C alpha |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone) |
CHEMBL1909046 |
| MAP kinase ERK1 |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase ERK1 |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase ERK2 |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase ERK2 |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase p38 alpha |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| MAP kinase p38 alpha |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein) |
CHEMBL1909046 |
| Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform |
IC50 |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Serine/threonine protein phosphatase 2B catalytic subunit, alpha isoform |
Ki |
|
|
|
DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Epidermal growth factor receptor erbB1 |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Epidermal growth factor receptor erbB1 |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase FYN |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase FYN |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Receptor protein-tyrosine kinase erbB-2 |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Receptor protein-tyrosine kinase erbB-2 |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase LCK |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Tyrosine-protein kinase LCK |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr)) |
CHEMBL1909046 |
| Leukocyte common antigen |
IC50 |
|
|
|
DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Leukocyte common antigen |
Ki |
|
|
|
DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP) |
CHEMBL1909046 |
| Serotonin 1a (5-HT1a) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) |
CHEMBL1909046 |
| Serotonin 1a (5-HT1a) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT) |
CHEMBL1909046 |
| Serotonin 1b (5-HT1b) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Serotonin 1b (5-HT1b) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol) |
CHEMBL1909046 |
| Serotonin 2a (5-HT2a) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) |
CHEMBL1909046 |
| Serotonin 2a (5-HT2a) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin) |
CHEMBL1909046 |
| Serotonin 2b (5-HT2b) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin 2b (5-HT2b) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin 2c (5-HT2c) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) |
CHEMBL1909046 |
| Serotonin 2c (5-HT2c) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630) |
CHEMBL1909046 |
| Serotonin 4 (5-HT4) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) |
CHEMBL1909046 |
| Serotonin 4 (5-HT4) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808) |
CHEMBL1909046 |
| Serotonin 6 (5-HT6) receptor |
IC50 |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin 6 (5-HT6) receptor |
Ki |
|
|
|
DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide) |
CHEMBL1909046 |
| Serotonin transporter |
IC50 |
|
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) |
CHEMBL1909046 |
| Serotonin transporter |
Ki |
|
|
|
DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine) |
CHEMBL1909046 |
| Sigma opioid receptor |
IC50 |
|
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) |
CHEMBL1909046 |
| Sigma opioid receptor |
Ki |
|
|
|
DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin) |
CHEMBL1909046 |
| Neurokinin 1 receptor |
IC50 |
|
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) |
CHEMBL1909046 |
| Neurokinin 1 receptor |
Ki |
|
|
|
DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P) |
CHEMBL1909046 |
| Neurokinin 2 receptor |
IC50 |
|
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) |
CHEMBL1909046 |
| Neurokinin 2 receptor |
Ki |
|
|
|
DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968) |
CHEMBL1909046 |
| Androgen Receptor |
IC50 |
|
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) |
CHEMBL1909046 |
| Androgen Receptor |
Ki |
|
|
|
DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone) |
CHEMBL1909046 |
| Thromboxane-A synthase |
IC50 |
|
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) |
CHEMBL1909046 |
| Thromboxane-A synthase |
Ki |
|
|
|
DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2) |
CHEMBL1909046 |
| Unchecked |
IC50 |
|
|
|
DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) |
CHEMBL1909046 |
| Unchecked |
Ki |
|
|
|
DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha) |
CHEMBL1909046 |
| Vascular endothelial growth factor receptor 1 |
IC50 |
|
|
|
DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) |
CHEMBL1909046 |
| Vascular endothelial growth factor receptor 1 |
Ki |
|
|
|
DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF) |
CHEMBL1909046 |
| Vasoactive intestinal polypeptide receptor 1 |
IC50 |
|
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) |
CHEMBL1909046 |
| Vasoactive intestinal polypeptide receptor 1 |
Ki |
|
|
|
DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP) |
CHEMBL1909046 |
| Vasopressin V1a receptor |
IC50 |
|
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) |
CHEMBL1909046 |
| Vasopressin V1a receptor |
Ki |
|
|
|
DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr) |
CHEMBL1909046 |
| Hepatotoxicity |
LTKB_BD DILI severity score |
= |
7.0 |
|
FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI |
CHEMBL1909281 |
| Hepatotoxicity |
HepSE_bilirubinemia |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_cholecystitis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_cholelithiasis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_cirrhosis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_elevated liver function tests |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatic failure |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatic necrosis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatitis |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_hepatomegaly |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_jaundice |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_liver disease |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_liver fatty |
= |
1.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_liver function tests abnormal |
= |
0.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal |
CHEMBL1909294 |
| Hepatotoxicity |
HepSE_Combined Scores |
= |
4.0 |
|
Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score |
CHEMBL1909294 |
| ADMET |
Ratio CC50/EC50 |
= |
2.3 |
|
Therapeutic index, ratio of CC50 for human HuH7 cells infected with HCV1b to EC50 for HCV genotype 1b |
CHEMBL1926658 |
| Hepatitis C virus |
EC50 |
= |
14000.0 |
nM |
Antiviral activity against HCV genotype 1b infected in human HuH7 cells after 3 days by renilla luciferase reporter assay |
CHEMBL1926658 |
| Huh-7 |
CC50 |
= |
32000.0 |
nM |
Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay |
CHEMBL1926658 |
| Hepatitis C virus |
Activity |
|
|
|
Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction in luciferase activity at 10 uM after 3 days |
CHEMBL1926658 |
| Huh-7 |
Activity |
|
|
|
Cytotoxicity against human HuH7 cells infected with HCV1b assessed as cell viability at 10 uM after 3 days by MTS assay |
CHEMBL1926658 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 2 strain G |
Activity |
|
|
|
Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 1 strain KOS |
Activity |
|
|
|
Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Vaccinia virus |
Activity |
|
|
|
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 5 strain AD169 |
Activity |
|
|
|
Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 5 |
Activity |
|
|
|
Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| NON-PROTEIN TARGET |
Activity |
|
|
|
Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human herpesvirus 3 |
Activity |
|
|
|
Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human parainfluenza virus 3 |
Activity |
|
|
|
Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Mammalian orthoreovirus 1 |
Activity |
|
|
|
Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Sindbis virus |
Activity |
|
|
|
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human coxsackievirus B4 |
Activity |
|
|
|
Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Punta Toro virus |
Activity |
|
|
|
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human coxsackievirus B4 |
Activity |
|
|
|
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Influenza B virus |
Activity |
|
|
|
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Felid herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Feline coronavirus |
Activity |
|
|
|
Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM |
CHEMBL1926651 |
| Human immunodeficiency virus 1 |
Activity |
|
|
|
Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL1926651 |
| Human immunodeficiency virus 2 |
Activity |
|
|
|
Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL1926651 |
| Influenza A virus |
IC50 |
= |
1900.0 |
nM |
Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs |
CHEMBL1955749 |
| Influenza A virus |
IC50 |
= |
3900.0 |
nM |
Antiinfluenza activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs |
CHEMBL1955749 |
| Influenza B virus |
IC50 |
= |
14700.0 |
nM |
Antiinfluenza activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs |
CHEMBL1955749 |
| MDCK |
TC50 |
= |
1278.0 |
uM |
Cytotoxicity against MDCK cells |
CHEMBL1955749 |
| Unchecked |
Selectivity Index |
= |
86.9 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for influenza B virus |
CHEMBL1955749 |
| Unchecked |
Selectivity Index |
= |
329.4 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for influenza A virus H3N2 |
CHEMBL1955749 |
| Unchecked |
Selectivity Index |
= |
665.6 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for influenza A virus H1N1 |
CHEMBL1955749 |
| Human enterovirus 71 |
IC50 |
= |
60.0 |
ug.mL-1 |
Antiviral activity against C4 type Human enterovirus 71 FY0805 infected in human RD cells assessed as inhibition of viral replication by plaque reduction assay |
CHEMBL1955845 |
| RD |
CC50 |
|
|
|
Cytotoxicity against human RD cells |
CHEMBL1955845 |
| Human enterovirus 71 |
Activity |
= |
5.0 |
% |
Antiviral activity against C4 type Human enterovirus 71 MP10 infected in ICR mouse assessed as increase in survival rate at 50 mg/kg, ip administered 2 hrs post infection qd for 7 days measured up to 14 days |
CHEMBL1955845 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
114800.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 48 hrs |
CHEMBL2016569 |
| MDCK |
MCC |
= |
20000.0 |
nM |
Cytotoxicity against MDCK cells assessed as morphological changes by microscopic analysis |
CHEMBL2021796 |
| Influenza B virus |
EC50 |
= |
4800.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay |
CHEMBL2021854 |
| Influenza A virus |
EC50 |
= |
5600.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay |
CHEMBL2021854 |
| Influenza A virus |
EC50 |
= |
6700.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay |
CHEMBL2021854 |
| Influenza B virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Influenza A virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Influenza A virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Respiratory syncytial virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Vesicular stomatitis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology |
CHEMBL2021854 |
| Punta Toro virus |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Mammalian orthoreovirus 1 |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Human parainfluenza virus 3 |
EC50 |
= |
29000.0 |
nM |
Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days |
CHEMBL2021854 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against african green monkey Vero cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology |
CHEMBL2021854 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology |
CHEMBL2021854 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay |
CHEMBL2021854 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Human herpesvirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against thymidine kinase-deficient Herpes simplex virus 1 infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Human herpesvirus 2 strain G |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Vesicular stomatitis virus |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Vesicular stomatitis virus |
EC50 |
= |
29000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in HeLa cells |
CHEMBL2021796 |
| Human coxsackievirus B4 |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Coxsackie virus B4 infected in HeLa cells |
CHEMBL2021796 |
| Respiratory syncytial virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in HeLa cells |
CHEMBL2021796 |
| Human immunodeficiency virus 1 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL2021796 |
| Human immunodeficiency virus type 2 (ISOLATE ROD) |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL2021796 |
| Human parainfluenza virus 3 |
EC50 |
= |
85000.0 |
nM |
Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Punta Toro virus |
EC50 |
= |
126000.0 |
nM |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Influenza A virus |
EC50 |
= |
5100.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Influenza A virus |
EC50 |
= |
2300.0 |
nM |
Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| Influenza B virus |
EC50 |
= |
4500.0 |
nM |
Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL2021796 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against HEL cells assessed as morphological changes by microscopic analysis |
CHEMBL2021796 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as morphological changes by microscopic analysis |
CHEMBL2021796 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against african green monkey Vero cells assessed as morphological changes by microscopic analysis |
CHEMBL2021796 |
| Tobacco mosaic virus |
Inhibition |
= |
38.5 |
% |
In vitro antiviral activity against TMV assessed as inhibition rate at 500 ug/mL |
CHEMBL2034979 |
| Tobacco mosaic virus |
Activity |
= |
34.2 |
% |
In vivo antiviral activity against TMV assessed as viral inactivation effect at 500 ug/mL |
CHEMBL2034979 |
| Tobacco mosaic virus |
Activity |
= |
32.7 |
% |
In vivo antiviral activity against TMV assessed as curative effect at 500 ug/mL |
CHEMBL2034979 |
| Tobacco mosaic virus |
Activity |
= |
39.6 |
% |
In vivo antiviral activity against TMV assessed as protection effect at 500 ug/mL |
CHEMBL2034979 |
| Unchecked |
IC50 |
= |
22000.0 |
nM |
Cytostatic activity against mouse L1210/0 after 48 hrs by cell counting |
CHEMBL2034826 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins |
CHEMBL2034826 |
| Unchecked |
IC50 |
= |
1000.0 |
nM |
Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins |
CHEMBL2034826 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins |
CHEMBL2034826 |
| Unchecked |
IC50 |
= |
1000.0 |
nM |
Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins |
CHEMBL2034826 |
| CCRF-CEM |
IC50 |
= |
63000.0 |
nM |
Cytostatic activity against human CEM/0 after 72 hrs by cell counting |
CHEMBL2034826 |
| Tobacco mosaic virus |
Inhibition |
= |
38.5 |
% |
In vitro antiviral activity against TMV at 500 ug/ml |
CHEMBL2040826 |
| Tobacco mosaic virus |
Activity |
= |
34.2 |
% |
In vivo antiviral activity against TMV assessed as inactivation effect at 500 ug/ml |
CHEMBL2040826 |
| Tobacco mosaic virus |
Activity |
= |
32.7 |
% |
In vivo antiviral activity against TMV assessed as curative effect at 500 ug/ml |
CHEMBL2040826 |
| Tobacco mosaic virus |
Activity |
= |
39.6 |
% |
In vivo antiviral activity against TMV assessed as protection effect at 500 ug/ml |
CHEMBL2040826 |
| Hepatitis C virus |
Inhibition |
= |
44.0 |
% |
Antiviral activity at Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication at 10 uM after 3 days by renilla luciferase reporter gene assay |
CHEMBL2057076 |
| Huh-7 |
Activity |
= |
92.0 |
% |
Cytotoxicity against human HuH7 cells assessed as cell viability at 10 uM after 3 days by CellTiter Glo assay |
CHEMBL2057076 |
| MDCK |
TC50 |
= |
4766.8 |
uM |
Cytotoxicity against MDCK cells incubated for 48 hrs by CPE method |
CHEMBL2062433 |
| Influenza A virus |
IC50 |
= |
8800.0 |
nM |
Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2062433 |
| Unchecked |
Selectivity Index |
= |
541.7 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) |
CHEMBL2062433 |
| Influenza B virus |
IC50 |
= |
45500.0 |
nM |
Antiviral activity against Influenza B virus (strain B/Jifang/13/97) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2062433 |
| Unchecked |
Selectivity Index |
= |
103.9 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus (strain B/Jifang/13/97) |
CHEMBL2062433 |
| Influenza A virus |
IC50 |
= |
35300.0 |
nM |
Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2062433 |
| Unchecked |
Selectivity Index |
= |
135.0 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) |
CHEMBL2062433 |
| Cellular tumor antigen p53 |
Potency |
|
31622.8 |
nM |
PubChem BioAssay. qHTS assay for small molecule activators of the p53 signaling pathway. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Geminin |
Potency |
|
183.6 |
nM |
PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Interleukin-8 |
Potency |
|
66824.2 |
nM |
PubChem BioAssay. qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Nuclear receptor ROR-gamma |
Potency |
|
18833.6 |
nM |
PubChem BioAssay. qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway. (Class of assay: confirmatory) |
CHEMBL1201862 |
| NON-PROTEIN TARGET |
EC50 |
= |
4600.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus 1-NADL ATCC VR534 infected in MDBK cells assessed as reduction of viral cytopathic effect after 2 days bt MTS assay |
CHEMBL2146401 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
6800.0 |
nM |
Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay |
CHEMBL2150984 |
| Influenza A virus |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay |
CHEMBL2150984 |
| NON-PROTEIN TARGET |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay |
CHEMBL2150984 |
| MDCK |
MCC |
>= |
20000.0 |
nM |
Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration measured on day 3 post infection by MTS assay |
CHEMBL2150984 |
| Hepatitis C virus |
Inhibition |
= |
50.0 |
% |
Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells at 20 to 50 ug/mL after 2 days by q-PCR analysis |
CHEMBL2150904 |
| Huh-7 |
CC50 |
|
|
|
Cytotoxicity against human HuH7 cells after 2 days by XTT assay |
CHEMBL2150904 |
| Hepatitis C virus |
EC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells after 2 days by q-PCR analysis |
CHEMBL2150904 |
| Hepatitis C virus |
Inhibition |
= |
35.0 |
% |
Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells at 10 ug/mL after 2 days by q-PCR analysis |
CHEMBL2150904 |
| Respiratory syncytial virus |
TIME |
= |
7.0 |
hr |
Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as post infection time duration of protection against virus-induced cytopathogenicity by Cell Titer-Glo assay |
CHEMBL2169872 |
| HEp-2 |
Activity |
= |
90.0 |
% |
Cytotoxicity against uninfected human Hep2 cells assessed as cell viability at 25 uM measured after 144 hrs by Cell Titer-Glo assay |
CHEMBL2169872 |
| Respiratory syncytial virus |
FC |
= |
2.5 |
|
Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as log reduction in virus titer at 25 uM by virus plaque reduction assay |
CHEMBL2169872 |
| Unchecked |
Ratio CC50/EC50 |
= |
3.6 |
|
Selectivity index, ratio of CC50 for human Hep2 cells to EC50 for Respiratory syncytial virus Long infected in human Hep2 cells |
CHEMBL2169872 |
| HEp-2 |
CC50 |
= |
113900.0 |
nM |
Cytotoxicity against human Hep2 cells by Cell Titer-Glo assay |
CHEMBL2169872 |
| Respiratory syncytial virus |
EC50 |
= |
28400.0 |
nM |
Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as reduction in virus-induced cytopathogenicity by Cell Titer-Glo assay |
CHEMBL2169872 |
| MDCK |
CC50 |
>= |
20000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay |
CHEMBL2203037 |
| MDCK |
MCC |
>= |
100000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as cell morphology alterations |
CHEMBL2203037 |
| Influenza A virus |
EC50 |
= |
8800.0 |
nM |
Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis |
CHEMBL2203037 |
| Influenza A virus |
EC50 |
= |
8800.0 |
nM |
Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis |
CHEMBL2203037 |
| Influenza A virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis |
CHEMBL2203037 |
| Influenza A virus |
EC50 |
= |
7600.0 |
nM |
Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis |
CHEMBL2203037 |
| NON-PROTEIN TARGET |
EC50 |
= |
8100.0 |
nM |
Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay |
CHEMBL2203037 |
| NON-PROTEIN TARGET |
EC50 |
= |
8000.0 |
nM |
Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis |
CHEMBL2203037 |
| Influenza A virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay |
CHEMBL2203037 |
| Influenza A virus |
EC50 |
= |
7700.0 |
nM |
Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis |
CHEMBL2203037 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8200.0 |
nM |
Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay |
CHEMBL2203037 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8700.0 |
nM |
Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis |
CHEMBL2203037 |
| Unchecked |
Selectivity Index |
> |
81.0 |
|
Selectivity index, ratio of CTD50 for MDCK cells to ED50 for influenza virus A/California/07/09 (H1N1) pdm09 |
CHEMBL2202980 |
| Influenza A virus |
ED50 |
= |
24.6 |
uM |
Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method |
CHEMBL2202980 |
| MDCK |
CTD50 |
> |
2000.0 |
uM |
Cytotoxicity against MDCK cells after 48 hrs by MTT assay |
CHEMBL2202980 |
| MDCK |
MCC |
= |
100000.0 |
nM |
Toxicity in MDCK cells assessed as induction of cell morphology changes |
CHEMBL2203009 |
| NON-PROTEIN TARGET |
EC50 |
= |
4600.0 |
nM |
Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Influenza A virus |
EC50 |
= |
6000.0 |
nM |
Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
6100.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2203009 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay |
CHEMBL2203281 |
| MDCK |
MCC |
> |
20000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as cell morphology alterations by microscopic analysis |
CHEMBL2203281 |
| NON-PROTEIN TARGET |
EC50 |
= |
140.0 |
nM |
Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay |
CHEMBL2203281 |
| NON-PROTEIN TARGET |
EC50 |
= |
94.0 |
nM |
Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis |
CHEMBL2203281 |
| Influenza A virus |
EC50 |
= |
8500.0 |
nM |
Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay |
CHEMBL2203281 |
| Influenza A virus |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis |
CHEMBL2203281 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8400.0 |
nM |
Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay |
CHEMBL2203281 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis |
CHEMBL2203281 |
| Nicotiana tabacum |
Activity |
|
|
|
Induction of systemic acquired resistance in Nicotiana tabacum (tobacco) mosaic virus infected Nicotiana tabacum (tobacco) plant at 100 ug/mL at 25 degC for 72 hr |
CHEMBL3044632 |
| Tobacco mosaic virus |
Inhibition |
= |
16.7 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) infected leaves assessed as viral inhibition at 50 ug/mL at 25 degC for 72 hr |
CHEMBL3044632 |
| Tobacco mosaic virus |
Inhibition |
= |
21.62 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) infected leaves assessed as viral inhibition at 100 ug/mL at 25 degC for 72 hr |
CHEMBL3044632 |
| Tobacco mosaic virus |
Inhibition |
= |
37.93 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) infected leaves assessed as viral inhibition at 500 ug/mL at 25 degC for 72 hr |
CHEMBL3044632 |
| Tobacco mosaic virus |
Inhibition |
= |
7.5 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana. tabacum L. leaves assessed as protection effect at 100 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days |
CHEMBL3045658 |
| Tobacco mosaic virus |
Inhibition |
= |
38.9 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana. tabacum L. leaves assessed as protection effect at 500 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days |
CHEMBL3045658 |
| Tobacco mosaic virus |
Inhibition |
= |
8.2 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana. tabacum L. leaves assessed as curative effect at 100 ug/mL measured after 3 to 4 days |
CHEMBL3045658 |
| Tobacco mosaic virus |
Inhibition |
= |
36.7 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana. tabacum L. leaves assessed as curative effect at 500 ug/mL measured after 3 to 4 days |
CHEMBL3045658 |
| Tobacco mosaic virus |
Inhibition |
= |
9.8 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana. tabacum L. leaves assessed as inactivation effect at 100 ug/mL co-incubated with virus measured after 3 to 4 days |
CHEMBL3045658 |
| Tobacco mosaic virus |
Inhibition |
= |
33.8 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana. tabacum L. leaves assessed as inactivation effect at 500 ug/mL co-incubated with virus measured after 3 to 4 days |
CHEMBL3045658 |
| Tobacco mosaic virus |
Inhibition |
= |
19.6 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 100 ug/mL at 25 degC after 72 hr by half-leaf method |
CHEMBL3045658 |
| Tobacco mosaic virus |
Inhibition |
= |
41.0 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 500 ug/mL at 25 degC after 72 hr by half-leaf method |
CHEMBL3045658 |
| Tobacco mosaic virus |
Activity |
= |
34.2 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus infection protective effect at 500 ug/mL measured 3 to 4 days post inoculation |
CHEMBL3045023 |
| Tobacco mosaic virus |
Activity |
= |
34.5 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus infection curative effect at 500 ug/mL measured 3 to 4 days post inoculation |
CHEMBL3045023 |
| Tobacco mosaic virus |
Activity |
= |
32.1 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus inactivation effect at 500 ug/mL measured 3 to 4 days post inoculation |
CHEMBL3045023 |
| Tobacco mosaic virus |
GI |
= |
38.5 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) assessed as inhibition of viral growth at 500 ug/mL |
CHEMBL3045023 |
| Nicotiana tabacum |
Activity |
= |
40.0 |
% |
Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 50 ug/ml |
CHEMBL3045927 |
| Nicotiana tabacum |
Activity |
= |
10.0 |
% |
Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 100 ug/ml |
CHEMBL3045927 |
| Tobacco mosaic virus |
Activity |
= |
57.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 100 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge |
CHEMBL3045927 |
| Tobacco mosaic virus |
Activity |
= |
71.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 500 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge |
CHEMBL3045927 |
| Tobacco mosaic virus |
Activity |
= |
14.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 100 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge |
CHEMBL3045927 |
| Tobacco mosaic virus |
Activity |
= |
46.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 500 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge |
CHEMBL3045927 |
| Tobacco mosaic virus |
Activity |
= |
40.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 100 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge |
CHEMBL3045927 |
| Tobacco mosaic virus |
Activity |
= |
44.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 500 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge |
CHEMBL3045927 |
| Tobacco mosaic virus |
Inhibition |
= |
28.0 |
% |
In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 100 ug/ml |
CHEMBL3045927 |
| Tobacco mosaic virus |
Inhibition |
= |
38.0 |
% |
In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 500 ug/ml |
CHEMBL3045927 |
| Nicotiana tabacum |
Activity |
|
|
|
Phytotoxicity against Nicotiana tabacum (tobacco) plant |
CHEMBL3044755 |
| Nicotiana tabacum |
Activity |
= |
31.0 |
% |
Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 50 ug/ml |
CHEMBL3044755 |
| Nicotiana tabacum |
Activity |
= |
28.0 |
% |
Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 100 ug/ml |
CHEMBL3044755 |
| Tobacco mosaic virus |
Activity |
= |
46.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 100 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge |
CHEMBL3044755 |
| Tobacco mosaic virus |
Activity |
= |
59.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 500 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge |
CHEMBL3044755 |
| Tobacco mosaic virus |
Activity |
|
|
|
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 100 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge |
CHEMBL3044755 |
| Tobacco mosaic virus |
Activity |
|
|
|
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 500 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge |
CHEMBL3044755 |
| Tobacco mosaic virus |
Activity |
= |
30.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 100 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge |
CHEMBL3044755 |
| Tobacco mosaic virus |
Activity |
= |
59.0 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 500 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge |
CHEMBL3044755 |
| Tobacco mosaic virus |
Inhibition |
= |
20.0 |
% |
In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 100 ug/ml |
CHEMBL3044755 |
| Tobacco mosaic virus |
Inhibition |
= |
32.0 |
% |
In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 500 ug/ml |
CHEMBL3044755 |
| Respiratory syncytial virus |
EC50 |
= |
15000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected cell system assessed as inhibition of viral replication |
CHEMBL3044857 |
| Tobacco mosaic virus |
Activity |
= |
7.5 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana tabacum L. leaves assessed as protection effect at 100 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days |
CHEMBL3045942 |
| Tobacco mosaic virus |
Activity |
= |
38.9 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana tabacum L. leaves assessed as protection effect at 500 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days |
CHEMBL3045942 |
| Tobacco mosaic virus |
Activity |
= |
8.2 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana tabacum L. leaves assessed as curative effect at 100 ug/mL measured after 3 to 4 days |
CHEMBL3045942 |
| Tobacco mosaic virus |
Activity |
= |
36.7 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana tabacum L. leaves assessed as curative effect at 500 ug/mL measured after 3 to 4 days |
CHEMBL3045942 |
| Tobacco mosaic virus |
Activity |
= |
9.8 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana tabacum L. leaves assessed as inactivation effect at 100 ug/mL co-incubated with virus measured after 3 to 4 days |
CHEMBL3045942 |
| Tobacco mosaic virus |
Activity |
= |
33.8 |
% |
In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana tabacum L. leaves assessed as inactivation effect at 500 ug/mL co-incubated with virus measured after 3 to 4 days |
CHEMBL3045942 |
| Tobacco mosaic virus |
Inhibition |
= |
12.5 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 100 ug/mL at 25 degC after 72 hr by half-leaf method |
CHEMBL3045942 |
| Tobacco mosaic virus |
Inhibition |
= |
40.0 |
% |
Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 500 ug/mL at 25 degC after 72 hr by half-leaf method |
CHEMBL3045942 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells after 3 days by microscopic analysis |
CHEMBL3046360 |
| Punta Toro virus |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Punta Toro virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Human coxsackievirus B4 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Reovirus sp. |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Mammalian orthoreovirus 1 virus infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Human parainfluenza virus 3 |
EC50 |
= |
45000.0 |
nM |
Antiviral activity against Human parainfluenza virus 3 infected Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Respiratory syncytial virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Human coxsackievirus B4 |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Human coxsackievirus B4 infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Vesicular stomatitis virus |
EC50 |
= |
29000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against Homo sapiens (human) HeLa cells after 3 days by microscopic analysis |
CHEMBL3046360 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against acyclovir-resistant TK-deficient Hepres simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Vesicular stomatitis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Vaccinia virus |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Human herpesvirus 2 strain G |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Human herpesvirus 2 strain G infected HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTT assay |
CHEMBL3046360 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against Homo sapiens (human) HEL cells after 3 days by microscopic analysis |
CHEMBL3046360 |
| Respiratory syncytial virus |
MIC |
= |
60.0 |
ug.mL-1 |
Antiviral activity against Respiratory syncytial virus infected HeLa cells |
CHEMBL3045159 |
| Human coxsackievirus B4 |
MIC |
> |
500.0 |
ug.mL-1 |
Antiviral activity against Human coxsackievirus B4 infected HeLa cells |
CHEMBL3045159 |
| Vesicular stomatitis virus |
MIC |
= |
60.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected HeLa |
CHEMBL3045159 |
| Punta Toro virus |
MIC |
= |
60.0 |
ug.mL-1 |
Antiviral activity against Punta Toro virus infected Vero cells |
CHEMBL3045159 |
| Human coxsackievirus B4 |
MIC |
> |
500.0 |
ug.mL-1 |
Antiviral activity against Human coxsackievirus B4 infected Vero cells |
CHEMBL3045159 |
| Sindbis virus |
MIC |
= |
300.0 |
ug.mL-1 |
Antiviral activity against Sindbis virus infected Vero cells |
CHEMBL3045159 |
| Mammalian orthoreovirus 1 |
MIC |
= |
300.0 |
ug.mL-1 |
Antiviral activity against Mammalian orthoreovirus 1 infected Vero cells |
CHEMBL3045159 |
| Human parainfluenza virus 3 |
MIC |
= |
300.0 |
ug.mL-1 |
Antiviral activity against Human parainfluenza virus 3 infected Vero cells |
CHEMBL3045159 |
| Human herpesvirus 1 strain KOS |
MIC |
> |
500.0 |
ug.mL-1 |
Antiviral activity against thymidine kinase-deficient, acylcovir-resistant Human herpesvirus 1 strain KOS infected in HEL cells |
CHEMBL3045159 |
| Vesicular stomatitis virus |
MIC |
> |
500.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected HEL cells |
CHEMBL3045159 |
| Vaccinia virus |
MIC |
= |
300.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected HEL cells |
CHEMBL3045159 |
| Human herpesvirus 2 strain G |
MIC |
> |
500.0 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 2 strain G infected HEL cells |
CHEMBL3045159 |
| Human herpesvirus 1 strain KOS |
MIC |
= |
500.0 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 1 strain KOS infected in HEL cells |
CHEMBL3045159 |
| HeLa |
MCC |
> |
500.0 |
ug.mL-1 |
Cytotoxicity against Homo sapiens (human) HeLa cells |
CHEMBL3045159 |
| Vero |
MCC |
> |
500.0 |
ug.mL-1 |
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells |
CHEMBL3045159 |
| HEL |
MCC |
> |
500.0 |
ug.mL-1 |
Cytotoxicity against Homo sapiens (human) HEL cells |
CHEMBL3045159 |
| MDCK |
MCC |
>= |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as change in cellular morphology |
CHEMBL3045116 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against Homo sapiens (human) HeLa cells assessed as change in cellular morphology |
CHEMBL3045116 |
| Influenza B virus |
EC50 |
= |
8400.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Influenza A virus H3N2 |
EC50 |
= |
6800.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Influenza A virus |
EC50 |
= |
11500.0 |
nM |
Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as change in cellular morphology |
CHEMBL3045116 |
| Punta Toro virus |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Human coxsackievirus B4 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Sendai virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sendai virus infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Mammalian orthoreovirus 1 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Human parainfluenza virus 3 |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against Human parainfluenza virus 3 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as change in cellular morphology |
CHEMBL3045116 |
| Respiratory syncytial virus |
EC50 |
= |
4600.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Human coxsackievirus B4 |
EC50 |
= |
28500.0 |
nM |
Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| Vesicular stomatitis virus |
EC50 |
= |
12100.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay |
CHEMBL3045116 |
| HeLa |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against Homo sapiens (human) HeLa cells assessed as change in cellular morphology |
CHEMBL3045116 |
| Measles virus |
IC50 |
= |
1160000.0 |
nM |
Antiviral activity against wild type Measles virus mWTFb infected in simian B95a cells assessed as virus-induced cytopathogenicity incubated for 30 mins prior to inoculation measured after 3 days by phase contrast microscopy |
CHEMBL2321734 |
| Lassa virus |
Activity |
= |
0.0 |
% |
Antiviral activity against Lassa virus infected in guinea pig strain 13 assessed as host survival rate at 80 mg/kg/day, ip administered at 1 hr prior to infection for 14 days relative to control |
CHEMBL2321741 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
24.6 |
ug.mL-1 |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method |
CHEMBL2331164 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
1032.3 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
1158.2 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
1158.2 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Tyrosyl-DNA phosphodiesterase 1 |
Potency |
|
1458.1 |
nM |
PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Influenza A virus |
IC50 |
= |
87000.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells after 48 hrs by CPE inhibition assay |
CHEMBL2385024 |
| Influenza A virus |
IC50 |
= |
410.0 |
nM |
Antiviral activity against Influenza A virus A/Hong Kong/8/68(H3N2) infected in dog MDCK cells after 3 days by CPE assay |
CHEMBL2384926 |
| Influenza A virus |
IC50 |
= |
20200.0 |
nM |
Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in dog MDCK cells after 3 days by CPE assay |
CHEMBL2384926 |
| Coxsackievirus |
IC50 |
= |
222200.0 |
nM |
Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL2384959 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
113100.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) PR/8 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 48 hrs by crystal-violet staining-based assay |
CHEMBL2407078 |
| Peroxisome proliferator-activated receptor delta |
Inhibition |
|
|
% |
Antagonist activity at human PPARdelta assessed as effect on TIPP-703-induced activity at 10 uM |
CHEMBL2412985 |
| Peroxisome proliferator-activated receptor alpha |
Inhibition |
|
|
% |
Antagonist activity at human PPARalpha assessed as effect on TIPP-703-induced activity at 10 uM |
CHEMBL2412985 |
| Peroxisome proliferator-activated receptor delta |
IC50 |
|
|
|
Antagonist activity at human PPARdelta assessed as effect on TIPP-703-induced activity |
CHEMBL2412985 |
| ADMET |
CC50 |
= |
100000.0 |
nM |
Cytotoxicity against african green monkey OR6 cells after 72 hrs by WST1 assay |
CHEMBL2412985 |
| Unchecked |
Selectivity Index |
= |
18.0 |
|
Selectivity index, ratio of CC50 for african green monkey OR6 cells to ED50 for HCV |
CHEMBL2412985 |
| Hepatitis C virus |
ED50 |
= |
5.6 |
uM |
Antiviral activity against HCV infected in african green monkey OR6 cells assessed as inhibition of viral RNA replication after 72 hrs by luciferase reporter gene assay |
CHEMBL2412985 |
| Unchecked |
Ratio CC50/EC50 |
> |
69.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza B virus (B/Florida/4/2006) |
CHEMBL2412956 |
| Unchecked |
Ratio CC50/EC50 |
> |
20.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) |
CHEMBL2412956 |
| Unchecked |
Ratio CC50/EC50 |
> |
20.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Perth/16/2009(H3N2)) |
CHEMBL2412956 |
| Unchecked |
Ratio CC50/EC50 |
> |
15.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/California/07/2009(H1N1)) |
CHEMBL2412956 |
| MDCK |
CC50 |
> |
323500.0 |
nM |
Cytotoxicity against MDCK cells |
CHEMBL2412956 |
| NON-PROTEIN TARGET |
EC50 |
= |
5730.0 |
nM |
Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay |
CHEMBL2412956 |
| Influenza A virus |
EC50 |
= |
18430.0 |
nM |
Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay |
CHEMBL2412956 |
| Influenza A virus |
EC50 |
= |
18430.0 |
nM |
Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay |
CHEMBL2412956 |
| Influenza A virus |
EC50 |
= |
23750.0 |
nM |
Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay |
CHEMBL2412956 |
| Influenza A virus |
EC50 |
|
|
|
Antiviral activity against influenza A virus H1N1 infected in dog MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method |
CHEMBL2417493 |
| Unchecked |
Ratio CC50/EC50 |
> |
15.0 |
|
Selectivity index, ratio of CC50 for human HeLa cells to EC50 for Adenovirus type 7 infected in human HeLa cells |
CHEMBL2417493 |
| unidentified adenovirus |
EC50 |
= |
27.8 |
ug.mL-1 |
Antiviral activity against Adenovirus type 7 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method |
CHEMBL2417493 |
| HeLa |
CC50 |
> |
500.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay |
CHEMBL2417493 |
| Unchecked |
Ratio CC50/EC50 |
> |
20.0 |
|
Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for Coxsackievirus B5 infected in human HepG2 cells |
CHEMBL2417493 |
| Human coxsackievirus B5 |
EC50 |
= |
22.3 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B5 infected in human HepG2 cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method |
CHEMBL2417493 |
| HepG2 |
CC50 |
> |
500.0 |
ug.mL-1 |
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay |
CHEMBL2417493 |
| Unchecked |
Ratio CC50/EC50 |
> |
10.0 |
|
Selectivity index, ratio of CC50 for human rhabdomyosarcoma cells to EC50 for Enterovirus 71 infected in human rhabdomyosarcoma cells |
CHEMBL2417493 |
| Enterovirus |
EC50 |
= |
49.2 |
ug.mL-1 |
Antiviral activity against Enterovirus 71 infected in human rhabdomyosarcoma cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method |
CHEMBL2417493 |
| ADMET |
CC50 |
> |
500.0 |
ug.mL-1 |
Cytotoxicity against human rhabdomyosarcoma cells after 72 hrs by MTT assay |
CHEMBL2417493 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as cell viability after 4 days by MTS assay |
CHEMBL2417501 |
| Influenza B virus |
EC50 |
= |
2800.0 |
nM |
Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay |
CHEMBL2417501 |
| Influenza A virus |
EC50 |
= |
1100.0 |
nM |
Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay |
CHEMBL2417501 |
| Influenza A virus |
EC50 |
= |
2500.0 |
nM |
Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay |
CHEMBL2417501 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against african green monkey Vero cells |
CHEMBL2417501 |
| Punta Toro virus |
EC50 |
= |
126000.0 |
nM |
Antiviral activity against Punts virus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Coxsackievirus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Human parainfluenza virus 3 |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells |
CHEMBL2417501 |
| Respiratory syncytial virus |
EC50 |
= |
5000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Coxsackievirus |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Vesicular stomatitis virus |
EC50 |
= |
29000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL2417501 |
| Influenza B virus |
EC50 |
= |
8300.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Influenza A virus |
EC50 |
= |
7200.0 |
nM |
Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Influenza A virus |
EC50 |
= |
9600.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as morphological changes |
CHEMBL2417481 |
| Punta Toro virus |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Human parainfluenza virus 3 |
EC50 |
= |
85000.0 |
nM |
Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Human coxsackievirus B4 |
EC50 |
= |
22000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Respiratory syncytial virus |
EC50 |
= |
5000.0 |
nM |
Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Vesicular stomatitis virus |
EC50 |
= |
5000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL2417481 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against african green monkey Vero cells assessed as morphological changes |
CHEMBL2417481 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as morphological changes |
CHEMBL2417481 |
| Unchecked |
Selectivity Index |
= |
9.0 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3 |
CHEMBL2429751 |
| Human coxsackievirus B3 |
IC50 |
= |
900000.0 |
nM |
Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 48 hrs by Reed-Muench analysis |
CHEMBL2429751 |
| Vero |
TC50 |
= |
8.1 |
uM/ml |
Cytotoxicity against African green monkey Vero cells after 48 hrs by Reed-Muench analysis |
CHEMBL2429751 |
| X5563 |
GI |
> |
50.0 |
% |
Cytotoxicity against mouse X5563 cells assessed as growth inhibition |
CHEMBL2434869 |
| NON-PROTEIN TARGET |
GI |
> |
50.0 |
% |
Cytotoxicity against mouse Gardner lymphosarcoma cells assessed as growth inhibition |
CHEMBL2434869 |
| NON-PROTEIN TARGET |
GI |
> |
50.0 |
% |
Cytotoxicity against mouse mammary carcinoma 755 cells assessed as growth inhibition |
CHEMBL2434869 |
| NON-PROTEIN TARGET |
GI |
> |
50.0 |
% |
Cytotoxicity against rat Walker 256 cells assessed as growth inhibition |
CHEMBL2434869 |
| Unchecked |
Ratio CC50/IC50 |
= |
9.0 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Coxsackie B3 virus Schmitt |
CHEMBL2434925 |
| Human coxsackievirus B6 |
IC50 |
= |
909960.0 |
nM |
Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs |
CHEMBL2434925 |
| Unchecked |
Ratio CC50/IC50 |
= |
5.2 |
|
Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Coxsackie B3 virus Nancy |
CHEMBL2434925 |
| Human coxsackievirus B3 |
IC50 |
= |
1576110.0 |
nM |
Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs |
CHEMBL2434925 |
| Vero |
CC50 |
= |
8189670.0 |
nM |
Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay |
CHEMBL2434925 |
| Unchecked |
Ratio CC50/IC50 |
|
|
|
Selectivity index, ratio of CC50 for human Huh7.5 cells to IC50 for HCV expressing pFL-J6/JFH/JC1 |
CHEMBL2434925 |
| Hepatitis C virus |
IC50 |
|
|
|
Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis |
CHEMBL2434925 |
| ADMET |
CC50 |
|
|
|
Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay |
CHEMBL2434925 |
| Solute carrier organic anion transporter family member 1B1 |
Inhibition |
= |
112.33 |
% |
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM |
CHEMBL3039007 |
| Solute carrier organic anion transporter family member 1B3 |
Inhibition |
= |
87.39 |
% |
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM |
CHEMBL3039007 |
| ADMET |
Activity |
= |
32.6 |
% |
Cytotoxicity against human BE(2)-C cells assessed as cell viability at 25 uM after 24 hrs by MTT assay relative to control |
CHEMBL3085701 |
| NON-PROTEIN TARGET |
Activity |
= |
9.3 |
10'6PFU/ml |
Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as reduction of viral titer at 25 uM after 24 hrs by plaque reduction assay (Rvb = 25.7 +/- 5.2 x 10'6 pfu/ml) |
CHEMBL3085701 |
| NON-PROTEIN TARGET |
Activity |
= |
53.5 |
10'6PFU/ml |
Antiviral activity against Fort Morgan virus infected in human BE(2)-C cells assessed as reduction of viral titer at 25 uM after 24 hrs by plaque reduction assay (Rvb = 47.1 +/- 10.5 x 10'6 pfu/ml) |
CHEMBL3085701 |
| NON-PROTEIN TARGET |
IC50 |
= |
16000.0 |
nM |
Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as inhibition of viral RNA replication after 18 to 20 hrs by luciferase reporter gene assay |
CHEMBL3085701 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 24 hrs by MTS assay |
CHEMBL3085678 |
| Influenza A virus |
EC99 |
= |
11.0 |
uM |
Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 2 log10 reduction of virus yield after 24 hrs by RT-PCR analysis |
CHEMBL3085678 |
| Influenza A virus |
EC90 |
= |
4.6 |
uM |
Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 1 log10 reduction of virus yield after 24 hrs by RT-PCR analysis |
CHEMBL3085678 |
| Influenza A virus |
IC50 |
= |
14000.0 |
nM |
Antiviral activity against Influenza A/PR8/H1N1 virus infected in MDCK cells assessed as inhibition of virus yield after 24 hrs |
CHEMBL3091354 |
| MDCK |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay |
CHEMBL3108691 |
| HEK293 |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by MTT assay |
CHEMBL3108691 |
| Influenza A virus |
EC50 |
= |
17000.0 |
nM |
Antiviral activity against oseltamivir-resistant Influenza A virus (A/Parma/24/2009(H1N1)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay |
CHEMBL3108691 |
| Unchecked |
EC50 |
= |
15000.0 |
nM |
Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay |
CHEMBL3108691 |
| Influenza A virus |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against Influenza A virus (A/Wisconsin/67/2005(H3N2)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay |
CHEMBL3108691 |
| Influenza A virus |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against influenza A virus A/Padova/253/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay |
CHEMBL3108691 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay |
CHEMBL3108691 |
| Influenza A virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against influenza A virus A/Padova/30/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay |
CHEMBL3108691 |
| NON-PROTEIN TARGET |
EC50 |
= |
6000.0 |
nM |
Antiviral activity against Influenza B virus (B/Lee/1940) clinical isolate infected in MDCK cells assessed as inhibition of viral replication after 2 days by toluidine blue staining assay |
CHEMBL3108691 |
| Influenza A virus |
EC50 |
= |
6000.0 |
nM |
Antiviral activity against influenza A virus A/Padova/72/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay |
CHEMBL3108691 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 12 hrs by toluidine blue staining assay |
CHEMBL3108691 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
84000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining technique |
CHEMBL3108726 |
| Influenza A virus |
IC50 |
= |
131000.0 |
nM |
Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay |
CHEMBL3108766 |
| Unchecked |
Selectivity Index |
= |
0.14 |
|
Selectivity index, ratio of beta-actin level in human HuH7 cells to viral RNA level in HCV infected in human Huh7 cells |
CHEMBL3112456 |
| Huh-7 |
Activity |
= |
12.0 |
% |
Cytotoxicity against human HuH7 cells assessed as beta-actin levels relative to control |
CHEMBL3112456 |
| Hepatitis C virus |
Activity |
= |
89.0 |
% |
Antiviral activity against HCV infected in human Huh7 cells assessed as reduction in RNA level by luciferase reporter gene assay relative to control |
CHEMBL3112456 |
| NON-PROTEIN TARGET |
Ratio CC50/EC50 |
> |
76.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza A virus H5N1 |
CHEMBL3120115 |
| NON-PROTEIN TARGET |
Ratio CC50/EC50 |
> |
32.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza A virus H1N1 |
CHEMBL3120115 |
| NON-PROTEIN TARGET |
Ratio CC50/EC50 |
> |
160.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza A virus H3N2 |
CHEMBL3120115 |
| NON-PROTEIN TARGET |
Ratio CC50/EC50 |
> |
130.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza B virus |
CHEMBL3120115 |
| Influenza A virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Influenza A virus H1N1 by cytopathy assay |
CHEMBL3120115 |
| Influenza A virus |
EC50 |
= |
4200.0 |
nM |
Antiviral activity against Influenza A virus H5N1 by cytopathy assay |
CHEMBL3120115 |
| Influenza B virus |
EC50 |
= |
2400.0 |
nM |
Antiviral activity against Influenza B virus by cytopathy assay |
CHEMBL3120115 |
| Influenza A virus |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against Influenza A virus H3N2 by cytopathy assay |
CHEMBL3120115 |
| Influenza B virus |
IC50 |
= |
3.27 |
ug.mL-1 |
Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of plaque formation after 3 to 4 days by crystal violet staining-based assay |
CHEMBL3124823 |
| Unchecked |
Selectivity Index |
= |
205.6 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus jifang/13/97 |
CHEMBL3124823 |
| Influenza B virus |
IC50 |
= |
7.84 |
ug.mL-1 |
Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs |
CHEMBL3124823 |
| Unchecked |
Selectivity Index |
= |
212.8 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus A/hanfang/359/95(H3N2) |
CHEMBL3124823 |
| Influenza A virus |
IC50 |
= |
5.59 |
ug.mL-1 |
Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs |
CHEMBL3124823 |
| Unchecked |
Selectivity Index |
= |
185.0 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) |
CHEMBL3124823 |
| Influenza A virus |
IC50 |
= |
6.5 |
ug.mL-1 |
Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs |
CHEMBL3124823 |
| Unchecked |
Selectivity Index |
= |
819.8 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/FM/1/1947(H1N1)) |
CHEMBL3124823 |
| Hepatitis C virus |
Inhibition |
= |
32.0 |
% |
Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level at 41 uM after 8 to 10 days by quantitative PCR analysis |
CHEMBL3124855 |
| Unchecked |
Ratio CC50/EC50 |
> |
10.0 |
|
Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for HCV subtype 1a |
CHEMBL3124855 |
| Huh-7 |
CC50 |
|
|
|
Cytotoxicity against human HuH7 cells after 2 days by XTT assay |
CHEMBL3124855 |
| Hepatitis C virus |
EC50 |
= |
81900.0 |
nM |
Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level after 8 to 10 days by quantitative PCR analysis |
CHEMBL3124855 |
| Hepatitis C virus |
Inhibition |
= |
50.0 |
% |
Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level at 81.9 uM after 8 to 10 days by quantitative PCR analysis |
CHEMBL3124855 |
| Influenza A virus |
IC50 |
= |
1.92 |
ug.mL-1 |
Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs |
CHEMBL3124823 |
| MDCK |
TC50 |
= |
1164.0 |
ug ml-1 |
Cytotoxicity against MDCK cells after 48 hrs |
CHEMBL3124823 |
| NON-PROTEIN TARGET |
EC50 |
= |
83.3 |
ug.mL-1 |
Antiviral activity against Chikungunya virus |
CHEMBL3124911 |
| NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
= |
3.0 |
|
Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
= |
33.0 |
% |
Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (acute) |
= |
2.0 |
|
Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (acute) |
= |
0.0 |
% |
Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (cytolytic) |
= |
1.0 |
|
Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (choleostasis) |
= |
1.0 |
|
Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (severe hepatitis) |
= |
1.0 |
|
Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (chronic liver disease) |
= |
0.0 |
|
Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (cirrhosis) |
= |
0.0 |
|
Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (granulomatous hepatitis) |
= |
0.0 |
|
Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (association with vascular disease) |
= |
0.0 |
|
Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (steatosis) |
= |
1.0 |
|
Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (malignant tumour) |
= |
0.0 |
|
Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (benign tumour) |
= |
0.0 |
|
Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (animal toxicity known) |
|
|
|
Animal toxicity known. [column 'TOXIC' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (successful reintroduction) |
|
|
|
Presence of at least one case with successful reintroduction. [column 'REINT' in source] |
CHEMBL3137667 |
| Unchecked |
Hepatotoxicity (comment) |
|
|
|
Comments (NB not yet translated). [column 'COMMENTAIRES' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (time to onset) |
|
|
|
Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] |
CHEMBL3137667 |
| NON-PROTEIN TARGET |
Hepatotoxicity (mechanism) |
|
|
|
Proposed mechanism(s) of liver damage. [column 'MEC' in source] |
CHEMBL3137667 |
| Rap guanine nucleotide exchange factor 3 |
Potency |
|
89125.1 |
nM |
PubChem BioAssay. qHTS for Agonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
35481.3 |
nM |
PubChem BioAssay. qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Cerebroside-sulfatase |
Potency |
|
16944.1 |
nM |
PubChem BioAssay. qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Molecular identity unknown |
Potency |
|
42163.2 |
nM |
PubChem BioAssay. qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Potency |
|
11220.2 |
nM |
PubChem BioAssay. qHTS for Inhibitors of binding or entry into cells for Marburg Virus. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Human herpesvirus 1 strain KOS |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Human herpesvirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against thymidine kinase-deficient Herpes simplex virus type 1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Human herpesvirus 2 strain G |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Herpes simplex virus type 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Vaccinia virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Vesicular stomatitis virus |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Vesicular stomatitis virus |
EC50 |
= |
29000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Human coxsackievirus B4 |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Respiratory syncytial virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Human immunodeficiency virus 1 |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL3217529 |
| Human immunodeficiency virus type 2 (ISOLATE ROD) |
EC50 |
> |
50000.0 |
nM |
Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis |
CHEMBL3217529 |
| Human parainfluenza virus 3 |
EC50 |
= |
85000.0 |
nM |
Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| NON-PROTEIN TARGET |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Punta Toro virus |
EC50 |
= |
126000.0 |
nM |
Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Influenza A virus H3N2 |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Influenza A virus |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| Influenza B virus |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL3217529 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells assessed as concentration required to cause microscopically visible alternation of cell morphology |
CHEMBL3217529 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as concentration required to cause microscopically visible alternation of cell morphology |
CHEMBL3217529 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as concentration required to cause microscopically visible alternation of cell morphology |
CHEMBL3217529 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as concentration required to cause microscopically visible alternation of cell morphology |
CHEMBL3217529 |
| Unchecked |
Inhibition |
|
|
% |
Inhibition of Escherichia coli topoisomerase assessed as bacterial proliferation at 200 uM after 24 hrs by visual inspection assay |
CHEMBL3217430 |
| DNA topoisomerase I |
IC50 |
= |
65880.0 |
nM |
Inhibition of human topoisomerase 1 activity assessed as DNA triplex formation and presence of supercoiled DNA by microplate assay |
CHEMBL3217430 |
| Unchecked |
Activity |
|
|
|
Activity at rat liver nucleoside kinase assessed as phosphorylation using [gamma-32P]-ATP after 10 to 20 mins |
CHEMBL3227955 |
| NON-PROTEIN TARGET |
IC50 |
= |
253100.0 |
nM |
Antiviral activity against Enterovirus 71 BrCr infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay |
CHEMBL3232875 |
| Vero |
CC50 |
> |
1000000.0 |
nM |
Cytotoxicity against African green monkey Vero cells after 4 days by MTT assay |
CHEMBL3232875 |
| Unchecked |
Ratio CC50/IC50 |
> |
4.0 |
|
Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Enterovirus 71 BrCr |
CHEMBL3232875 |
| Dengue virus 2 |
Inhibition |
= |
32.03 |
% |
Antiviral activity against DENV2 16681 infected in human Huh-7 cells at 5 uM after 3 days by luciferase reporter gene assay |
CHEMBL3232713 |
| Dengue virus 2 |
Inhibition |
= |
67.47 |
% |
Antiviral activity against DENV2 16681 infected in human Huh-7 cells at 20 uM after 3 days by luciferase reporter gene assay |
CHEMBL3232713 |
| ADMET |
Activity |
= |
71.37 |
% |
Cytotoxicity against human HuH7 cells assessed as cell viability at 20 uM after 3 days by XTT assay |
CHEMBL3232713 |
| ADMET |
Activity |
= |
26.78 |
% |
Cytotoxicity against human HuH7 cells assessed as cell viability at 100 uM after 3 days by XTT assay |
CHEMBL3232713 |
| Dengue virus 2 |
IC50 |
= |
12610.0 |
nM |
Antiviral activity against DENV2 16681 infected in human Huh-7 cells after 3 days by luciferase reporter gene assay |
CHEMBL3232713 |
| ADMET |
CC50 |
= |
56310.0 |
nM |
Cytotoxicity against human HuH7 cells assessed as cell viability after 3 days by XTT assay |
CHEMBL3232713 |
| Unchecked |
Ratio CC50/IC50 |
= |
4.47 |
|
Selectivity index, ratio of CC50 for human HuH7 cells to IC50 for DENV2 16681 |
CHEMBL3232713 |
| Mus musculus |
Activity |
|
|
|
Toxicity in mouse assessed as survival at 99 mg/kg, po |
CHEMBL3244326 |
| Human parainfluenza virus 1 |
TIME |
= |
240.0 |
hr |
Antiviral activity against type 1 parainfluenza virus infected in mouse assessed as mouse mean death day at 99 mg/kg, po thrice a day for 8 days after 1 hr viral infection (Rvb = 8.9 days) |
CHEMBL3244326 |
| Human parainfluenza virus 1 |
TIME |
= |
288.0 |
hr |
Antiviral activity against type 1 parainfluenza virus infected in mouse assessed as mouse mean death day at 49.5 mg/kg, po thrice a day for 8 days after 1 hr viral infection (Rvb = 8.9 days) |
CHEMBL3244326 |
| Vesicular stomatitis virus |
MIC50 |
= |
70.0 |
ug.mL-1 |
Antiviral activity against Vesicular stomatitis virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection |
CHEMBL3244367 |
| Human herpesvirus 1 |
MIC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 1 infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 3 days after virus infection |
CHEMBL3244367 |
| Vaccinia virus |
MIC50 |
= |
20.0 |
ug.mL-1 |
Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection |
CHEMBL3244367 |
| Human poliovirus 1 |
MIC50 |
= |
40.0 |
ug.mL-1 |
Antiviral activity against Poliovirus type 1 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection |
CHEMBL3244367 |
| Human coxsackievirus B4 |
MIC50 |
= |
40.0 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection |
CHEMBL3244367 |
| Unchecked |
ID50 |
= |
20.0 |
ug ml-1 |
Inhibition of DNA synthesis in primary rabbit kidney cells assessed as inhibition of [3H]thymidine incorporation into DNA |
CHEMBL3244367 |
| NON-PROTEIN TARGET |
Activity |
= |
127.0 |
% |
Immunosuppressive activity against PHA-stimulated proliferation in rat T-lymphocytes assessed as cell viability at 1 uM after 6 days by [3H]thymidine incorporation method relative to control |
CHEMBL3244180 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs |
CHEMBL3244032 |
| Vaccinia virus |
Activity |
|
|
|
Antiviral activity against Vaccinia virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs |
CHEMBL3244032 |
| Human parainfluenza virus 3 |
Activity |
|
|
|
Antiviral activity against Parainfluenza virus type 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs |
CHEMBL3244032 |
| KB |
Activity |
|
|
|
Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs |
CHEMBL3244032 |
| KB |
Activity |
|
|
|
Antiviral activity against Adenovirus type 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs |
CHEMBL3244032 |
| Influenza A virus |
Activity |
< |
4.0 |
HAU/ml |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 2 measured on day 2 relative to untreated control |
CHEMBL3244172 |
| Influenza A virus |
Activity |
< |
4.0 |
HAU/ml |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 3 relative to untreated control |
CHEMBL3244172 |
| Influenza A virus |
Activity |
= |
12.0 |
HAU/ml |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 3 relative to untreated control |
CHEMBL3244172 |
| Influenza A virus |
Activity |
< |
4.0 |
HAU/ml |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 2 measured on day 2 relative to untreated control |
CHEMBL3244172 |
| Influenza A virus |
Activity |
< |
4.0 |
HAU/ml |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 3 relative to untreated control |
CHEMBL3244172 |
| MDCK |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against MDCK cells infected with Influenza A virus Port Chalmers/1/73 (H3N2) after 3 days by carbol fuchsin staining-based assay |
CHEMBL3244172 |
| Influenza A virus |
IZ |
= |
30.0 |
mm |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in MDCK cells at 1 mg/ml by agar diffusion method |
CHEMBL3244172 |
| Influenza A virus |
PDD50 |
= |
2.0 |
ug ml-1 |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in MDCK cells assessed as plaque reduction after 3 days by agar diffusion method |
CHEMBL3244172 |
| Mustela putorius furo |
Activity |
= |
-4.5 |
% |
Toxicity in ferret infected with Influenza A virus Port Chalmers/1/73 (H3N2) assessed as change in body weight at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured after 7 days relative to untreated control |
CHEMBL3244172 |
| Mustela putorius furo |
Activity |
= |
-22.2 |
% |
Toxicity in ferret infected with Influenza A virus Port Chalmers/1/73 (H3N2) assessed as change in body weight at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured after 7 days relative to untreated control |
CHEMBL3244172 |
| Mustela putorius furo |
Activity |
= |
-20.1 |
% |
Toxicity in ferret infected with Influenza A virus Port Chalmers/1/73 (H3N2) assessed as change in body weight at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured after 7 days relative to untreated control |
CHEMBL3244172 |
| Influenza A virus |
T |
> |
39.5 |
degrees C |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in rectal temperature at 7 to 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 relative to untreated control |
CHEMBL3244172 |
| Influenza A virus |
Activity |
< |
4.0 |
HAU/ml |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 4 relative to untreated control |
CHEMBL3244172 |
| Influenza A virus |
Activity |
< |
4.0 |
HAU/ml |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 2 measured on day 2 relative to untreated control |
CHEMBL3244172 |
| Influenza A virus |
Activity |
< |
4.0 |
HAU/ml |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 4 relative to untreated control |
CHEMBL3244172 |
| Influenza A virus |
Activity |
< |
4.0 |
HAU/ml |
Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured on day 4 relative to untreated control |
CHEMBL3244172 |
| KB |
Activity |
|
|
|
Antiviral activity against Adenovirus type 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control |
CHEMBL3244072 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against HSV1 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control |
CHEMBL3244072 |
| Human herpesvirus 2 |
Activity |
|
|
|
Antiviral activity against HSV2 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control |
CHEMBL3244072 |
| Vaccinia virus |
Activity |
|
|
|
Antiviral activity against Vaccinia virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control |
CHEMBL3244072 |
| Human parainfluenza virus 3 |
Activity |
|
|
|
Antiviral activity against Parainfluenza virus 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control |
CHEMBL3244072 |
| KB |
Activity |
|
|
|
Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control |
CHEMBL3244072 |
| Ehrlich |
Inhibition |
= |
14.0 |
% |
Inhibition of adenine nucleotide biosynthesis in human EAC assessed as [14C]hypoxanthine incorporation at 1 mM after 60 mins by TLC analysis |
CHEMBL3244072 |
| Ehrlich |
Inhibition |
= |
65.0 |
% |
Inhibition of guanine nucleotide biosynthesis in human EAC assessed as [14C]hypoxanthine incorporation at 1 mM after 60 mins by TLC analysis |
CHEMBL3244072 |
| Bacillus subtilis |
MIC |
|
|
|
Antibacterial activity against Bacillus subtilis |
CHEMBL3244280 |
| Staphylococcus aureus |
MIC |
|
|
|
Antibacterial activity against Staphylococcus aureus Oxford |
CHEMBL3244280 |
| Staphylococcus aureus |
MIC |
|
|
|
Antibacterial activity against Staphylococcus aureus Russel |
CHEMBL3244280 |
| Staphylococcus aureus |
MIC |
|
|
|
Antibacterial activity against Staphylococcus aureus 1517 |
CHEMBL3244280 |
| Enterococcus faecalis |
MIC |
|
|
|
Antibacterial activity against Streptococcus faecalis I |
CHEMBL3244280 |
| Streptococcus pyogenes |
MIC |
|
|
|
Antibacterial activity against Streptococcus pyogenes CN10 |
CHEMBL3244280 |
| Influenza A virus |
PDD50 |
= |
1.0 |
ug ml-1 |
Antiviral activity against influenza A virus NWS/H0N1 infected in BHK cells by agar diffusion assay |
CHEMBL3244280 |
| ADMET |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against BHK cells |
CHEMBL3244280 |
| Human coxsackievirus B1 |
PDD50 |
> |
100.0 |
ug ml-1 |
Antiviral activity against Coxsackievirus B1 infected in human HeLa cells by agar diffusion assay |
CHEMBL3244280 |
| HeLa |
MCC |
> |
100.0 |
ug.mL-1 |
Cytotoxicity against human HeLa cells by neutral red assay |
CHEMBL3244280 |
| Influenza A virus |
IZ |
= |
28.0 |
mm |
Antiviral activity against influenza A virus NWS/H0N1 infected in BHK cells at 1 mg/ml by agar diffusion assay |
CHEMBL3244280 |
| Human coxsackievirus B1 |
IZ |
= |
0.0 |
mm |
Antiviral activity against Coxsackievirus B1 infected in human HeLa cells at 1 mg/ml by agar diffusion assay |
CHEMBL3244280 |
| Bovine viral diarrhea virus |
EC50 |
= |
1300.0 |
nM |
Antiviral activity against BVDV AV-69 infected in MDBK cells assessed as cytopathic effect after 3 to 4 days by plaque reduction assay |
CHEMBL3259604 |
| ADMET |
CC50 |
> |
20000.0 |
nM |
Cytotoxicity against MDBK cells after 48 hrs by MTT assay |
CHEMBL3259604 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against Herpes simplex virus type 1 infected in human KB cells |
CHEMBL3272117 |
| KB |
Activity |
|
|
|
Antiviral activity against Rhinovirus type 13 infected in human KB cells |
CHEMBL3272117 |
| Human parainfluenza virus 3 |
Activity |
|
|
|
Antiviral activity against Parainfluenza virus type 3 infected in human KB cells |
CHEMBL3272117 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus (A2/Asian/J305) infected in Swiss albino mouse assessed as increase in host survival at 20 mg/kg, ip administered 4 hrs before infection, 1 hr after infection followed by twice daily for next 6 days for total of 14 treatments measured on 21st day post-infection |
CHEMBL3272201 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus A2/Asian/J305 infected in Swiss albino mouse assessed as increase in host survival at 50 mg/kg, ip administered as 7 doses immediately before virus inoculation and at 1, 5, 24, 30, 48 and 72 hrs after virus infection measured on 21st day post-infection |
CHEMBL3272124 |
| Enterovirus |
Inhibition |
|
|
% |
Antiviral activity against Rhinovirus 1A infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control |
CHEMBL3272052 |
| Enterovirus |
Inhibition |
|
|
% |
Antiviral activity against Rhinovirus 2 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control |
CHEMBL3272052 |
| Enterovirus |
Inhibition |
|
|
% |
Antiviral activity against Rhinovirus 8 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control |
CHEMBL3272052 |
| Enterovirus |
Inhibition |
|
|
% |
Antiviral activity against Rhinovirus 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control |
CHEMBL3272052 |
| Enterovirus |
Inhibition |
|
|
% |
Antiviral activity against Rhinovirus 30 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control |
CHEMBL3272052 |
| Respiratory syncytial virus |
IC50 |
= |
20400.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as virus-induced cytopathicity by XTT assay |
CHEMBL3286135 |
| ADMET |
TC50 |
> |
3000.0 |
uM |
Cytotoxicity against mock-infected human Hep2 cells by XTT assay |
CHEMBL3286135 |
| ADMET |
TI |
> |
147.0 |
|
Therapeutic ratio of TC50 for mock-infected human Hep2 cells to IC50 for Respiratory syncytial virus infected in human Hep2 cells |
CHEMBL3286135 |
| Unchecked |
IC50 |
|
|
|
Inhibition of Influenza A virus GST-tagged PB1 (1 to 25) expressed in Escherichia coli binding to Influenza A virus 6His-tagged PA (239 to 716) expressed in Escherichia coli BL21(DE3) by ELISA |
CHEMBL3286353 |
| Unchecked |
EC50 |
= |
24900.0 |
nM |
Inhibition of Influenza A virus RdRP infected in human HEK293T cells after 24 hrs by dual luciferase reporter gene assay |
CHEMBL3286353 |
| Influenza A virus |
EC50 |
= |
15600.0 |
nM |
Inhibition of Influenza A virus A/PR/8/34 infected in MDCK cells after 48 hrs by plaque reduction assay |
CHEMBL3286353 |
| HEK-293T |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay |
CHEMBL3286353 |
| MDCK |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against MDCK cells after 48 hrs by MTT assay |
CHEMBL3286353 |
| Hepatitis C virus |
Inhibition |
|
|
% |
Inhibition of HCV RNA replication in human Li23 cells (ORL8 system) in presence of 1 IU/mL IFN-alpha by renilla luciferase reporter gene based replication assay |
CHEMBL3352101 |
| Influenza A virus |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy |
CHEMBL3351374 |
| Influenza A virus |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay |
CHEMBL3351374 |
| NON-PROTEIN TARGET |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy |
CHEMBL3351374 |
| NON-PROTEIN TARGET |
EC50 |
= |
8200.0 |
nM |
Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay |
CHEMBL3351374 |
| NON-PROTEIN TARGET |
EC50 |
= |
7300.0 |
nM |
Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay |
CHEMBL3351374 |
| NON-PROTEIN TARGET |
EC50 |
= |
6800.0 |
nM |
Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy |
CHEMBL3351374 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
6800.0 |
nM |
Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy |
CHEMBL3351374 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
21000.0 |
nM |
Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay |
CHEMBL3351374 |
| MDCK |
MCC |
>= |
20000.0 |
nM |
Cytotoxicity against MDCK cells assessed as change in cell morphology after 72 hrs by microscopy |
CHEMBL3351374 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay |
CHEMBL3351374 |
| Vesicular stomatitis virus |
EC50 |
= |
17000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity |
CHEMBL3352515 |
| MT4 |
CC50 |
= |
31000.0 |
nM |
Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay |
CHEMBL3351523 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected MDBK cells after 48 to 96 hrs by MTT assay |
CHEMBL3351523 |
| Bovine viral diarrhea virus |
EC50 |
= |
8000.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3351523 |
| NON-PROTEIN TARGET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay |
CHEMBL3351523 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3351523 |
| Reovirus sp. |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3351523 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay |
CHEMBL3351523 |
| Human coxsackievirus B5 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay |
CHEMBL3351523 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
101000.0 |
nM |
Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay |
CHEMBL3351981 |
| Human poliovirus 1 strain Sabin |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay |
CHEMBL3351523 |
| Respiratory syncytial virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay |
CHEMBL3351523 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay |
CHEMBL3351523 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay |
CHEMBL3351523 |
| Human herpesvirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay |
CHEMBL3351523 |
| Unchecked |
Ratio CC50/EC50 |
> |
14.28 |
|
Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Respiratory syncytial virus |
CHEMBL3351523 |
| Hepatitis C virus |
EC50 |
= |
8700.0 |
nM |
Inhibition of HCV RNA replication in human Li23 cells (ORL8 system) by renilla luciferase reporter gene based replication assay |
CHEMBL3352101 |
| Dengue virus 2 |
EC50 |
= |
12600.0 |
nM |
Antiviral activity against dengue virus 2 infected in human HuH7 cells after 72 hrs by Western blot and ECL detection based assay |
CHEMBL3351709 |
| ADMET |
CC50 |
= |
56000.0 |
nM |
Cytotoxicity against human HuH7 cells after 72 hrs by MTS assay |
CHEMBL3351709 |
| Unchecked |
Ratio CC50/EC50 |
= |
4.47 |
|
Selectivity index, ratio of CC50 against human HuH7 cells to EC50 against dengue virus 2 |
CHEMBL3351709 |
| Hepatitis C virus |
EC50 |
= |
5600.0 |
nM |
Antiviral activity against Hepatitis C virus infected in African green monkey OR6 cells after 72 hrs by luciferase reporter gene assay |
CHEMBL3352698 |
| ADMET |
CC50 |
= |
100000.0 |
nM |
Cytotoxicity against human ORL8 cells after 72 hrs by WST-1 assay |
CHEMBL3352698 |
| Unchecked |
Ratio CC50/EC50 |
= |
18.0 |
|
Selectivity index, ratio of CC50 for human ORL8 cells to EC50 for Hepatitis C virus infected in African green monkey OR6 cells |
CHEMBL3352698 |
| Dengue virus |
EC50 |
= |
49000.0 |
nM |
Antiviral activity against Dengue virus |
CHEMBL3352310 |
| ADMET |
TI |
> |
150.0 |
|
Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Respiratory syncytial virus |
CHEMBL3352331 |
| ADMET |
TC50 |
> |
3000.0 |
uM |
Cytotoxicity against human Hep2 cells after 48 hrs |
CHEMBL3352331 |
| Respiratory syncytial virus |
IC50 |
= |
20000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by XTT assay |
CHEMBL3352331 |
| Dengue virus 2 |
EC50 |
= |
47900.0 |
nM |
Antiviral activity against DENV serotype 2 strain New Guinea C infected in african green monkey Vero cells assessed as reduction in production and release of infectious progeny virions after 2 hrs by virus yield-reduction assay |
CHEMBL3400080 |
| ADMET |
CC50 |
> |
410000.0 |
nM |
Cytotoxicity against DENV serotype 2 strain New Guinea C infected african green monkey Vero B cells by virus yield-reduction assay |
CHEMBL3400080 |
| Unchecked |
Selectivity Index |
> |
9.0 |
|
Selectivity index, CC50 for african green monkey Vero B cells to EC50 for DENV serotype 2 strain New Guinea C by virus yield-reduction assay |
CHEMBL3400080 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells after 72 hrs by microscopic analysis |
CHEMBL3414508 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells after 72 hrs by MTS assay |
CHEMBL3414508 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis |
CHEMBL3414508 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay |
CHEMBL3414508 |
| NON-PROTEIN TARGET |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis |
CHEMBL3414508 |
| NON-PROTEIN TARGET |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay |
CHEMBL3414508 |
| NON-PROTEIN TARGET |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis |
CHEMBL3414508 |
| NON-PROTEIN TARGET |
EC50 |
= |
3400.0 |
nM |
Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay |
CHEMBL3414508 |
| MDCK |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay |
CHEMBL3414446 |
| Influenza A virus |
IC50 |
= |
1050.0 |
nM |
Antiviral activity against OSV-resistant influenza A virus A/LiaoNing-ZhenXing/1109/2010 (H1N1) strain |
CHEMBL3414446 |
| Influenza A virus |
IC50 |
> |
150380.0 |
nM |
Antiviral activity against amantadine and ribavirin-resistant influenza A virus A/HuNan-huHui/1222/2010 (H3N2) strain |
CHEMBL3414446 |
| ADMET |
CC50 |
= |
57000.0 |
nM |
Cytotoxicity against bovine MDBK cells assessed as cell viability after 72 hrs by MTT method |
CHEMBL3421576 |
| Bovine viral diarrhea virus |
EC50 |
= |
19000.0 |
nM |
Antiviral activity against BVDV infected in bovine MDBK cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method |
CHEMBL3421576 |
| Unchecked |
Ratio CC50/EC50 |
= |
3.0 |
|
Selectivity index, ratio of CC50 for bovine MDBK cells to EC50 for BVDV infected in bovine MDBK cells |
CHEMBL3421576 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method |
CHEMBL3421576 |
| Respiratory syncytial virus |
EC50 |
= |
35000.0 |
nM |
Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay |
CHEMBL3421576 |
| Unchecked |
Ratio CC50/EC50 |
> |
2.8 |
|
Selectivity index, ratio of CC50 for African green monkey Vero 76 cells to EC50 for RSV infected in African green monkey Vero 76 cells |
CHEMBL3421576 |
| Coxsackievirus |
IC50 |
= |
694600.0 |
nM |
Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect |
CHEMBL3425484 |
| Vero |
TC50 |
= |
8197.0 |
uM |
Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell growth after 24 hrs by CPE assay |
CHEMBL3425484 |
| Unchecked |
Selectivity Index |
= |
11.8 |
|
Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B3 infected in african green monkey Vero cells |
CHEMBL3425484 |
| Coxsackievirus |
IC50 |
= |
1951000.0 |
nM |
Antiviral activity against Coxsackievirus B1 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect |
CHEMBL3425484 |
| Coxsackievirus |
IC50 |
= |
2101000.0 |
nM |
Antiviral activity against Coxsackievirus B2 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect |
CHEMBL3425484 |
| Coxsackievirus |
IC50 |
= |
910800.0 |
nM |
Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect |
CHEMBL3425484 |
| Coxsackievirus |
IC50 |
= |
1708000.0 |
nM |
Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect |
CHEMBL3425484 |
| Unchecked |
Selectivity Index |
= |
4.2 |
|
Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B1 infected in african green monkey Vero cells |
CHEMBL3425484 |
| Unchecked |
Selectivity Index |
= |
3.9 |
|
Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B2 infected in african green monkey Vero cells |
CHEMBL3425484 |
| Unchecked |
Selectivity Index |
= |
9.0 |
|
Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B5 infected in african green monkey Vero cells |
CHEMBL3425484 |
| Unchecked |
Selectivity Index |
= |
4.8 |
|
Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B6 infected in african green monkey Vero cells |
CHEMBL3425484 |
| Voltage-gated L-type calcium channel |
IC50 |
= |
622500.0 |
nM |
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits |
CHEMBL3436045 |
| Unchecked |
AC50 |
|
510.0 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
0.5012 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
17782.8 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
0.631 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
17.78 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
3.162 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
631.0 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
Ac50 |
|
2.239 |
uM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
3162.3 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| Unchecked |
AC50 |
|
2238.7 |
nM |
PubChem BioAssay. qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel. (Class of assay: confirmatory) |
CHEMBL1201862 |
| PA/PB1 |
IC50 |
|
|
|
Inhibition of Influenza A virus (A/PR/8/34) (H1N1) RNA-dependent-RNA polymerase 6His-tagged-PA/GST-tagged-BP 1 interaction by ELISA |
CHEMBL3576796 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8000.0 |
nM |
Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay |
CHEMBL3576796 |
| HEK-293T |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against human HEK293T cells assessed as decrease in cell viability by MTT assay |
CHEMBL3576796 |
| MDCK |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTT assay |
CHEMBL3576796 |
| Unchecked |
EC50 |
= |
18000.0 |
nM |
Inhibition of Influenza A virus (A/PR/8/34) RNA-dependent-RNA polymerase transfected in HEK293T cells after 24 hrs by renilla luciferase activity/minireplicon assay |
CHEMBL3576796 |
| ADMET |
CC50 |
= |
409000.0 |
nM |
Cytotoxicity against african green monkey Vero B cells |
CHEMBL3580596 |
| Dengue virus 2 |
EC50 |
= |
42000.0 |
nM |
Antiviral activity against DENV serotype 2 strain New Guinea V infected in African green monkey Vero B cells assessed as inhibition of virus replication after 4 days by qRT-PCR analysis |
CHEMBL3580596 |
| Unchecked |
Ratio CC50/EC50 |
> |
10.0 |
|
Selectivity index, ratio of CC50 for African green monkey Vero B cells to EC50 for DENV serotype 2 strain New Guinea V |
CHEMBL3580596 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
115000.0 |
nM |
Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells incubated for 48 hrs assessed as inhibition of virus-induced cytopathic effect by crystal violet staining assay |
CHEMBL3580656 |
| Punta Toro virus |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity |
CHEMBL3585293 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as alternation of cell morphology by microscopic analysis |
CHEMBL3585293 |
| Unchecked |
Selectivity Index |
= |
813.4 |
|
Selectivity index, ratio of TC50 for African green monkey MDCK cells to IC50 for influenza A virus (A/Hanfang/359/95(H3N2)) |
CHEMBL3588851 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
185900.0 |
nM |
Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay |
CHEMBL3588819 |
| Vero |
TC50 |
= |
8189.67 |
uM |
Cytotoxic activity against African green monkey Vero cells assessed as cytopathogenic effect incubated for 48 hrs |
CHEMBL3588851 |
| Human coxsackievirus B3 |
IC50 |
= |
1197580.0 |
nM |
Antiviral activity against coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption |
CHEMBL3588851 |
| Unchecked |
Selectivity Index |
= |
6.8 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for coxsackievirus B3 infected in African green monkey Vero cells |
CHEMBL3588851 |
| MDCK |
TC50 |
= |
4766.8 |
uM |
Cytotoxic activity against MDCK cells assessed as cytopathogenic effect incubated for 48 hrs |
CHEMBL3588851 |
| Influenza A virus |
IC50 |
= |
5860.0 |
nM |
Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption |
CHEMBL3588851 |
| Human coxsackievirus B3 |
IC50 |
= |
1200000.0 |
nM |
Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL3593156 |
| Vero |
TC50 |
= |
8196.0 |
uM |
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CPE assay |
CHEMBL3593156 |
| Unchecked |
Selectivity Index |
= |
6.8 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3-induced cytopathic effect in African green monkey Vero cells |
CHEMBL3593156 |
| SARS coronavirus |
INH |
= |
500.0 |
ug ml-1 |
Antiviral activity against SARS-CoV assessed as inhibition of viral replication |
CHEMBL3596107 |
| Hepatitis C virus |
Activity |
< |
50.0 |
% |
Antiviral activity against HCV genotype 1 in patient assessed as virological response rate |
CHEMBL3600371 |
| Rift Valley fever virus |
IC50 |
= |
37300.0 |
nM |
Antiviral activity against Rift Valley fever virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay |
CHEMBL3603790 |
| Tacaribe virus |
IC50 |
= |
26700.0 |
nM |
Antiviral activity against Tacaribe virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay |
CHEMBL3603790 |
| Influenza B virus |
IC50 |
= |
9000.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells after 3 days by neutral red dye-based plaque reduction assay |
CHEMBL3603790 |
| ADMET |
CC50 |
> |
1000000.0 |
nM |
Cytotoxicity against African green monkey Vero 76 cells |
CHEMBL3603790 |
| ADMET |
CC50 |
> |
1000000.0 |
nM |
Cytotoxicity against African green monkey Vero 76 cells relative to control |
CHEMBL3603790 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells relative to control |
CHEMBL3603790 |
| Human enterovirus 71 |
Activity |
= |
15.0 |
% |
Antiviral activity against human enterovirus 71 infected in ICR mouse assessed as increase in survival rate at 50 mg/kg, ip qd for 8 days dosed 2 hrs post infection and measured at 14 days post infection |
CHEMBL3608223 |
| Unchecked |
Ratio CC50/EC50 |
> |
2.0 |
|
Selectivity index, ratio of CC50 for MDCK cells by neutral red method to EC50 for Influenza A virus (A/California/07/2009(H1N1) virus by neutral red method |
CHEMBL3616454 |
| Unchecked |
Ratio CC50/EC50 |
> |
32.0 |
|
Selectivity index, ratio of CC50 for MDCK cells by visual method to EC50 for Influenza A virus (A/California/07/2009(H1N1) virus by visual method |
CHEMBL3616454 |
| MDCK |
CC50 |
> |
320.0 |
ug.mL-1 |
Cytotoxicity against MDCK cells assessed as cell viability by neutral red assay |
CHEMBL3616454 |
| MDCK |
CC50 |
> |
320.0 |
ug.mL-1 |
Cytotoxicity against MDCK cells assessed as cell viability by visual assay |
CHEMBL3616454 |
| NON-PROTEIN TARGET |
EC50 |
= |
16.0 |
ug.mL-1 |
Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by neutral red assay |
CHEMBL3616454 |
| NON-PROTEIN TARGET |
EC50 |
= |
24.0 |
ug.mL-1 |
Antiviral activity against Influenza A virus (A/California/07/2009(H1N1) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by visual assay |
CHEMBL3616454 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
6800.0 |
nM |
Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 1-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis |
CHEMBL3621162 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC99 |
= |
11.0 |
uM |
Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 2-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis |
CHEMBL3621162 |
| MDCK |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against MDCK cells assessed as cell viability measured at 24 hrs by MTS assay |
CHEMBL3621162 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8400.0 |
nM |
Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in HEK293T cells assessed as reduction in viral RNP reconstitution measured at 24 hrs by luciferase reporter gene assay |
CHEMBL3621162 |
| HEK-293T |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against HEK293T cells assessed as cell viability measured at 24 hrs by MTS assay |
CHEMBL3621162 |
| NON-PROTEIN TARGET |
EC50 |
= |
30400.0 |
nM |
Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs |
CHEMBL3627618 |
| ADMET |
CC50 |
> |
30000.0 |
nM |
Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability incubated for 1 hr by WST-1 assay |
CHEMBL3627618 |
| NON-PROTEIN TARGET |
EC50 |
= |
33500.0 |
nM |
Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs and fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs measured at 72 hrs |
CHEMBL3627618 |
| ADMET |
CC50 |
= |
30500.0 |
nM |
Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability preincubated for 1 hr followed by fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs by WST-1 assay |
CHEMBL3627618 |
| Unchecked |
Ratio CC50/EC50 |
> |
1.0 |
|
Selectivity index, ratio of CC50 for human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene incubated for 1 hr to EC50 for HCV JFH1 infected in human HuH7-J20 cells preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs |
CHEMBL3627618 |
| Unchecked |
Ratio CC50/EC50 |
= |
0.91 |
|
Selectivity index, ratio of CC50 for human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene preincubated for 1 hr followed by fresh drug administration every 24 hrs for 48 hrs to EC50 for HCV JFH1 infected in human HuH7-J20 cells preincubated with cells for 1 hr followed by viral inoculation for 3 hrs and fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs measured at 72 hrs |
CHEMBL3627618 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as alteration in cell morphology by microscopy |
CHEMBL3627667 |
| Human parainfluenza virus 3 |
EC50 |
= |
73500.0 |
nM |
Antiviral activity against Parainfluenza virus 3 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity |
CHEMBL3627667 |
| NON-PROTEIN TARGET |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Reovirus 1 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity |
CHEMBL3627667 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity |
CHEMBL3627667 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackievirus B4 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity |
CHEMBL3627667 |
| Punta Toro virus |
EC50 |
= |
150000.0 |
nM |
Antiviral activity against Punta Toro virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity |
CHEMBL3627667 |
| MT4 |
CC50 |
= |
31000.0 |
nM |
Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay |
CHEMBL3734667 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDBK cells assessed as cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3734667 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay |
CHEMBL3734667 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method |
CHEMBL3734667 |
| Bovine viral diarrhea virus |
EC50 |
= |
8000.0 |
nM |
Antiviral activity against BVDV infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| Yellow fever virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| NON-PROTEIN TARGET |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| Human coxsackievirus B5 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay |
CHEMBL3734667 |
| Human respiratory syncytial virus |
EC50 |
= |
7000.0 |
nM |
Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay |
CHEMBL3734667 |
| Human poliovirus 1 strain Sabin |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay |
CHEMBL3734667 |
| Unchecked |
Ratio CC50/EC50 |
> |
12.5 |
|
Selectivity index, ratio of CC50 for MDBK cells to EC50 for BVDV |
CHEMBL3734667 |
| Unchecked |
Ratio CC50/EC50 |
> |
14.3 |
|
Selectivity index, ratio of CC50 for african green monkey Vero76 cells to EC50 for human RSV |
CHEMBL3734667 |
| Human immunodeficiency virus 1 |
EC50 |
|
|
|
Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay |
CHEMBL3734667 |
| Dengue virus 2 |
EC50 |
|
|
|
Antiviral activity against DENV-2 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| West Nile virus |
EC50 |
|
|
|
Antiviral activity against WNV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3734667 |
| Human herpesvirus 1 |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against HSV1 |
CHEMBL3734667 |
| Vesicular stomatitis virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against VSV |
CHEMBL3734667 |
| Vaccinia virus |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against Vaccinia virus |
CHEMBL3734667 |
| NON-PROTEIN TARGET |
EC50 |
= |
13100.0 |
nM |
Antiviral activity against Chikungunya virus infected in HEK293T cells assessed as reduction of infectivity measured at 24 hrs postinfection by gaussia luciferase reporter gene assay |
CHEMBL3739406 |
| ADMET |
Activity |
> |
80.0 |
% |
Cytotoxicity against HEK293T cells assessed as cell viability at antiviral EC50 after 24 hrs by cell titer-glo luminescent cell viability assay |
CHEMBL3739406 |
| NON-PROTEIN TARGET |
EC50 |
= |
20000.0 |
nM |
Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis |
CHEMBL3739406 |
| NON-PROTEIN TARGET |
Inhibition |
|
|
% |
Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis |
CHEMBL3739406 |
| NON-PROTEIN TARGET |
Inhibition |
= |
10.0 |
% |
Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of infectivity at 5 uM measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis |
CHEMBL3739406 |
| NON-PROTEIN TARGET |
Inhibition |
|
|
% |
Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of nsP1 protein expression at 5 uM measured at 24 hrs postinfection by Western blot method |
CHEMBL3739406 |
| NON-PROTEIN TARGET |
Inhibition |
|
|
% |
Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of nsP3 protein expression at 5 uM measured at 24 hrs postinfection by Western blot method |
CHEMBL3739406 |
| NON-PROTEIN TARGET |
Inhibition |
|
|
% |
Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of viral capsid protein at 5 uM measured at 24 hrs postinfection by Western blot method |
CHEMBL3739406 |
| NON-PROTEIN TARGET |
Inhibition |
|
|
% |
Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of E2 protein expression at 5 uM measured at 24 hrs postinfection by Western blot method |
CHEMBL3739406 |
| NON-PROTEIN TARGET |
EC50 |
= |
18400.0 |
nM |
Antiviral activity against O'nyong-nyong virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis |
CHEMBL3739406 |
| Sindbis virus |
EC50 |
= |
5120.0 |
nM |
Antiviral activity against wild type Sindbis virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis |
CHEMBL3739406 |
| ADMET |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against mock-infected human Huh7.5 cells assessed as reduction in cell viability incubated for 5 hrs by MTT assay |
CHEMBL3751796 |
| Hepatitis C virus |
EC50 |
= |
16300.0 |
nM |
Antiviral activity against recombinant HCV genotype 2a JFH1 infected in human Huh7 cells incubated for 5 hrs measured on day 3 post infection by luciferase reporter gene assay |
CHEMBL3751796 |
| Unchecked |
Ratio CC50/EC50 |
> |
6.1 |
|
Selectivity index, ratio of CC50 for mock-infected human Huh7.5 cells to EC50 for recombinant HCV genotype 2a JFH1 |
CHEMBL3751796 |
| Influenza A virus H3N2 |
IC50 |
= |
87.7 |
ug.mL-1 |
Antiviral activity against Influenza A virus H3N2 A3/JINGKE/30/95 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs |
CHEMBL3751821 |
| MDCK |
TC50 |
= |
3277.4 |
ug ml-1 |
Cytotoxicity against MDCK cells after 72 hrs by MTT assay |
CHEMBL3751821 |
| ADMET |
TI |
= |
37.37 |
|
Therapeutic index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus H3N2 A3/JINGKE/30/95 |
CHEMBL3751821 |
| Human herpesvirus 2 |
EC50 |
|
|
|
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 72 hrs by crystal violet staining technique |
CHEMBL3758103 |
| Dengue virus 2 |
EC50 |
|
|
|
Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 8 days by crystal violet staining technique |
CHEMBL3758103 |
| Human herpesvirus 1 |
EC50 |
|
|
|
Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique |
CHEMBL3758103 |
| Human herpesvirus 2 |
EC50 |
|
|
|
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique |
CHEMBL3758103 |
| Dengue virus 2 |
EC50 |
= |
13500.0 |
nM |
Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 8 days by crystal violet staining technique |
CHEMBL3758103 |
| Human herpesvirus 2 |
FC |
|
|
|
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction of viral titer at maximal non-toxic concentration after 72 hrs by crystal violet staining assay relative to control |
CHEMBL3758103 |
| Human herpesvirus 2 |
MNTD |
|
|
|
Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as maximal non toxic concentration causing reduction of viral titer after 72 hrs by crystal violet staining assay |
CHEMBL3758103 |
| Dengue virus 2 |
Activity |
|
|
|
Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining based inverted microscopic analysis relative to control |
CHEMBL3758103 |
| Human herpesvirus 1 |
FC |
|
|
|
Antiviral activity against HHV1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction of viral titer at maximal non-toxic concentration after 48 hrs by crystal violet staining assay relative to control |
CHEMBL3758103 |
| Human herpesvirus 1 |
MNTD |
|
|
|
Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as maximal non toxic concentration causing reduction of viral titer after 48 hrs by crystal violet staining assay |
CHEMBL3758103 |
| Dengue virus 2 |
MNTD |
= |
123.0 |
uM |
Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as maximal non toxic concentration causing inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining based inverted microscopic analysis |
CHEMBL3758103 |
| Vero |
IC50 |
|
|
|
Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 72 hrs |
CHEMBL3758103 |
| Vero |
IC50 |
|
|
|
Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 8 days |
CHEMBL3758103 |
| Human herpesvirus 1 |
EC50 |
|
|
|
Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 72 hrs by crystal violet staining technique |
CHEMBL3758103 |
| Dengue virus 2 |
Activity |
= |
8.3 |
PbU |
Antiviral activity against Dengue virus 2 infected in human HepG2 cells assessed as NS1 level at < maximum non-toxic concentration after 72 hrs by sandwich ELISA (Rvb = 44.5 +/- 3.2 PbU) |
CHEMBL3763009 |
| MDCK |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay |
CHEMBL3769343 |
| Influenza A virus |
EC50 |
= |
1050.0 |
nM |
Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay |
CHEMBL3769343 |
| Influenza A virus |
EC50 |
= |
1430.0 |
nM |
Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay |
CHEMBL3769343 |
| Influenza A virus |
EC50 |
= |
3560.0 |
nM |
Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay |
CHEMBL3769343 |
| Influenza B virus |
EC50 |
= |
4280.0 |
nM |
Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay |
CHEMBL3769343 |
| ADMET |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay |
CHEMBL3792357 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
12800.0 |
nM |
Antiviral activity against Influenza A virus PR/8/34 infected in MDCK cells assessed as inhibition of plaque formation treated for 1 hr measured after 2 days by toluidine blue staining-based assay |
CHEMBL3792357 |
| PA/PB1 |
IC50 |
|
|
|
Inhibition of Influenza A virus PR/8/34 6His-tagged PA (239 to 716 residues) interaction with GST-tagged PB1 (1 to 25 residues) expressed in Escherichia coli compound treated in PBS buffer measured after overnight incubation by ELISA |
CHEMBL3792357 |
| MDCK |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay |
CHEMBL3792357 |
| Unchecked |
EC50 |
= |
23800.0 |
nM |
Inhibition of Influenza A virus RdRp transfected in HEK293T cells at 24 hrs by dual luciferase reporter gene-based minireplicon assay |
CHEMBL3792357 |
| Unchecked |
Ratio CC50/EC50 |
> |
19.5 |
|
Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus PR/8/34 infected in MDCK cells |
CHEMBL3792357 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8700.0 |
nM |
Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect |
CHEMBL3797100 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
7500.0 |
nM |
Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay |
CHEMBL3797100 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay |
CHEMBL3797100 |
| NON-PROTEIN TARGET |
EC50 |
= |
1300.0 |
nM |
Antiviral activity against BVDV NADL infected in MDBK cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay |
CHEMBL3808296 |
| ADMET |
CC50 |
= |
5000.0 |
nM |
Cytotoxicity against mock-infected MDBK cells assessed as reduction in cell viability after 72 hrs by MTT assay |
CHEMBL3808296 |
| Unchecked |
Ratio CC50/EC50 |
= |
3.8 |
|
Selectivity index, ratio of CC50 for MDBK cells to EC50 for mock-infected BVDV NADL infected in MDBK cells |
CHEMBL3808296 |
| Hepatitis C virus |
IC50 |
= |
40.0 |
nM |
Antiviral activity against Hepatitis C virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect |
CHEMBL3813617 |
| Human herpesvirus 1 |
IC50 |
= |
10000.0 |
nM |
Antiviral activity against Herpes simplex virus type 1 L2 infected in African green monkey Vero E6 cells assessed as reduction of virus-induced cytopathic effect |
CHEMBL3813617 |
| ADMET |
CC50 |
= |
300.0 |
nM |
Cytotoxicity against African green monkey Vero E6 cells |
CHEMBL3813617 |
| NON-PROTEIN TARGET |
EC50 |
= |
1300.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus 1 infected in MDBK cells |
CHEMBL3853301 |
| NON-PROTEIN TARGET |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as alterations in cell morphology by microscopic analysis |
CHEMBL3875201 |
| NON-PROTEIN TARGET |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis |
CHEMBL3875201 |
| NON-PROTEIN TARGET |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis |
CHEMBL3875201 |
| NON-PROTEIN TARGET |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis |
CHEMBL3875201 |
| NON-PROTEIN TARGET |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis |
CHEMBL3875201 |
| NON-PROTEIN TARGET |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis |
CHEMBL3875201 |
| NON-PROTEIN TARGET |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis |
CHEMBL3875201 |
| Schistosoma mansoni |
ALT |
= |
48.5 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
41800.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
390.83 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
89.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
148.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
24830000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
100.83 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
725.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
503.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1630.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
316.83 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
9.83 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
115.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
6.16 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
142.62 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
58000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
16.5 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
40.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
13599.5 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
239.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
1021.17 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5710000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
36.35 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
140500.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
14900.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
91.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
24.62 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
386500.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
63.7 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
1.5 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
7.17 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.33 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1225500.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
50.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
42800.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
380.17 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
82.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
153.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
27170000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
100.33 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
606.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
441.5 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
1.6 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1460.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
189.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
9.17 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
116.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
6.86 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
142.33 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
61200.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
18.2 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
21.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
14288.5 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
205.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
968.5 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.17 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5830000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
36.53 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
144000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
15480.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
92.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
24.72 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
394300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
62.68 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
1.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
6.5 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.17 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1280500.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
53.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
43000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
371.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
93.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
136.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
27670000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
101.0 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
713.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
286.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
1.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1576.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
257.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
9.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
133.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
6.94 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
145.03 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
2.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
59700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
19.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
33.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
13109.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
126.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
1164.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5440000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
33.17 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
127700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
14430.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
91.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
23.47 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
385300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
60.97 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
0.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
7.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.0 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1365670.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
43.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
43700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
347.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
75.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
136.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
26000000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
102.0 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
630.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
230.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
1.6 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1533.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
88.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
8.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
116.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
6.69 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
143.93 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
60000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
15.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
17320.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
316.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
1397.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
5460000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
34.3 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
134700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
19030.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
91.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
24.7 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
392300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
62.87 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
1.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
7.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.0 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1248670.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
55.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
31700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
195.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
225.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
133.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
20000000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
113.33 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
880.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
1322.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
1.2 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
2116.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
634.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
7.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
140.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
7.0 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
151.47 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
44700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
26.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
6405.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
112.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
1482.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
6370000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
39.37 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
157700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
8000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
80.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
24.77 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
400700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
61.7 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
1.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
18.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.0 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1071000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
185.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
37000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
293.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
480.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
163.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
16000000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
104.33 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
830.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
1211.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
2.2 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1710.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
651.67 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
35.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
148.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
7.1 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
148.0 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
2.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
53300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
47.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
216.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
9535.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
1715.67 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
2.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
6280000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
39.7 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
148000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
11470.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
82.67 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
23.53 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
373000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
63.2 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
15.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.0 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1269330.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALT |
= |
34.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALB |
= |
36300.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
ALP |
= |
197.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
AST |
= |
117.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BUN |
= |
150.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CO2 |
= |
16000000.0 |
nM |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHLORIDE |
= |
107.67 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CHOL |
= |
656.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CK |
= |
1121.0 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
CREAT |
= |
1.9 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
GLUC |
= |
1603.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LDH |
= |
427.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LIPASE |
= |
14.33 |
U.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PHOS |
= |
170.7 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
POTASSIUM |
= |
7.12 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
SODIUM |
= |
147.03 |
mEq.L-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BILI |
= |
1.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PROT |
= |
52000.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
URATE |
= |
30.3 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOS |
= |
179.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYM |
= |
10736.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONO |
= |
0.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTSG |
= |
2451.33 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
BASOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
EOSLE |
= |
1.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBC |
= |
6480000.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HCT |
= |
40.57 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
HGB |
= |
153700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
WBC |
= |
13370.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
LYMLE |
= |
81.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCH |
= |
23.67 |
pg |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCHC |
= |
378700.0 |
ug.mL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MCV |
= |
62.53 |
fL |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
MONOLE |
= |
0.0 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
NEUTLE |
= |
17.33 |
% |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
RBCNUC |
= |
0.33 |
/100WBC |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
PLAT |
= |
1066330.0 |
cells.uL-1 |
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| Schistosoma mansoni |
Tissue Severity Score |
|
|
|
In vitro activity on S. mansoni schistosomula at 50 uM |
CHEMBL3885881 |
| HEL |
MCC |
>= |
250000.0 |
nM |
Cytotoxicity against virus infected HEL cells assessed as alteration in cell morphology by microscopic method |
CHEMBL3994569 |
| Human coronavirus 229E |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Human coronavirus 229E infected in HEL cells assessed as reduction in virus-induced cytopathogenicity |
CHEMBL3994569 |
| Influenza A virus |
IC50 |
= |
1300.0 |
nM |
Antiviral activity against Influenza A virus A/95-359 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL3994572 |
| MDCK |
TC50 |
= |
1164.0 |
umol/L |
Cytotoxicity against MDCK cells assessed as growth inhibition after 48 hrs |
CHEMBL3994572 |
| Unchecked |
Selectivity Index |
= |
895.0 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/95-359) infected in MDCK cells |
CHEMBL3994572 |
| Human coxsackievirus B3 |
IC50 |
= |
292000.0 |
nM |
Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL3994572 |
| Unchecked |
Selectivity Index |
= |
6.8 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3 infected in African green monkey Vero cells |
CHEMBL3994572 |
| MDCK |
TC50 |
= |
1164.1 |
ug ml-1 |
Cytotoxicity against MDCK cells after 48 hrs by by Reed and Muench analysis |
CHEMBL3997818 |
| Influenza A virus H3N2 |
IC50 |
= |
1.1 |
ug.mL-1 |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 40 hrs |
CHEMBL3997818 |
| Influenza A virus |
IC50 |
= |
2.1 |
ug.mL-1 |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 40 hrs |
CHEMBL3997818 |
| Influenza B virus |
IC50 |
= |
0.8 |
ug.mL-1 |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 40 hrs |
CHEMBL3997818 |
| Unchecked |
Selectivity Index |
= |
1100.0 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus H3N2 infected in MDCK cells |
CHEMBL3997818 |
| Unchecked |
Selectivity Index |
= |
560.0 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus H1N1 infected in MDCK cells |
CHEMBL3997818 |
| Unchecked |
Selectivity Index |
= |
1400.0 |
|
Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus infected in MDCK cells |
CHEMBL3997818 |
| Influenza A virus |
EC50 |
= |
6900.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Influenza B virus |
EC50 |
= |
4000.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Influenza A virus |
EC50 |
= |
7200.0 |
nM |
Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| MDCK |
CC50 |
= |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as inhibition of cell viability by colorimetric formazan-based MTS assay |
CHEMBL4000146 |
| MDCK |
MCC |
= |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as alteration of normal cell morphology by microscopic analysis |
CHEMBL4000146 |
| Punta Toro virus |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Coxsackievirus |
EC50 |
= |
250000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Human parainfluenza virus 3 |
EC50 |
= |
85000.0 |
nM |
Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Human respiratory syncytial virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Coxsackievirus |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Vesicular stomatitis virus |
EC50 |
= |
22000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis |
CHEMBL4000146 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against african green monkey Vero cells assessed as alteration of normal cell morphology by microscopic analysis |
CHEMBL4000146 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as alteration of normal cell morphology by microscopic analysis |
CHEMBL4000146 |
| Vero |
TC50 |
= |
6355.7 |
uM |
Cytotoxicity against African green monkey Vero cells assessed as cytopathic effect after 48 hrs |
CHEMBL4002549 |
| Unchecked |
IC50 |
= |
379100.0 |
nM |
Antiviral activity against Coxsackievirus B3 Nancy infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4002549 |
| Unchecked |
Selectivity Index |
= |
11.8 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3 Nancy infected in African green monkey Vero cells |
CHEMBL4002549 |
| Human coxsackievirus B1 |
IC50 |
= |
2375000.0 |
nM |
Antiviral activity against Coxsackievirus B1 Conn 5 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4002549 |
| Unchecked |
IC50 |
> |
500000.0 |
nM |
Antiviral activity against Coxsackievirus B2 Ohio-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4002549 |
| Human coxsackievirus B4 |
IC50 |
> |
500000.0 |
nM |
Antiviral activity against Coxsackievirus B4 JVB infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4002549 |
| Human coxsackievirus B5 |
IC50 |
= |
3316000.0 |
nM |
Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4002549 |
| Unchecked |
IC50 |
= |
2088000.0 |
nM |
Antiviral activity against Coxsackievirus B6 Schmitt infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect |
CHEMBL4002549 |
| Unchecked |
IC50 |
= |
379120.0 |
nM |
Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis |
CHEMBL4002621 |
| Vero |
TC50 |
>= |
6355.68 |
uM |
Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs |
CHEMBL4002621 |
| Unchecked |
Selectivity Index |
= |
16.76 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3 (strain Nancy) infected in African green monkey Vero cells |
CHEMBL4002621 |
| Human coxsackievirus B1 |
IC50 |
= |
2375000.0 |
nM |
Antiviral activity against Coxsackievirus B1 Conn-5 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis |
CHEMBL4002621 |
| Unchecked |
IC50 |
> |
40948000.0 |
nM |
Antiviral activity against Coxsackievirus B2 (strain Ohio-1) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis |
CHEMBL4002621 |
| Human coxsackievirus B4 |
IC50 |
> |
40948000.0 |
nM |
Antiviral activity against Coxsackievirus B4 J.V.B infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis |
CHEMBL4002621 |
| Human coxsackievirus B5 |
IC50 |
= |
3316000.0 |
nM |
Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis |
CHEMBL4002621 |
| Unchecked |
IC50 |
= |
2088000.0 |
nM |
Antiviral activity against Coxsackievirus B6 (strain Schmitt) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis |
CHEMBL4002621 |
| Unchecked |
Selectivity Index |
> |
17.2 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B1 Conn-5 infected in African green monkey Vero cells |
CHEMBL4002621 |
| Unchecked |
Selectivity Index |
> |
12.3 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B5 Faulkner infected in African green monkey Vero cells |
CHEMBL4002621 |
| Unchecked |
Selectivity Index |
> |
19.6 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B6 (strain Schmitt) infected in African green monkey Vero cells |
CHEMBL4002621 |
| Coxsackievirus A16 |
IC50 |
= |
9622000.0 |
nM |
Antiviral activity against Coxsackievirus A16 shzh05-1 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis |
CHEMBL4002621 |
| Unchecked |
Selectivity Index |
> |
4.3 |
|
Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus A16 shzh05-1 infected in African green monkey Vero cells |
CHEMBL4002621 |
| Unchecked |
Inhibition |
= |
85.47 |
% |
Antiviral activity against Influenza virus A/WSN/33(H1N1) infected in human 293T cells assessed as inhibition of viral replication at 20 uM preincubated for 2 hrs followed by viral infection measured after 24 hrs by luciferase reporter gene assay relative to control |
CHEMBL4007499 |
| HEK-293T |
Inhibition |
= |
0.0 |
% |
Cytotoxicity against human 293T cells expressing Gluc assessed as inhibition of cell proliferation at 20 uM after 24 hrs by CCK8 assay relative to control |
CHEMBL4007499 |
| Unchecked |
EC50 |
= |
17950.0 |
nM |
Antiviral activity against Influenza virus A/WSN/33(H1N1) infected in human 293T cells assessed as inhibition of viral replication preincubated for 2 hrs followed by viral infection measured after 24 hrs by luciferase reporter gene assay |
CHEMBL4007499 |
| HEK-293T |
CC50 |
> |
205000.0 |
nM |
Cytotoxicity against human 293T cells expressing Gluc assessed as inhibition of cell proliferation after 24 hrs by CCK8 assay |
CHEMBL4007499 |
| Unchecked |
Ratio CC50/EC50 |
> |
11.42 |
|
Selectivity index, ratio of CC50 for human 293T cells expressing Gluc to EC50 for Influenza A virus WSN/33(H1N1) |
CHEMBL4007499 |
| Chikungunya virus |
EC50 |
= |
16200.0 |
nM |
Antiviral activity against full length Gaussia princeps Gluc-tagged Chikungunya virus IMT infected in HEK293T cells assessed as reduction in virus infection after 24 hrs by Gaussia luciferase reporter gene assay |
CHEMBL4007509 |
| HEK-293T |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay |
CHEMBL4007509 |
| Chikungunya virus |
EC50 |
= |
1890.0 |
nM |
Antiviral activity against full length gluc-tagged Chikungunya virus 2008 Singapore SGP11 infected in HEK293T cells assessed as reduction in virus infection after 24 hrs by gaussia luciferase reporter gene assay |
CHEMBL4007509 |
| Chikungunya virus |
EC50 |
= |
1970.0 |
nM |
Antiviral activity against full length gluc-tagged Chikungunya virus 2013 Caribbean CNR20235 infected in HEK293T cells assessed as reduction in virus infection after 24 hrs by gaussia luciferase reporter gene assay |
CHEMBL4007509 |
| Chikungunya virus |
EC50 |
= |
9710.0 |
nM |
Antiviral activity against full length gluc-tagged Chikungunya virus IMT infected in human BJ cells assessed as reduction in virus infection after 24 hrs by gaussia luciferase reporter gene assay |
CHEMBL4007509 |
| BJ |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay |
CHEMBL4007509 |
| Vero C1008 |
MCC |
> |
4095000.0 |
nM |
Cytotoxicity against African green monkey Vero E6 cells measured after 3 days by trypan blue assay |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
512000.0 |
nM |
Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
8.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 L2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
1024000.0 |
nM |
Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
4.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
1024000.0 |
nM |
Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
4.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
1024000.0 |
nM |
Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
4.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 F+ infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
1024000.0 |
nM |
Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
4.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC50 |
= |
1024000.0 |
nM |
Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Unchecked |
Selectivity Index |
> |
4.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
= |
2048000.0 |
nM |
Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
> |
4095000.0 |
nM |
Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
> |
4095000.0 |
nM |
Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
> |
4095000.0 |
nM |
Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
> |
4095000.0 |
nM |
Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Human herpesvirus 1 |
IC95 |
> |
4095000.0 |
nM |
Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect |
CHEMBL4017472 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
16000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by microscopic method |
CHEMBL4024772 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
45000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by MTS assay |
CHEMBL4024772 |
| Unchecked |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against Influenza A virus (A/Virginia/ATCC3/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by microscopic method |
CHEMBL4024772 |
| Unchecked |
EC50 |
= |
9800.0 |
nM |
Antiviral activity against Influenza A virus (A/Virginia/ATCC3/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by MTS assay |
CHEMBL4024772 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs by MTS assay |
CHEMBL4024772 |
| MDCK |
MCC |
>= |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as effect on cell morphology after 72 hrs by microscopic method |
CHEMBL4024772 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) clone 1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity measured after 3 passages with 12.5 to 50 uM 2-Isopropyl-N-[2-(piperidin-1-yl)ethyl]aniline hydrochloride by microscopic method |
CHEMBL4024772 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) clone 2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity measured after 3 passages with 12.5 to 50 uM 2-Isopropyl-N-[2-(piperidin-1-yl)ethyl]aniline hydrochloride by microscopic method |
CHEMBL4024772 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
15000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) clone 1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity measured after passage in absence of 2-Isopropyl-N-[2-(piperidin-1-yl)ethyl]aniline hydrochloride by microscopic method |
CHEMBL4024772 |
| Bile salt export pump |
IC50 |
> |
133000.0 |
nM |
Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Canalicular multispecific organic anion transporter 1 |
IC50 |
> |
133000.0 |
nM |
Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Canalicular multispecific organic anion transporter 2 |
IC50 |
> |
133000.0 |
nM |
Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Multidrug resistance-associated protein 4 |
IC50 |
> |
133000.0 |
nM |
Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay |
CHEMBL4028801 |
| Homo sapiens |
DILI_severity_class |
= |
7.0 |
|
Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index |
CHEMBL4028802 |
| Homo sapiens |
DILI_Concern |
|
|
|
Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status |
CHEMBL4028802 |
| Unchecked |
EC50 |
= |
8400.0 |
nM |
Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay |
CHEMBL4052640 |
| Unchecked |
EC50 |
= |
19000.0 |
nM |
Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay |
CHEMBL4052640 |
| Influenza A virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay |
CHEMBL4052640 |
| Influenza A virus |
EC50 |
= |
7600.0 |
nM |
Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay |
CHEMBL4052640 |
| Influenza B virus |
EC50 |
= |
4900.0 |
nM |
Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay |
CHEMBL4052640 |
| Unchecked |
EC50 |
= |
3900.0 |
nM |
Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay |
CHEMBL4052640 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay |
CHEMBL4052640 |
| MDCK |
MCC |
>= |
100000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as alterations in normal cell morphology measured after 5 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Vesicular stomatitis virus |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Human coxsackievirus B4 |
EC50 |
= |
85000.0 |
nM |
Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Human parainfluenza virus 3 |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Punta Toro virus |
EC50 |
= |
29000.0 |
nM |
Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Yellow fever virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Respiratory syncytial virus |
EC50 |
= |
5800.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis |
CHEMBL4052640 |
| Unchecked |
EC50 |
= |
7700.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus 1-NADL infected in bovine MDBK cells assessed as reduction in plaque forming units after 72 hrs by crystal violet staining-based assay |
CHEMBL4052663 |
| Unchecked |
CC50 |
= |
54400.0 |
nM |
Cytotoxicity against bovine MDBK cells assessed as reduction in cell viability after 3 days by MTS/PES assay |
CHEMBL4052663 |
| Unchecked |
Ratio CC50/EC50 |
= |
7.1 |
|
Selectivity index, ratio of CC50 for bovine MDBK cells to EC50 for Bovine viral diarrhea virus 1-NADL |
CHEMBL4052663 |
| MDCK |
CC50 |
> |
2130000.0 |
nM |
Cytotoxicity against MDCK cells after 48 hrs by MTT assay |
CHEMBL4118151 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
44000.0 |
nM |
Antiviral activity against amantadine/rimantadine-resistant Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutination test |
CHEMBL4118151 |
| Unchecked |
Ratio CC50/IC50 |
= |
48.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to IC50 for amantadine/rimantadine-resistant Influenza A virus (A/Puerto Rico/8/34(H1N1)) |
CHEMBL4118151 |
| Human parainfluenza virus 3 |
EC50 |
= |
95000.0 |
nM |
Antiviral activity against Parainfluenza virus 3 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Reovirus-1 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Vesicular stomatitis virus |
EC50 |
= |
146000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Respiratory syncytial virus |
EC50 |
= |
25000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Influenza A virus |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay |
CHEMBL4118253 |
| Influenza A virus H3N2 |
EC50 |
= |
8600.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay |
CHEMBL4118253 |
| Influenza B virus |
EC50 |
= |
9800.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay |
CHEMBL4118253 |
| Sindbis virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Sindbis Virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Punta Toro virus |
EC50 |
= |
126000.0 |
nM |
Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Yellow fever virus |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity |
CHEMBL4118253 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL4118253 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL4118253 |
| Influenza A virus |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity |
CHEMBL4118253 |
| Influenza A virus H3N2 |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity |
CHEMBL4118253 |
| Influenza B virus |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity |
CHEMBL4118253 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as alteration of cell morphology by microscopic analysis |
CHEMBL4118253 |
| RD |
CC50 |
= |
485.9 |
ug.mL-1 |
Cytotoxicity against human RD cells assessed as reduction in cell viability after 3 days by MTT assay |
CHEMBL4130414 |
| HEp-2 |
CC50 |
= |
571.6 |
ug.mL-1 |
Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 3 days by MTT assay |
CHEMBL4130414 |
| Human enterovirus 71 |
EC50 |
= |
32.5 |
ug.mL-1 |
Antiviral activity against EV71 Xiangyang-Hubei-09 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect by MTT dye based assay |
CHEMBL4130414 |
| Unchecked |
Ratio CC50/EC50 |
= |
15.0 |
|
Selectivity index, ratio of CC50 for human RD cells to EC50 for EV71 Xiangyang-Hubei-09 infected in human RD cells |
CHEMBL4130414 |
| Human coxsackievirus B3 |
EC50 |
= |
42.9 |
ug.mL-1 |
Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in human HEP2 cells assessed as inhibition of virus-induced cytopathic effect by MTT dye based assay |
CHEMBL4130414 |
| Unchecked |
Ratio CC50/EC50 |
= |
13.3 |
|
Selectivity index, ratio of CC50 for human HEP2 cells to EC50 for Coxsackievirus B3 (strain Nancy) infected in human HEP cells |
CHEMBL4130414 |
| Human enterovirus 71 |
Inhibition |
|
|
% |
Antiviral activity against EV71 Xiangyang-Hubei-09 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect at 16 ug/ml treated 1 hr post viral infection measured after 48 hrs by MTT dye based assay relative to control |
CHEMBL4130414 |
| Human coxsackievirus B3 |
Inhibition |
|
|
% |
Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in human HEP2 cells assessed as inhibition of virus-induced cytopathic effect at 16 ug/ml after 48 hrs by MTT dye based assay |
CHEMBL4130414 |
| Unchecked |
CC50 |
= |
62000.0 |
nM |
Cytotoxicity against bovine MDBK cells assessed as decrease in cell viability after 72 hrs by MTT assay |
CHEMBL4130485 |
| Bovine viral diarrhea virus |
EC50 |
= |
20000.0 |
nM |
Antiviral activity against Bovine viral diarrhea virus NADL ATCC VR 534 infected in bovine MDBK cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay |
CHEMBL4130485 |
| Unchecked |
Ratio CC50/EC50 |
= |
3.0 |
|
Selectivity index, ratio of CC50 for bovine MDBK cells to EC50 for Bovine viral diarrhea virus NADL ATCC VR 534 |
CHEMBL4130485 |
| Vero 76 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay |
CHEMBL4130485 |
| Human respiratory syncytial virus |
EC50 |
= |
1200.0 |
nM |
Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay |
CHEMBL4130485 |
| Dengue virus 2 |
Inhibition |
= |
10.14 |
% |
Antiviral activity against Fluc-tagged DENV2 strain 16681 infected in human HuH7 cells assessed as inhibition of viral replication at 1 uM after 3 days by luciferase reporter gene assay relative to control |
CHEMBL4130503 |
| Dengue virus 2 |
Inhibition |
= |
32.53 |
% |
Antiviral activity against Fluc-tagged DENV2 strain 16681 infected in human HuH7 cells assessed as inhibition of viral replication at 10 uM after 3 days by luciferase reporter gene assay relative to control |
CHEMBL4130503 |
| Huh-7 |
Activity |
= |
71.37 |
% |
Cytotoxicity against human HuH7 cells assessed as cell viability at 20 uM after 3 days by XTT method relative to control |
CHEMBL4130503 |
| Huh-7 |
Activity |
= |
26.78 |
% |
Cytotoxicity against human HuH7 cells assessed as cell viability at 200 uM after 3 days by XTT method relative to control |
CHEMBL4130503 |
| Dengue virus 2 |
IC50 |
= |
12610.0 |
nM |
Antiviral activity against Fluc-tagged DENV2 strain 16681 infected in human HuH7 cells after 3 days by luciferase reporter gene assay |
CHEMBL4130503 |
| Huh-7 |
CC50 |
= |
56310.0 |
nM |
Cytotoxicity against human HuH7 cells assessed as growth inhibition after 3 days by XTT method |
CHEMBL4130503 |
| Unchecked |
Ratio CC50/IC50 |
= |
4.47 |
|
Selectivity index, ratio of CC50 for human HuH7 cells to IC50 for Fluc-tagged DENV2 strain 16681 infected in human HuH7 cells |
CHEMBL4130503 |
| Influenza A virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis |
CHEMBL4130627 |
| Influenza A virus |
EC50 |
= |
13000.0 |
nM |
Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay |
CHEMBL4130627 |
| Influenza B virus |
EC50 |
= |
5900.0 |
nM |
Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis |
CHEMBL4130627 |
| Influenza B virus |
EC50 |
= |
4500.0 |
nM |
Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay |
CHEMBL4130627 |
| MDCK |
MCC |
= |
59000.0 |
nM |
Cytotoxicity against MDCK cells assessed as change in cell morphology after 3 days by microscopic analysis |
CHEMBL4130627 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay |
CHEMBL4130627 |
| Influenza A virus |
EC50 |
= |
5000.0 |
nM |
Antiviral activity against Influenza virus A/X-31 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis |
CHEMBL4130627 |
| Influenza A virus |
EC50 |
= |
5800.0 |
nM |
Antiviral activity against Influenza virus A/X-31 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay |
CHEMBL4130627 |
| Influenza B virus |
EC50 |
= |
2200.0 |
nM |
Antiviral activity against Influenza virus B/Ned/537/05 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis |
CHEMBL4130627 |
| Influenza B virus |
EC50 |
= |
1500.0 |
nM |
Antiviral activity against Influenza virus B/Ned/537/05 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay |
CHEMBL4130627 |
| MDCK |
MCC |
= |
35000.0 |
nM |
Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as change in cell morphology after 3 days by microscopic analysis |
CHEMBL4130627 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay |
CHEMBL4130627 |
| Hepatitis C virus |
Inhibition |
= |
31.2 |
% |
Antiviral activity against HCV infected in human Ava5 cells assessed as inhibition of viral RNA replication at 5 uM after 3 days by RT-qPCR method relative to control |
CHEMBL4138248 |
| Unchecked |
Ratio CC50/IC50 |
= |
8.08 |
|
Selectivity index, ratio of CC50 for human Ava5 cells to IC50 for HCV |
CHEMBL4138248 |
| Unchecked |
CC50 |
= |
106270.0 |
nM |
Cytotoxicity against human Ava5 cells assessed as decrease in cell viability after 72 hrs by XTT assay |
CHEMBL4138248 |
| Hepatitis C virus |
IC50 |
= |
13160.0 |
nM |
Antiviral activity against HCV infected in human Ava5 cells assessed as inhibition of viral RNA replication after 3 days by RT-qPCR method |
CHEMBL4138248 |
| Unchecked |
Activity |
= |
26.78 |
% |
Cytotoxicity against human Ava5 cells assessed as cell viability at 200 uM after 72 hrs by XTT assay relative to control |
CHEMBL4138248 |
| Unchecked |
Activity |
= |
71.37 |
% |
Cytotoxicity against human Ava5 cells assessed as cell viability at 20 uM after 72 hrs by XTT assay relative to control |
CHEMBL4138248 |
| Hepatitis C virus |
Inhibition |
= |
65.74 |
% |
Antiviral activity against HCV infected in human Ava5 cells assessed as inhibition of viral RNA replication at 20 uM after 3 days by RT-qPCR method relative to control |
CHEMBL4138248 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as alterations in normal cell morphology measured after 3 to 6 days by microscopic analysis |
CHEMBL4152296 |
| Respiratory syncytial virus |
EC50 |
= |
5800.0 |
nM |
Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 to 6 days by MTS based microscopy |
CHEMBL4152296 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay |
CHEMBL4152296 |
| Influenza B virus |
EC50 |
= |
3200.0 |
nM |
Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay |
CHEMBL4152296 |
| MDCK |
MCC |
>= |
20000.0 |
nM |
Cytotoxicity against MDCK cells assessed as alterations in normal cell morphology measured after 3 to 6 days by microscopic analysis |
CHEMBL4152296 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay |
CHEMBL4152296 |
| Chikungunya virus |
EC50 |
= |
341000.0 |
nM |
Antiviral activity against Chikungunya virus C347 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect after 2 days by microscopic analysis |
CHEMBL4177563 |
| Unchecked |
Ratio CC50/IC50 |
= |
529.0 |
|
Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Chikungunya virus KC969207 |
CHEMBL4177563 |
| Vero |
CC50 |
= |
1622000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by MTT assay |
CHEMBL4177563 |
| Chikungunya virus |
IC50 |
= |
3060.0 |
nM |
Antiviral activity against Chikungunya virus KC969207 infected in African green monkey Vero cells after 48 hrs by MTT dye-based assay |
CHEMBL4177563 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
103000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 48 hrs by crystal-violet staining-based assay |
CHEMBL4184132 |
| Unchecked |
CC50 |
= |
75.0 |
ug.mL-1 |
Cytotoxicity against pig SPEV cells by microscopic analysis |
CHEMBL4184172 |
| Hepatitis C virus |
IC50 |
= |
12.5 |
ug.mL-1 |
Antiviral activity against Hepatitis C virus infected in pig SPEV cells assessed as protection against virus-induced cytopathic effect |
CHEMBL4184172 |
| Human herpesvirus 1 |
IC50 |
= |
125.0 |
ug.mL-1 |
Antiviral activity against Human herpesvirus 1 L2 infected in African green monkey Vero E6 cells assessed as protection against virus-induced cytopathic effect |
CHEMBL4184172 |
| Influenza A virus |
IC50 |
= |
12.5 |
ug.mL-1 |
Antiviral activity against Influenza A virus H5N1 (A/duck/Novosibirsk/56/2005) infected in pig SPEV cells assessed as protection against virus-induced cytopathic effect |
CHEMBL4184172 |
| Influenza A virus |
IC50 |
= |
2.0 |
nM |
Antiviral activity against VSV-G pseudotyped Influenza A virus infected in human SupT1 cells after 48 hrs by firefly luciferase reporter gene assay |
CHEMBL4190193 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells measured after 48 hrs post infection by plaque reduction assay |
CHEMBL4190233 |
| MDCK |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay |
CHEMBL4190233 |
| Genome polyprotein |
EC50 |
> |
100000.0 |
nM |
Inhibition of Enterovirus 71 Shenzhen/120F1/09 capsid infected in human RD cells assessed as reduction in virus-induced cell death after 72 hrs by CCK-8 assay |
CHEMBL4190331 |
| Mus musculus |
Activity |
|
|
|
Toxicity in ICR mouse infected with EV71 695F assessed as death at 100 mg/kg, ip qd administered for 7 days measured on day 5 |
CHEMBL4190331 |
| Mus musculus |
Activity |
|
|
|
Toxicity in ICR mouse infected with EV71 695F assessed as death at 50 mg/kg, ip qd administered for 7 days measured on day 6 |
CHEMBL4190331 |
| Influenza A virus |
Inhibition |
|
|
% |
Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells cocultured with human 293T-Gluc cells at 20 uM preincubated with compound for 2 hrs followed by virus infection measured after 24 hrs by luciferase reporter gene assay relative to control |
CHEMBL4219201 |
| Influenza A virus |
Inhibition |
|
|
% |
Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells cocultured with human 293T-Gluc cells at 100 uM preincubated with compound for 2 hrs followed by virus infection measured after 24 hrs by luciferase reporter gene assay relative to control |
CHEMBL4219201 |
| Influenza A virus |
IC50 |
= |
22600.0 |
nM |
Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells cocultured with human 293T-Gluc cells preincubated with compound for 2 hrs followed by virus infection measured after 24 hrs by luciferase reporter gene assay |
CHEMBL4219201 |
| MDCK |
CC50 |
|
|
|
Cytotoxicity against MDCK cells assessed as reduction in cell viability by CCK8 assay |
CHEMBL4219201 |
| MDCK |
CC50 |
= |
1365500.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by crystal violet staining based method |
CHEMBL4229464 |
| Influenza A virus |
IC50 |
= |
99600.0 |
nM |
Antiviral activity against Influenza A virus (A/Aichi/2/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 48 hrs by crystal violet staining based method |
CHEMBL4229464 |
| Influenza A virus |
IC50 |
= |
66700.0 |
nM |
Antiviral activity against Influenza A virus (A/Virginia/ATCC1/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 48 hrs by crystal violet staining based method |
CHEMBL4229464 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
24600.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in viral titer preincubated with cells for 1 hr followed by viral inoculation and measured after 48 hrs by hemagglutination test |
CHEMBL4261492 |
| MDCK |
CC50 |
> |
2000000.0 |
nM |
Cytotoxicity against MDCK cells after 48 hrs by MTT assay |
CHEMBL4261492 |
| Unchecked |
Ratio CC50/EC50 |
> |
81.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) |
CHEMBL4261492 |
| unidentified influenza virus |
MIC |
= |
6.0 |
ug.mL-1 |
Antiviral activity against Influenza virus H5N1 |
CHEMBL4270610 |
| Newcastle disease virus |
MIC |
= |
3.0 |
ug.mL-1 |
Antiviral activity against Newcastle disease virus |
CHEMBL4270610 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
12800.0 |
nM |
Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells measured after 2 days by plaque reduction assay |
CHEMBL4270618 |
| MDCK |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay |
CHEMBL4270618 |
| PA/PB1 |
EC50 |
= |
23800.0 |
nM |
Inhibition of Influenza A virus A/PR/8/34 (H1N1) PA-PB1 interaction expressed in HEK293T cells assessed as decrease in RNA polymerase activity incubated for 24 hrs by minireplicon based luciferase reporter gene assay |
CHEMBL4270618 |
| HEK-293T |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay |
CHEMBL4270618 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
8400.0 |
nM |
Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4270630 |
| Influenza A virus (A/PR/8/34(H1N1)) |
EC50 |
= |
9100.0 |
nM |
Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells after 3 days by MTS assay |
CHEMBL4270630 |
| Influenza A virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4270630 |
| Influenza A virus |
EC50 |
= |
8500.0 |
nM |
Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells after 3 days by MTS assay |
CHEMBL4270630 |
| Influenza A virus |
EC50 |
= |
13000.0 |
nM |
Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4270630 |
| Influenza A virus |
EC50 |
= |
5900.0 |
nM |
Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells after 3 days by MTS assay |
CHEMBL4270630 |
| Influenza B virus |
EC50 |
= |
2300.0 |
nM |
Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method |
CHEMBL4270630 |
| Influenza B virus |
EC50 |
= |
2200.0 |
nM |
Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells after 3 days by MTS assay |
CHEMBL4270630 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay |
CHEMBL4270630 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as alteration in cell morphology after 3 days by microscopic method |
CHEMBL4270630 |
| Influenza A virus |
EC50 |
= |
11270.0 |
nM |
Antiviral activity against Influenza A virus A/goose/Guangdong/SH7/2013(H5N1) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay |
CHEMBL4270670 |
| Influenza A virus |
EC50 |
= |
15810.0 |
nM |
Antiviral activity against Influenza A virus A/Chicken/Hebei/LZF/2014(H5N2) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay |
CHEMBL4270670 |
| Influenza A virus |
EC50 |
= |
5060.0 |
nM |
Antiviral activity against Influenza A virus A/duck/Guangdong/674/2014(H5N6) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay |
CHEMBL4270670 |
| Influenza A virus |
EC50 |
= |
11330.0 |
nM |
Antiviral activity against Influenza A virus A/goose/Jiangsu/1306/2014(H5N8) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay |
CHEMBL4270670 |
| Fibroblasts |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay |
CHEMBL4270670 |
| SARS-CoV-2 |
Inhibition index |
= |
0.527 |
|
Inhibition of cell viability relative to arbidol control (inhibition index > 1 indicates higher activity) measured by fluorescence (OD590nm) in Vero E6 cells infected with SARS-CoV-2 (strain BavPat1) at MOI 0.002 after 72hrs |
CHEMBL4303097 |
| SARS-CoV-2 |
Inhibition |
= |
11.83 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging |
CHEMBL4303101 |
| SARS-CoV-2 |
Hit score |
= |
0.2922 |
|
Antiviral activity against SARS-CoV-2 (USA-WA1/2020 strain) measured by imaging in HRCE cells at MOI 0.4 after 96 hrs (reported as hit score from 0-1 for on-disease vs off-disease activity: scores >0.6 considered hits) |
CHEMBL4303122 |
| SARS-CoV-2 |
Hit score |
= |
0.1047 |
|
Antiviral activity against SARS-CoV-2 (USA-WA1/2020 strain) measured by imaging in Vero cells at MOI 0.08 after 48 hrs (reported as hit score from 0-1 for on-disease vs off-disease activity: scores >0.6 considered hits) |
CHEMBL4303122 |
| SARS-CoV-2 |
Activity |
|
|
|
Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound by crystal violet staining 3) Cell viability (cytotoxicity) measuring percentage viable Vero E6 cells 48 h after compound addition by AlamarBlue assay. |
CHEMBL4303773 |
| ADMET |
AUC Ratio |
= |
1.015 |
|
Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay. |
CHEMBL4303773 |
| SARS-CoV-2 |
AUC |
= |
248.7 |
|
AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells). |
CHEMBL4303773 |
| Vero C1008 |
AUC cytotoxicity |
= |
252.5 |
|
AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay. |
CHEMBL4303773 |
| Vero C1008 |
pCC50 |
~ |
4.664 |
|
Cytotoxicity of compound against Vero E6 cells by MTT assay. |
CHEMBL4303773 |
| SARS-CoV-2 |
IC50 |
~ |
81470.43 |
nM |
IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells). |
CHEMBL4303773 |
| Rabies virus |
Inhibition |
|
|
% |
Antiviral activity against RABV infected in BSR cells preincubated for 4 hrs followed by viral infection and further incubated with compounds for 24 hrs by immunostaining-based assay |
CHEMBL4304791 |
| Influenza A virus |
EC50 |
= |
2200.0 |
nM |
Antiviral activity against Influenza A virus (A/California/7/2009(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured on day 5 by Celltiter-Glo luminescence assay |
CHEMBL4316619 |
| Influenza A virus |
EC90 |
= |
3.5 |
uM |
Antiviral activity against Influenza A virus (A/California/7/2009(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured on day 5 by Celltiter-Glo luminescence assay |
CHEMBL4316619 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability measured on day 5 by Celltiter-Glo luminescence assay |
CHEMBL4316619 |
| Influenza A virus H3N2 |
EC50 |
= |
28800.0 |
nM |
Antiviral activity against Influenza A virus (A/Brisbane/10/2007(H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured on day 5 by Celltiter-Glo luminescence assay |
CHEMBL4316619 |
| Influenza A virus H3N2 |
EC90 |
= |
34.9 |
uM |
Antiviral activity against Influenza A virus (A/Brisbane/10/2007(H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured on day 5 by Celltiter-Glo luminescence assay |
CHEMBL4316619 |
| Influenza A virus |
EC50 |
= |
32200.0 |
nM |
Antiviral activity against influenza A virus A/Vietnam/1203/2004 x A/PR/8/34 (H5N1) harboring recombinant NS1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured on day 5 by Celltiter-Glo luminescence assay |
CHEMBL4316619 |
| Influenza A virus |
EC90 |
= |
68.6 |
uM |
Antiviral activity against influenza A virus A/Vietnam/1203/2004 x A/PR/8/34 (H5N1) harboring recombinant NS1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured on day 5 by Celltiter-Glo luminescence assay |
CHEMBL4316619 |
| Unchecked |
Ratio CC50/EC50 |
> |
44.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against MDCK cells to EC50 for Influenza A virus (A/California/7/2009(H1N1)) infected in MDCK cells |
CHEMBL4316619 |
| Unchecked |
Ratio CC50/EC50 |
> |
3.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against MDCK cells to EC50 for Influenza A virus (A/Brisbane/10/2007(H3N2)) infected in MDCK cells |
CHEMBL4316619 |
| Unchecked |
Ratio CC50/EC50 |
> |
3.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against MDCK cells to EC50 for influenza A virus A/Vietnam/1203/2004 x A/PR/8/34 (H5N1) harboring recombinant NS1 infected in MDCK cells |
CHEMBL4316619 |
| A549 |
CC50 |
= |
307000.0 |
nM |
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay |
CHEMBL4330122 |
| Argentinian mammarenavirus |
EC50 |
= |
19200.0 |
nM |
Antiviral activity against Junin virus IV4454 infected in human A549 cells assessed as reduction in vrius yield after 48 hrs by plaque assay |
CHEMBL4330122 |
| Unchecked |
Ratio CC50/EC50 |
= |
15.9 |
|
Selectivity index, ratio of CC50 for human A549 cells to EC50 for Junin virus IV4454 infected in human A549 cells |
CHEMBL4330122 |
| Vero |
CC50 |
> |
400000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay |
CHEMBL4330122 |
| Argentinian mammarenavirus |
EC50 |
= |
18500.0 |
nM |
Antiviral activity against Junin virus IV4454 infected in African green monkey Vero cells assessed as reduction in vrius yield after 48 hrs by plaque assay |
CHEMBL4330122 |
| Unchecked |
Ratio CC50/EC50 |
> |
21.6 |
|
Selectivity index, ratio of CC50 for African green monkey Vero cells to EC50 for Junin virus IV4454 infected in African green monkey Vero cells |
CHEMBL4330122 |
| RD |
CC50 |
= |
1485000.0 |
nM |
Cytotoxicity against human RD cells assessed as reduction in cell viability after 12 hrs by CCK8 assay |
CHEMBL4334442 |
| Coxsackievirus A16 |
EC50 |
= |
143610.0 |
nM |
Antiviral activity against Coxsackievirus A16 TA271 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect preincubated with viral suspension for 2 hrs followed by cell addition and measured after 24 hrs by CCK-8 assay |
CHEMBL4334442 |
| Coxsackievirus A16 |
Activity |
|
|
|
Antiviral activity against Coxsackievirus A16 TA271 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect preincubated with viral suspension for 2 hrs followed by cell addition and measured after 24 hrs by CCK-8 assay |
CHEMBL4334442 |
| Unchecked |
Ratio CC50/EC50 |
= |
10.34 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human RD cells to EC50 for antiviral activity against Coxsackievirus A16 TA271 infected in human RD cells |
CHEMBL4334442 |
| Dengue virus 2 |
EC50 |
= |
11900.0 |
nM |
Antiviral activity against Dengue virus type 2 NGC infected in African green monkey Vero B cells assessed as reduction in virus yield |
CHEMBL4339220 |
| Zika virus |
EC50 |
= |
12000.0 |
nM |
Antiviral activity against Zika virus |
CHEMBL4339220 |
| Dengue virus |
EC50 |
= |
11900.0 |
nM |
Antiviral activity against Dengue virus |
CHEMBL4339220 |
| Unchecked |
CC50 |
> |
409000.0 |
nM |
Cytotoxicity in African green monkey Vero B cells assessed as reduction in cell viability by MTS assay |
CHEMBL4339220 |
| Zika virus |
EC50 |
|
|
|
Antiviral activity against Zika virus MR766 infected in African green monkey Vero E6 cells assessed as reduction in virus yield |
CHEMBL4339220 |
| Vero C1008 |
CC50 |
|
|
|
Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability by MTS assay |
CHEMBL4339220 |
| Unchecked |
Ratio CC50/EC50 |
> |
34.0 |
|
Selectivity index, ratio of CC50 for African green monkey Vero B cells to EC50 for Dengue virus type 2 NGC infected in African green monkey Vero B cells |
CHEMBL4339220 |
| Unchecked |
Ratio CC50/EC50 |
|
|
|
Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for Zika virus MR766 infected in African green monkey Vero E6 cells |
CHEMBL4339220 |
| Vero |
TC50 |
> |
200.0 |
ug ml-1 |
Cytotoxicity against African green monkey Vero cells infected with Herpes simplex virus 1 after 72 hrs by MTT assay |
CHEMBL4340503 |
| Human herpesvirus 1 |
IC50 |
= |
38.49 |
ug.mL-1 |
Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect by microscopic analysis |
CHEMBL4340503 |
| Unchecked |
Selectivity Index |
> |
5.2 |
|
Selectivity index, ratio of TC50 against African green monkey Vero cells infected with Herpes simplex virus 1 after 72 hrs by MTT assay to IC50 against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect by microscopic analysis |
CHEMBL4340503 |
| Coxsackievirus |
IC50 |
= |
884900.0 |
nM |
Antiviral activity against CVB3 infected in African green monkey Vero cells by MTT assay |
CHEMBL4342433 |
| Vero |
TC50 |
= |
31.25 |
uM |
Cytotoxicity in African green monkey Vero cells assessed as reduction in cell viability by MTT assay |
CHEMBL4342433 |
| ADMET |
TI |
= |
28.3 |
|
Therapeutic Index, ratio of TC50 for African green monkey Vero cells to IC50 for CVB3 infected in African green monkey Vero cells |
CHEMBL4342433 |
| Vero |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero cells |
CHEMBL4354808 |
| NS5 |
EC50 |
= |
20800.0 |
nM |
Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity after 72 hrs by DAPI staining based assay |
CHEMBL4354808 |
| MDCK |
CC50 |
> |
2130000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay |
CHEMBL4368876 |
| Influenza A virus |
IC50 |
= |
30000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in virus titer pretreated with cells for 1 hr followed by viral infection for 1 hr and subsequent unbound virion washout measured after 24 to 48 hrs by hemagglutination test |
CHEMBL4368876 |
| Unchecked |
Ratio CC50/IC50 |
= |
71.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells |
CHEMBL4368876 |
| Adenosine A1 receptor |
Ki |
= |
7410.0 |
nM |
Displacement of [3H]N6-R-phenylisopropyladenosine from human A1A adenosine receptor expressed in CHO cell membranes after 60 mins by scintillation proximity assay |
CHEMBL4368904 |
| Adenosine A1 receptor |
Ki |
= |
4430.0 |
nM |
Displacement of [3H]N6-R-phenylisopropyladenosine from mouse A1A adenosine receptor expressed in CHO cell membranes after 60 mins by scintillation proximity assay |
CHEMBL4368904 |
| Adenosine A2a receptor |
Inhibition |
= |
23.0 |
% |
Displacement of [3H]2-[p-(2-carboxyethyl)phenylethylamino]-5-N-ethylcarboxamidoadenosine from human A2A adenosine receptor expressed in HEK293 cell membranes at 10 uM after 60 mins by scintillation proximity assay relative to adenosine 5-N-ethyluronamide |
CHEMBL4368904 |
| Adenosine A3 receptor |
Inhibition |
= |
16.0 |
% |
Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5-N-methyluronamide from human A3A adenosine receptor expressed in CHO cell membranes at 10 uM after 60 mins by scintillation proximity assay relative to adenosine 5-N-ethyluronamide |
CHEMBL4368904 |
| Adenosine A3 receptor |
Inhibition |
= |
0.0 |
% |
Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5-N-methyluronamide from mouse A3A adenosine receptor expressed in CHO cell membranes at 10 uM after 60 mins by scintillation proximity assay relative to adenosine 5-N-ethyluronamide |
CHEMBL4368904 |
| Unchecked |
Selectivity Index |
= |
714.0 |
|
Selectivity index, ratio of TC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza B virus infected in dog MDCK cells |
CHEMBL4373726 |
| Influenza B virus |
IC50 |
= |
8000.0 |
nM |
Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition in virus-induced cytopathic effect incubated for 40 hrs |
CHEMBL4373726 |
| Unchecked |
Selectivity Index |
= |
476.3 |
|
Selectivity index, ratio of TC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza A virus H3N2 infected in dog MDCK cells |
CHEMBL4373726 |
| Influenza A virus H3N2 |
IC50 |
= |
10600.0 |
nM |
Antiviral activity against Influenza A virus H3N2 infected in dog MDCK cells assessed as inhibition in virus-induced cytopathic effect incubated for 40 hrs |
CHEMBL4373726 |
| Unchecked |
Selectivity Index |
= |
362.9 |
|
Selectivity index, ratio of TC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells |
CHEMBL4373726 |
| Influenza A virus |
IC50 |
= |
8500.0 |
nM |
Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells assessed as inhibition in virus-induced cytopathic effect incubated for 40 hrs |
CHEMBL4373726 |
| MDCK |
TC50 |
= |
4764.5 |
uM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs |
CHEMBL4373726 |
| Tobacco mosaic virus |
Inhibition |
= |
37.6 |
% |
Antiviral activity against Tobacco mosaic virus inoculated in Nicotiana tabacum leaves assessed as passivation by measuring local lesion numbers at 500 mg/l pre-incubated with virus for 30 mins followed by inoculation and measured up to 4 days |
CHEMBL4390648 |
| Tobacco mosaic virus |
Inhibition |
= |
11.9 |
% |
Antiviral activity against Tobacco mosaic virus inoculated in Nicotiana tabacum leaves assessed as passivation by measuring local lesion numbers at 100 mg/l pre-incubated with virus for 30 mins followed by inoculation and measured up to 4 days |
CHEMBL4390648 |
| Influenza A virus |
EC50 |
= |
9116.0 |
nM |
Antiviral activity against Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as reduction in viral replication preincubated for 1 hr followed by compound washout and measured after 48 hrs |
CHEMBL4390701 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by alamar blue assay |
CHEMBL4390701 |
| Dengue virus 1 |
IC50 |
= |
6660.0 |
nM |
Antiviral activity against Dengue virus 1 DGL2 replicon infected in BHK cells assessed as inhibition of viral replicon RNA replication incubated for 72 hrs by Gaussia-luciferase reporter gene assay |
CHEMBL4392858 |
| Unchecked |
CC50 |
= |
48980.0 |
nM |
Cytotoxicity in BHK cells assessed as reduction in cell viability incubated for 72 hrs by cell count reagent SF based microplate spectrophotometry |
CHEMBL4392858 |
| Unchecked |
Ratio CC50/IC50 |
= |
7.35 |
|
Selectivity index, ratio of CC50 for cytotoxicity in BHK cells to IC50 for antiviral activity against Dengue virus 1 DGL2 replicon infected in BHK cells |
CHEMBL4392858 |
| Pichinde virus |
EC50 |
= |
12.0 |
ug.mL-1 |
Antiviral activity against Pichinde virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect |
CHEMBL4396935 |
| Tacaribe virus |
EC50 |
= |
9.3 |
ug.mL-1 |
Antiviral activity against Tacaribe virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect |
CHEMBL4396935 |
| Unchecked |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HELF cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis |
CHEMBL4406859 |
| Human coronavirus 229E |
EC50 |
= |
112000.0 |
nM |
Antiviral activity against Human coronavirus 229E infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method |
CHEMBL4406859 |
| MDCK |
MCC |
> |
100000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis |
CHEMBL4406859 |
| Influenza B virus |
EC50 |
= |
4600.0 |
nM |
Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay |
CHEMBL4406859 |
| Influenza A virus H3N2 |
EC50 |
= |
1400.0 |
nM |
Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay |
CHEMBL4406859 |
| Influenza A virus |
EC50 |
= |
18200.0 |
nM |
Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay |
CHEMBL4406859 |
| Influenza B virus |
EC50 |
= |
5600.0 |
nM |
Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Influenza A virus H3N2 |
EC50 |
= |
2300.0 |
nM |
Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Influenza A virus |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis |
CHEMBL4406859 |
| Influenza A virus (A/PR/8/34(H1N1)) |
IC50 |
= |
25000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of virus replication compound incubated with uninfected host cell for 1 hr followed by viral infection for 24 hrs measured after viral cultivation in host cell for 48 hrs by hemagglutination test |
CHEMBL4406883 |
| MDCK |
CTD50 |
> |
2000.0 |
uM |
Cytotoxicity against dog MDCK cells assessed as cell death incubated for 48 hrs by MTT assay |
CHEMBL4406883 |
| Unchecked |
Selectivity Index |
> |
81.0 |
|
Selectivity index, ratio of CTD50 for dog MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34 (H1N1)) pdm09 infected in MDCK cells |
CHEMBL4406883 |
| THP-1 |
Ratio IC50 |
= |
0.5 |
|
Ratio of cytotoxic IC50 for human THP1 (+/+) cells expressing wild type SAMHD1 to cytotoxic IC50 for human THP1 cells with CRISP/CAS9 SAMHD1 knockout |
CHEMBL4420068 |
| THP-1 |
Ratio IC50 |
= |
0.5 |
|
Ratio of cytotoxic IC50 for human THP1 cells with constitutively expressing high SAMHD1 expression to cytotoxic IC50 for parental human THP1 cells expressing low SAMHD1 expression |
CHEMBL4420068 |
| Dengue virus 2 |
EC50 |
= |
40000.0 |
nM |
Antiviral activity against Dengue virus 2 16681 infected in human HuH7 cells after 72 hrs by indirect immunofluorescent flow cytometry |
CHEMBL4431301 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus (H1N1) infected in mouse assessed as reduction in virus-infection induced mortality by measuring mouse survival at 75 mg/kg, ip qd for 5 days dosed 4 hrs before virus infection |
CHEMBL4476870 |
| Cytochrome P450 3A4 |
FC |
= |
1.0 |
|
Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone |
CHEMBL4477225 |
| Cytochrome P450 2D6 |
FC |
= |
1.0 |
|
Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone |
CHEMBL4477225 |
| Cytochrome P450 2C9 |
FC |
= |
1.0 |
|
Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NADPH measured after 24 hrs in absence of compound, CYP3A4 and NADPH by cell titer-glo luminescence assay relative to BSO alone |
CHEMBL4477225 |
| West Nile virus |
EC50 |
= |
46000.0 |
nM |
Antiviral activity against West Nile virus infected in human A549 cells incubated for 4 days by crystal violet staining based plaque reduction assay |
CHEMBL4480403 |
| West Nile virus |
EC50 |
= |
95000.0 |
nM |
Antiviral activity against West Nile virus infected in African green monkey Vero cells incubated for 4 days by crystal violet staining based plaque reduction assay |
CHEMBL4480403 |
| West Nile virus |
EC50 |
= |
90000.0 |
nM |
Antiviral activity against West Nile virus infected in human HuH7 cells incubated for 4 days by crystal violet staining based plaque reduction assay |
CHEMBL4480403 |
| A549 |
IC50 |
|
|
|
Cytotoxicity against human A549 cells after 3 days by MTT assay |
CHEMBL4480403 |
| Vero |
IC50 |
|
|
|
Cytotoxicity against African green monkey Vero cells after 3 days by MTT assay |
CHEMBL4480403 |
| Huh-7 |
IC50 |
> |
200000.0 |
nM |
Cytotoxicity against human HuH7 cells after 3 days by MTT assay |
CHEMBL4480403 |
| West Nile virus |
EC50 |
= |
71200.0 |
nM |
Antiviral activity against West Nile virus |
CHEMBL4480403 |
| Replicase polyprotein 1ab |
Inhibition |
= |
10.13 |
% |
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate |
CHEMBL4495564 |
| SARS-CoV-2 |
Inhibition |
= |
-0.06 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| Chikungunya virus |
Activity |
|
|
|
Antiviral activity against Chikungunya virus infected in African green monkey Vero cells assessed as reduction in viral replication at 10 uM treated with compound up to 12 hrs post infection by plaque formation assay |
CHEMBL4602650 |
| Unchecked |
Ratio CC50/EC50 |
= |
122.0 |
|
Selectivity index, ratio of CC50 for African monkey Vero cells to EC50 for Chikungunya virus infected in African green monkey Vero cells |
CHEMBL4602650 |
| Chikungunya virus |
EC50 |
= |
2420.0 |
nM |
Antiviral activity against Chikungunya virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection |
CHEMBL4602650 |
| Unchecked |
Ratio CC50/EC50 |
= |
75.2 |
|
Selectivity index, ratio of CC50 for African monkey Vero cells to EC50 for Zika virus infected in African green monkey Vero cells |
CHEMBL4602650 |
| Zika virus |
EC50 |
= |
3950.0 |
nM |
Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection |
CHEMBL4602650 |
| Vero |
CC50 |
= |
297000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay |
CHEMBL4602650 |
| Zika virus |
Activity |
|
|
|
Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as reduction in viral replication at 10 uM treated with compound at 6 hrs post infection by plaque formation assay |
CHEMBL4602650 |
| Influenza A virus H3N2 |
EC50 |
= |
8400.0 |
nM |
Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method |
CHEMBL4609985 |
| Influenza A virus H3N2 |
EC50 |
= |
4600.0 |
nM |
Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay |
CHEMBL4609985 |
| MDCK |
MCC |
>= |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 4 days by MTS assay |
CHEMBL4609985 |
| MDCK |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay |
CHEMBL4609985 |
| Zika virus |
Inhibition |
= |
37.0 |
% |
Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as inhibition of viral induced cytopathic effect at 40 uM relative to control |
CHEMBL4610048 |
| Vero C1008 |
Activity |
= |
94.5 |
% |
Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability at 40 uM relative to control |
CHEMBL4610048 |
| Vero C1008 |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability |
CHEMBL4610048 |
| Zika virus |
EC50 |
= |
33000.0 |
nM |
Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in viral induced cytopathic effect |
CHEMBL4610048 |
| Unchecked |
Ratio CC50/EC50 |
> |
3.0 |
|
Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for Zika virus infected in African green monkey Vero E6 cells assessed as inhibition of viral induced cytopathic effect |
CHEMBL4610048 |
| Zika virus |
EC50 |
= |
33000.0 |
nM |
Antiviral activity against Zika virus infected in Vero E6 cells assessed as reduction in virus-induced cytopathic effect incubated for 96 hrs by CCK8 assay |
CHEMBL4613269 |
| Vero C1008 |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability |
CHEMBL4613269 |
| Unchecked |
Ratio CC50/EC50 |
> |
6.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity in African green monkey Vero E6 cells to EC50 for Antiviral activity against Zika virus infected in Vero E6 cells |
CHEMBL4613269 |
| Dengue virus 2 |
IC50 |
= |
4000.0 |
nM |
Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infected and measured after 72 hrs by immunodetection assay |
CHEMBL4613314 |
| Huh-7 |
CC50 |
= |
100000.0 |
nM |
Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay |
CHEMBL4613314 |
| Unchecked |
Ratio CC50/EC50 |
= |
25.0 |
|
Selectivity index, ratio of CC50 for human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay to EC50 for Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infected and measured after 72 hrs by immunodetection assay |
CHEMBL4613314 |
| Influenza A virus |
IC50 |
= |
15360.0 |
nM |
Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human 293T cells pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene assay |
CHEMBL4619735 |
| Unchecked |
Ratio CC50/IC50 |
= |
20.8 |
|
Selectivity index, ratio of CC50 for cytotoxicity in dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by crystal violet staining based assay to IC50 for cytotoxicity in dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by crystal violet staining based assay |
CHEMBL4619773 |
| Influenza A virus |
IC50 |
= |
98300.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay |
CHEMBL4619773 |
| SARS-CoV-2 |
Inhibition |
= |
-0.06 |
% |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4495565 |
| SARS-CoV-2 |
IC50 |
> |
50100.0 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| SARS-CoV-2 |
IC50 |
< |
50118.72 |
nM |
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging |
CHEMBL4651402 |
| Unchecked |
Ratio CC50/IC50 |
= |
61.0 |
|
Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34 (H1N1)) infected in MDCK cells |
CHEMBL4673281 |
| MDCK |
CC50 |
> |
2130000.0 |
nM |
Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay |
CHEMBL4673281 |
| Influenza A virus |
IC50 |
= |
35000.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34 (H1N1) infected in MDCK cells assessed as decrease in viral titer preincubated for 1 hr followed by viral infection and cultivated for 48 hrs followed by supernatant transferred to chicken erythrocyte for 1 hr followed by measuring ability to cause positive hemagglutination |
CHEMBL4673281 |
| MDA-MB-231 |
IC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay |
CHEMBL4680136 |
| MDA-MB-435 |
IC50 |
= |
38300.0 |
nM |
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay |
CHEMBL4680136 |
| B16-F10 |
IC50 |
= |
3500.0 |
nM |
Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay |
CHEMBL4680136 |
| Caco-2 |
IC50 |
= |
34500.0 |
nM |
Antiproliferative activity against human CaCo-2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay |
CHEMBL4680136 |
| Huh-7 |
IC50 |
= |
53700.0 |
nM |
Antiproliferative activity against human HuH-7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay |
CHEMBL4680136 |
| DU-145 |
IC50 |
> |
100000.0 |
nM |
Antiproliferative activity against human DU-145 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay |
CHEMBL4680136 |
| SNB-75 |
IC50 |
= |
18530.0 |
nM |
Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay |
CHEMBL4680136 |
| C6 |
IC50 |
= |
13510.0 |
nM |
Antiproliferative activity against rat C6 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay |
CHEMBL4680136 |
| A-431 |
IC50 |
= |
3180.0 |
nM |
Antiproliferative activity against human A-431 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay |
CHEMBL4680136 |
| MDA-MB-231 |
Inhibition |
= |
40.0 |
% |
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control |
CHEMBL4680136 |
| MDA-MB-435 |
Inhibition |
= |
50.0 |
% |
Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control |
CHEMBL4680136 |
| B16-F10 |
Inhibition |
= |
80.0 |
% |
Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control |
CHEMBL4680136 |
| Caco-2 |
Inhibition |
= |
60.0 |
% |
Antiproliferative activity against human CaCo-2 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control |
CHEMBL4680136 |
| Huh-7 |
Inhibition |
= |
60.0 |
% |
Antiproliferative activity against human HuH-7 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control |
CHEMBL4680136 |
| DU-145 |
Inhibition |
= |
50.0 |
% |
Antiproliferative activity against human DU-145 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control |
CHEMBL4680136 |
| SNB-75 |
Inhibition |
= |
70.0 |
% |
Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control |
CHEMBL4680136 |
| C6 |
Inhibition |
= |
75.0 |
% |
Antiproliferative activity against rat C6 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control |
CHEMBL4680136 |
| A-431 |
Inhibition |
= |
70.0 |
% |
Antiproliferative activity against human A-431 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control |
CHEMBL4680136 |
| SK-OV-3 |
IC50 |
= |
9.0 |
ug.mL-1 |
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay |
CHEMBL4680136 |
| SK-OV-3 |
IC50 |
= |
10.0 |
ug.mL-1 |
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay |
CHEMBL4680136 |
| SK-OV-3 |
IC50 |
= |
10.0 |
ug.mL-1 |
Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay |
CHEMBL4680136 |
| IGROV-1 |
IC50 |
= |
25.0 |
ug.mL-1 |
Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay |
CHEMBL4680136 |
| IGROV-1 |
IC50 |
= |
21.0 |
ug.mL-1 |
Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay |
CHEMBL4680136 |
| IGROV-1 |
IC50 |
= |
16.0 |
ug.mL-1 |
Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay |
CHEMBL4680136 |
| Unchecked |
Activity |
|
|
|
Cytotoxicity against human MET5A cells assessed as effect on cell morphology at 20 ug/ml measured upto 7 days by laser scanning confocal microscopy |
CHEMBL4680136 |
| Unchecked |
EC50 |
> |
100000.0 |
nM |
Antiviral activity against recombinant HCV genotype 2a JFH-1 infected in human Huh7.5 cells after 3 days by renilla luciferase reporter gene assay |
CHEMBL4680152 |
| Unchecked |
CC50 |
= |
16300.0 |
nM |
Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability after 3 days by MTT assay |
CHEMBL4680152 |
| Unchecked |
Ratio CC50/EC50 |
> |
6.1 |
|
Selectivity index, ratio of CC50 for human Huh7.5 cells to EC50 for HCV genotype 2a JFH-1 infected in human Huh7.5 cells |
CHEMBL4680152 |
| Influenza A virus |
EC50 |
= |
22000.0 |
nM |
Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by microscopic analysis |
CHEMBL4680243 |
| Influenza A virus |
EC50 |
= |
31000.0 |
nM |
Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by MTS assay |
CHEMBL4680243 |
| MDCK |
MCC |
= |
100000.0 |
nM |
Cytotoxicity against MDCK cells assessed as change in cell morphology measured after 72 hrs by microscopic analysis |
CHEMBL4680243 |
| MDCK |
CC50 |
= |
58000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by MTS assay |
CHEMBL4680243 |
| Influenza A virus |
EC50 |
= |
11000.0 |
nM |
Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) clone 1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by microscopic analysis |
CHEMBL4680243 |
| Influenza A virus |
EC50 |
= |
20000.0 |
nM |
Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) clone 1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by MTS assay |
CHEMBL4680243 |
| Influenza A virus |
EC50 |
= |
13000.0 |
nM |
Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) clone 2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by microscopic analysis |
CHEMBL4680243 |
| Influenza A virus |
EC50 |
= |
21000.0 |
nM |
Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) clone 2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by MTS assay |
CHEMBL4680243 |
| Unchecked |
EC50 |
= |
43000.0 |
nM |
Antiviral activity against human Norovirus |
CHEMBL4680252 |
| SARS-CoV-2 |
EC50 |
= |
109500.0 |
nM |
Antiviral activity against nCoV-2019 BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated for 1 hr followed by viral infection and further replacement of fresh medium containing compound and measured at 48 hrs post infection by qRT-PCR method |
CHEMBL4680271 |
| Vero C1008 |
CC50 |
> |
400000.0 |
nM |
Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay |
CHEMBL4680271 |
| Influenza A virus |
IC50 |
= |
47220.0 |
nM |
Antiviral activity against Influenza A virus (A/Duck/Guangdong/212/2004(H5N1)) infected in A549 cells assessed as reduction in virus-induced cytopathic effect by CPE reduction assay |
CHEMBL4699479 |
| A549 |
CC50 |
= |
129650.0 |
nM |
Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay |
CHEMBL4699479 |
| Unchecked |
Ratio CC50/IC50 |
= |
2.7 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human A549 cells to IC50 for antiviral activity against for influenza A virus (A/Duck/Guangdong/212/2004(H5N1)) infected in A549 cells |
CHEMBL4699479 |
| Influenza A virus |
Activity |
|
|
|
Antiviral activity against Influenza A virus (A/Duck/Guangdong/212/2004(H5N1)) infected in Balb/c mouse assessed as increase in animal survival rate at 80 mg/kg administered intranasally once daily for 5 days starting from 1 day prior to infection and monitored daily for 14 days |
CHEMBL4699479 |
| Unchecked |
IC50 |
= |
44000.0 |
nM |
Antiviral activity against Influenza A virus (A/California/07/09(H1N1))pdm09 infected in MDCK cells assessed as reduction in viral replication preincubated with compound for 1 hr followed by viral infection and measured after viral cultivation for 48 hrs by hemagglutination test |
CHEMBL4699606 |
| MDCK |
CC50 |
> |
2130000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay |
CHEMBL4699606 |
| Unchecked |
Ratio CC50/IC50 |
= |
48.0 |
|
Selectivity index, ratio of CC50 for dog MDCK cells to IC50 for Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells |
CHEMBL4699606 |
| Vesicular stomatitis virus |
EC50 |
= |
23000.0 |
nM |
Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Human coxsackievirus B4 |
EC50 |
= |
61000.0 |
nM |
Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Respiratory syncytial virus |
EC50 |
= |
15000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| HeLa |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HeLa cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Unchecked |
Ratio |
> |
11.0 |
|
Selectivity index, ratio of MCC for human HeLa cells to EC50 for Vesicular stomatitis virus infected in human HeLa cells |
CHEMBL4715693 |
| Unchecked |
Ratio |
> |
4.0 |
|
Selectivity index, ratio of MCC for human HeLa cells to EC50 for Human coxsackievirus B4 infected in human HeLa cells |
CHEMBL4715693 |
| Unchecked |
Ratio |
> |
17.0 |
|
Selectivity index, ratio of MCC for human HeLa cells to EC50 for Respiratory syncytial virus infected in human HeLa cells |
CHEMBL4715693 |
| Human parainfluenza virus 3 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Human parainfluenza virus 3 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Mammalian orthoreovirus 1 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Mammalian orthoreovirus 1 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Sindbis virus |
EC50 |
= |
250000.0 |
nM |
Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Human coxsackievirus B4 |
EC50 |
> |
250000.0 |
nM |
Antiviral activity against Human coxsackievirus B4 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Punta Toro virus |
EC50 |
= |
50000.0 |
nM |
Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Vero |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopy |
CHEMBL4715693 |
| Unchecked |
Ratio |
> |
1.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero cells to EC50 for Sindbis virus infected in African green monkey Vero cells |
CHEMBL4715693 |
| Unchecked |
Ratio |
> |
5.0 |
|
Selectivity index, ratio of MCC for African green monkey Vero cells to EC50 for Punta Toro virus infected in African green monkey Vero cells |
CHEMBL4715693 |
| Influenza A virus |
EC50 |
= |
8900.0 |
nM |
Antiviral activity against influenza A virus infected in dog MDCK cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| Influenza B virus |
EC50 |
= |
2300.0 |
nM |
Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis |
CHEMBL4715693 |
| HEL |
MCC |
> |
250000.0 |
nM |
Cytotoxicity against human HEL cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopy |
CHEMBL4715693 |
| MDCK |
MCC |
= |
100000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopy |
CHEMBL4715693 |
| Unchecked |
CC50 |
|
|
|
Cytotoxicity against cat CRFK cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay |
CHEMBL4715693 |
| MT4 |
CC50 |
|
|
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay |
CHEMBL4715693 |
| Unchecked |
EC50 |
= |
15830.0 |
nM |
Antiviral activity against GFP-fused wild-type RSV subgroup A Long infected in human HEp-2 cells measured 24 to 72 hrs post infection by fluorescence assay |
CHEMBL4715831 |
| HEp-2 |
CC50 |
= |
273800.0 |
nM |
Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay |
CHEMBL4715831 |
| ADMET |
Ratio CC50/EC50 |
= |
17.3 |
|
Safety index, ratio of CC50 for human HEp-2 cells to EC50 for GFP-fused wild-type RSV subgroup A long infected in human HEp-2 cells |
CHEMBL4715831 |
| Unchecked |
RFU |
= |
0.04 |
|
Antiviral activity against GFP-fused wild-type RSV subgroup A Long infected in human HEp-2 cells assessed as relative fluorescence intensity at 20 uM pretreated for 1 hr followed by viral infection measured 24 to 72 hrs post infection by fluorescence assay |
CHEMBL4715831 |
| Influenza A virus |
EC50 |
= |
25080.0 |
nM |
Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human HEK293T cells measured after 24 hrs by Gaussia luciferase reporter gene method |
CHEMBL4715831 |
| HEK-293T |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay |
CHEMBL4715831 |
| ADMET |
Ratio CC50/EC50 |
> |
3.99 |
|
Safety index, ratio of CC50 for HEK293T cells to EC50 for antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human HEK293T cells |
CHEMBL4715831 |
| Influenza A virus |
EC50 |
= |
16000.0 |
nM |
Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells measured after 24 hrs by Gaussia luciferase reporter gene method |
CHEMBL4715831 |
| Unchecked |
EC50 |
= |
20500.0 |
nM |
Antiviral activity against H3N2 infected in MDCK cells measured after 24 hrs by Gaussia luciferase reporter gene method |
CHEMBL4715831 |
| Influenza A virus |
RFU |
= |
0.67 |
|
Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in HEK293T cells assessed as relative fluorescence intensity at 20 uM pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene method |
CHEMBL4715831 |
| SARS-CoV-2 |
IC50 |
= |
109500.0 |
nM |
Antiviral activity against 2019-nCoV BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated with virus for 1 hr followed by cell infection and measured after 2 hrs by qRT-PCR method |
CHEMBL4715853 |
| Vero C1008 |
CC50 |
> |
400000.0 |
nM |
Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay |
CHEMBL4715853 |
| Unchecked |
Ratio CC50/EC50 |
> |
3.65 |
|
Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for 2019-nCoV Beta CoV/Wuhan/WIV04/2019 infected in African green monkey Vero E6 cells |
CHEMBL4715853 |
| Unchecked |
EC50 |
= |
16300.0 |
nM |
Antiviral activity against HCV genotype 2a JFH-1 infected in human Huh7.5 cells after 3 days by renilla luciferase reporter gene assay |
CHEMBL4725397 |
| Unchecked |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human Huh7.5 cells assessed as decrease in cell viability after 3 days by MTT assay |
CHEMBL4725397 |
| Unchecked |
Selectivity ratio |
> |
6.1 |
|
Selectivity index, ratio of CC50 for human Huh7.5 cells to EC50 for genotype 2a HCV JFH-1 infected in human Huh7.5 cells |
CHEMBL4725397 |
| Zika virus |
Survival |
= |
82.0 |
% |
Antiviral activity against Zika virus 976 Uganda infected in human HepG2 cells assessed as protection against viral infection by measuring cell survival at 100 uM measured after 4 days by CellTiter-Glo luminescent cell viability assay relative to control |
CHEMBL4725430 |
| HepG2 |
Activity |
= |
100.0 |
% |
Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM measured after 4 days by CellTiter-Glo luminescent cell viability assay relative to control |
CHEMBL4725430 |
| Influenza A virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells assessed as reduction in plaque formation treated 1 hr post viral infection and measured after 48 hrs post-infection by toluidine blue staining based plaque reduction assay |
CHEMBL4732130 |
| MDCK |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay |
CHEMBL4732130 |
| RNA-directed RNA polymerase |
EC50 |
= |
24000.0 |
nM |
Inhibition of RdRP activity in Influenza A virus A/PR/8/34 (H1N1) infected in HEK293T cells co-transfected with NP/PA/PB1/PB2/pPolI-Flu-ffLuc/pRL-SV40 incubated for 24 hrs by minireplicon based dual luciferase assay |
CHEMBL4732130 |
| Respiratory syncytial virus |
IC50 |
= |
17330.0 |
nM |
Antiviral activity against RSV Long expressing mGFP infected in HEp-2 cells assessed as reduction in viral replication after 48 hrs by MTS assay |
CHEMBL4732200 |
| HEp-2 |
CC50 |
= |
3039670.0 |
nM |
Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability after 48 hrs by MTS assay |
CHEMBL4732200 |
| Unchecked |
Ratio CC50/IC50 |
= |
175.4 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human HEp-2 cells to IC50 for antiviral activity against RSV Long expressing mGFP infected in HEp-2 cells |
CHEMBL4732200 |
| Influenza A virus |
IC50 |
= |
15360.0 |
nM |
Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human HEK-293T cells assessed as inhibition of viral replication after 48 hrs by CCK-8 assay |
CHEMBL4732200 |
| HEK-293T |
IC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HEK-293T cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay |
CHEMBL4732200 |
| Unchecked |
Ratio CC50/IC50 |
> |
6.51 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human HEK-293T cells to IC50 for antiviral activity against Influenza A virus A/WSN/33(H1N1) expressing mGFP infected in HEp-2 cells |
CHEMBL4732200 |
| Influenza A virus |
IC50 |
= |
4010.0 |
nM |
Antiviral activity against Influenza A virus (A/goose/Guangdong/SH7/2013(H5N1)) group-1 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hemagglutination titre method |
CHEMBL4765273 |
| Influenza A virus |
IC50 |
> |
10000.0 |
nM |
Antiviral activity against Influenza A virus (A/chicken/Hebei/LZF/ 2014(H5N2)) group-2 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hemagglutination titre method |
CHEMBL4765273 |
| Influenza A virus |
IC50 |
= |
6680.0 |
nM |
Antiviral activity against Influenza A virus (A/Duck/Guangdong/674/2014 (H5N6)) group-2 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hemagglutination titre method |
CHEMBL4765273 |
| Influenza A virus |
IC50 |
= |
1960.0 |
nM |
Antiviral activity against Influenza A virus (A/goose/Jiangsu/1306/2014 (H5N8)) group-1 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hemagglutination titre method |
CHEMBL4765273 |
| Unchecked |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay |
CHEMBL4765273 |
| Influenza A virus |
IC50 |
= |
2840.0 |
nM |
Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 48 hrs by microscopic analysis |
CHEMBL4765325 |
| Influenza A virus |
IC50 |
= |
15360.0 |
nM |
Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in HEK293T-Gluc cells pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene assay |
CHEMBL4765426 |
| HEK-293T |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HEK293T cells assessed as reduction in cell viability after 48 hrs by CCK8 assay |
CHEMBL4765426 |
| Unchecked |
Ratio CC50/IC50 |
> |
6.51 |
|
Selectivity index, ratio of CC50 for human HEK293T cells to IC50 for Influenza A virus A/WSN/33(H1N1) infected in HEK293T-Gluc cells |
CHEMBL4765426 |
| MDCK |
CC50 |
= |
20000.0 |
nM |
Cytotoxicity against MDCK cells by MTT assay |
CHEMBL4811236 |
| Hantaan orthohantavirus |
IC50 |
|
|
|
Antiviral activity against Hantaan 76-118 pseudovirus infected in MDCK cells assessed as reduction in virus replication incubated for 48 hrs by luminescence assay |
CHEMBL4811236 |
| HEK-293T |
CC50 |
|
|
|
Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay |
CHEMBL4811236 |
| Vesicular stomatitis virus |
IC50 |
|
|
|
Antiviral activity against pseudotyped recombinant vesicular stomatitis virus delta G Gn-Gc infected HEK293T cells assessed as reduction in virus replication incubated for 48 hrs by luminescence assay |
CHEMBL4811236 |
| Chikungunya virus |
Inhibition |
= |
97.0 |
% |
Antiviral activity against CHIKV infected in African green monkey Vero cells assessed as inhibition of viral replication at 20 uM measured after 4 days relative to control |
CHEMBL4811249 |
| Zika virus |
Inhibition |
= |
93.0 |
% |
Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as inhibition of viral replication at 20 uM measured after 4 days relative to control |
CHEMBL4811249 |
| Vero |
CC50 |
= |
300000.0 |
nM |
Cytotoxicity against African green monkey Vero cells by MTT assay |
CHEMBL4811249 |
| Influenza A virus |
IC50 |
= |
4280.0 |
nM |
Antiviral activity against Influenza A virus (H1N1) infected in dog MDCK cells assessed as inhibition of surface glycoprotein hemagglutinin |
CHEMBL4825697 |
| MDCK |
CC50 |
> |
200000.0 |
nM |
Cytotoxicity against dog MDCK cells assessed as reduction in cell viability |
CHEMBL4825697 |
| ADMET |
Selectivity Index |
> |
46.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza A virus HINI infected in dog MDCK cells |
CHEMBL4825697 |
| Influenza A virus |
IC50 |
= |
4280.0 |
nM |
Antiviral activity against Oseltamivir resistant Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1) infected in dog MDCK cells assessed as inhibition of surface glycoprotein hemagglutinin |
CHEMBL4825697 |
| ADMET |
Selectivity Index |
> |
46.0 |
|
Selectivity index, ratio of CC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Oseltamivir resistant Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in dog MDCK cells |
CHEMBL4825697 |
| Respiratory syncytial virus |
EC50 |
= |
18530.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells incubated for 60 hrs by MTT assay |
CHEMBL4831503 |
| HEp-2 |
CC50 |
= |
418210.0 |
nM |
Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 60 hrs by MTT assay |
CHEMBL4831503 |
| ADMET |
Selectivity Index |
= |
22.57 |
|
Selectivity index, ratio of CC50 for human HEp-2 cells to EC50 for Respiratory syncytial virus infected in human HEp-2 cells |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
= |
0.3 |
% |
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as early apoptotic cells at 25 uM measured after 60 hrs by Annexin V-FITC/PI staining based flow cytometry analysis (Rvb = 10.3%) |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
= |
7.6 |
% |
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as late apoptotic cells at 25 uM measured after 60 hrs by Annexin V-FITC/PI staining based flow cytometry analysis (Rvb = 20.2%) |
CHEMBL4831503 |
| Respiratory syncytial virus |
Inhibition |
|
|
% |
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as reduction in PARP cleavage measured after 48 hrs by Western blot analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Inhibition |
|
|
% |
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as reduction in cleaved caspase-7 expression measured after 48 hrs by Western blot analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Inhibition |
|
|
% |
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as reduction in cleaved caspase-9 expression measured after 48 hrs by Western blot analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Inhibition |
|
|
% |
Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as reduction in cleaved caspase-3 expression measured after 60 hrs by Western blot analysis |
CHEMBL4831503 |
| Unchecked |
Activity |
= |
62.7 |
% |
Inhibition of RSV induced ROS production in human HEp-2 cells assessed as reduction in accumulation of ROS-positive cells at 25 uM measured after 36 hrs by DCHF-DA staining based flow cytometry analysis (Rvb = 82.2%) |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in human HEp-2 cells assessed as downregulation of NF-kappaB expression at 25 uM treated 48 hpi and measured after 48 hrs by Western blot analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in human HEp-2 cells assessed as downregulation of RIG-1 expression at 25 uM treated 48 hpi and measured after 48 hrs by Western blot analysis |
CHEMBL4831503 |
| ADMET |
Activity |
|
|
|
Toxicity in BALB/c mouse infected with RSV-Long assessed as body weight loss at 50 mg/kg/day administered via gastric gavage once daily for 6 days |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV Long infected in BALB/c mouse assessed as reduction in lung tissue damage by measuring lung index at 50 mg/kg/day measured after 4 to 6 days of virus infection |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV Long infected in BALB/c mouse assessed as improvement in lung congestion at 25 to 100 mg/kg/day observed on day 6 after infection by H and E staining based microscopic analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV Long infected in BALB/c mouse assessed as inhibition of alveolar infiltrates accumulation at 50 mg/kg/day observed on day 6 after infection by H and E staining based microscopic analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in BALB/c mouse assessed as inhibition of viral replication by measuring RSV-M gene expression in lung after 2 to 6 days post infection by RT-PCR analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of RIG-1 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 days post infection by RT-PCR analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of IRF3 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 4 days post infection by RT-PCR analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of TLR3 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of IL-6 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 days post infection by RT-PCR analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of IL-8 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of IL-10 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of iNOS expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis |
CHEMBL4831503 |
| Respiratory syncytial virus |
Activity |
|
|
|
Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of TNF-alpha expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis |
CHEMBL4831503 |
| A549 |
CC20 |
= |
409.84 |
uM |
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay |
CHEMBL4831514 |
| A549 |
CC50 |
= |
7611100.0 |
nM |
Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay |
CHEMBL4831514 |
| Vesicular stomatitis virus |
Activity |
|
|
|
Antiviral activity against Vesicular stomatitis virus Indiana infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 48 hrs by MTT assay |
CHEMBL4831514 |
| Human herpesvirus 1 |
Activity |
|
|
|
Antiviral activity against Human herpesvirus-1 MacIntyre infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 48 hrs by MTT assay |
CHEMBL4831514 |
| Enterovirus E |
Activity |
|
|
|
Antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 72 hrs by MTT assay |
CHEMBL4831514 |
| Human adenovirus type 5 |
Activity |
|
|
|
Antiviral activity against Human adenovirus 5 Adenoid 75 infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 72 hrs by MTT assay |
CHEMBL4831514 |
| Enterovirus E |
EC50 |
= |
102500.0 |
nM |
Antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as reduction in virus titer treated 1 hr post viral infection followed by replacement with fresh medium with compounds and measured after 72 hrs by MTT assay |
CHEMBL4831514 |
| ADMET |
Selectivity Index |
= |
74.3 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human A549 cells to EC50 for antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as reduction in virus titer treated 1 hr post viral infection followed by replacement with fresh medium with compounds and measured after 72 hrs by MTT assay |
CHEMBL4831514 |
| Influenza A virus |
EC50 |
= |
10000.0 |
nM |
Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells assessed as inhibition of plaque formation for 48 hrs by plaque reduction assay |
CHEMBL4837208 |
| MDCK |
CC50 |
> |
250000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay |
CHEMBL4837208 |
| RNA-directed RNA polymerase |
EC50 |
= |
16000.0 |
nM |
Inhibition of RdRP activity in Influenza A virus A/PR/8/34(H1N1) infected in HEK293T cells incubated for 24 hrs by minireplicon based dual luciferase assay |
CHEMBL4837208 |
| Unchecked |
Inhibition |
= |
99.07 |
% |
Inhibition of Infectious hematopoietic necrosis virus glycoprotein G assessed as antiviral activity at 25 uM measured by RT-qPCR method relative to control |
CHEMBL4840322 |
| Respiratory syncytial virus |
EC50 |
= |
2000.0 |
nM |
Antiviral activity against Respiratory syncytial virus assessed as reduction in virus-induced cytopathic effect by MTS assay |
CHEMBL4842312 |
| HEp-2 |
CC50 |
= |
250000.0 |
nM |
Cytotoxicity in human Hep2 cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method |
CHEMBL4842312 |
| ADMET |
Selectivity Index |
> |
1.3 |
|
Selectivity index, ratio of CC50 for human A549 cells to IC50 for Influenza A Puerto Rico/8/34/H1N1 infected in human A549 cells |
CHEMBL4842338 |
| Influenza A virus |
IC50 |
= |
37400.0 |
nM |
Antiviral activity against Influenza A Puerto Rico/8/34/H1N1 infected in human A549 cells assessed as inhibition of viral replication after 24 hrs by hemagglutination assay |
CHEMBL4842338 |
| A549 |
CC50 |
> |
50000.0 |
nM |
Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay |
CHEMBL4842338 |
| Huh-7 |
CC50 |
= |
200000.0 |
nM |
Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay |
CHEMBL4842338 |
| Dengue virus 2 |
IC50 |
= |
4000.0 |
nM |
Antiviral activity against Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay |
CHEMBL4842338 |
| Dengue virus 2 |
IC50 |
= |
7600.0 |
nM |
Antiviral activity against Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay |
CHEMBL4842338 |
| Dengue virus 2 |
IC50 |
= |
4100.0 |
nM |
Antiviral activity against Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay |
CHEMBL4842338 |
| ADMET |
Selectivity Index |
= |
50.0 |
|
Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay |
CHEMBL4842338 |
| ADMET |
Selectivity Index |
= |
26.0 |
|
Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay |
CHEMBL4842338 |
| ADMET |
Selectivity Index |
= |
49.0 |
|
Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay |
CHEMBL4842338 |
| Zika virus |
IC50 |
= |
4400.0 |
nM |
Antiviral activity against Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay |
CHEMBL4842338 |
| Zika virus |
IC50 |
= |
3800.0 |
nM |
Antiviral activity against Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay |
CHEMBL4842338 |
| Zika virus |
IC50 |
= |
2200.0 |
nM |
Antiviral activity against Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay |
CHEMBL4842338 |
| ADMET |
Selectivity Index |
= |
45.0 |
|
Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay |
CHEMBL4842338 |
| ADMET |
Selectivity Index |
= |
53.0 |
|
Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay |
CHEMBL4842338 |
| ADMET |
Selectivity Index |
= |
91.0 |
|
Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay |
CHEMBL4842338 |
| West Nile virus |
IC50 |
|
|
|
Antiviral activity against West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based secondary yield reduction assay |
CHEMBL4842338 |
| West Nile virus |
IC50 |
= |
9500.0 |
nM |
Antiviral activity against West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based direct yield reduction assay |
CHEMBL4842338 |
| West Nile virus |
IC50 |
= |
6700.0 |
nM |
Antiviral activity against West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based plaque reduction assay |
CHEMBL4842338 |
| ADMET |
Selectivity Index |
= |
21.0 |
|
Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based direct yield reduction assay |
CHEMBL4842338 |
| ADMET |
Selectivity Index |
= |
30.0 |
|
Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based plaque reduction assay |
CHEMBL4842338 |
| MDCK |
CC50 |
> |
50000.0 |
nM |
Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 24 hrs by MTT assay |
CHEMBL4842338 |
| Influenza A virus |
IC50 |
= |
9500.0 |
nM |
Antiviral activity against Influenza A Puerto Rico/8/34/H1N1 infected in MDCK cells assessed as inhibition of viral replication measured in supernatants of infected cells after 24 hrs by hemagglutination assay |
CHEMBL4842338 |
| ADMET |
Selectivity Index |
= |
21.6 |
|
Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A Puerto Rico/8/34/H1N1 infected in MDCK cells |
CHEMBL4842338 |
| Huh-7 |
CC50 |
|
|
|
Cytotoxicity against human Huh-7 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay |
CHEMBL4842338 |
| SARS-CoV-2 |
IC50 |
|
|
|
Antiviral activity against SARS-COV 2 infected in human Huh-7 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by direct yield reduction assay |
CHEMBL4842338 |
| Vero C1008 |
CC50 |
> |
400000.0 |
nM |
Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay |
CHEMBL4842338 |
| Caco-2 |
CC50 |
|
|
|
Cytotoxicity against human Caco2 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay |
CHEMBL4842338 |
| SARS-CoV-2 |
IC50 |
|
|
|
Antiviral activity against SARS-COV 2 infected in human Caco-2 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by immunodetection assay |
CHEMBL4842338 |
| SARS-CoV-2 |
IC50 |
= |
109500.0 |
nM |
Antiviral activity against SARS-COV 2 infected in monkey Vero E6 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by direct yield reduction assay |
CHEMBL4842338 |
| Calu-3 |
CC50 |
|
|
|
Cytotoxicity against human Calu-3 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay |
CHEMBL4842338 |
| SARS-CoV-2 |
IC50 |
|
|
|
Antiviral activity against SARS-COV 2 infected in human Calu-3 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by direct yield reduction assay |
CHEMBL4842338 |
| Human herpesvirus 1 |
Activity |
= |
100.0 |
PFU/ml |
Antiviral activity against HSV-1 infected in human Huh-7 cells assessed as reduction in plaque forming units at 1 uM measured after 48 hrs by virus titre method |
CHEMBL5053525 |
| Zika virus |
Inhibition |
= |
80.0 |
% |
Antiviral activity against Zika virus infected in human Huh-7 cells assessed as inhibition of viral replication at 12.5 uM measured after 48 hrs by Renilla reporter based luciferase assay relative to control |
CHEMBL5053560 |
| West Nile virus |
Inhibition |
= |
90.0 |
% |
Antiviral activity against West Nile virus infected in human Huh-7 cells assessed as inhibition of viral replication at 12.5 uM measured after 48 hrs by plaque assay relative to control |
CHEMBL5053560 |
| Dengue virus |
Inhibition |
= |
75.0 |
% |
Antiviral activity against Dengue virus infected in human Huh-7 cells assessed as inhibition of viral replication at 12.5 uM measured after 48 hrs by plaque assay relative to control |
CHEMBL5053560 |
| Unchecked |
IC50 |
= |
5000.0 |
nM |
Cytotoxicity against paclitaxel-resistant human HCT116tax cells assessed as DNA damage by measuring fluorescence intensity incubated for 30 mins by Hoechst 33342 staining accumulation assay |
CHEMBL5104221 |
| HCT-116 |
Activity |
|
|
|
Cytotoxicity against human HCT-116 cells overexpressing human MDR1 assessed as DNA damage by measuring fluorescence intensity at 100 uM incubated for 30 mins by Hoechst 33342 staining accumulation assay |
CHEMBL5104221 |
| HCT-116 |
Activity |
|
|
|
Cytotoxicity against in human HCT-116 cells overexpressing human BCRP assessed as DNA damage by measuring fluorescence intensity at 100 uM incubated for 30 mins by Hoechst 33342 staining accumulation assay |
CHEMBL5104221 |
| HCT-116 |
EC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay |
CHEMBL5104221 |
| Unchecked |
EC50 |
> |
100000.0 |
nM |
Cytotoxicity against paclitaxel-resistant human HCT116tax cells incubated for 48 hrs by MTT assay |
CHEMBL5104221 |
| HCT-116 |
EC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HCT-116 cells overexpressing human MDR1 incubated for 48 hrs by MTT assay |
CHEMBL5104221 |
| HCT-116 |
EC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HCT-116 cells overexpressing human BCRP incubated for 48 hrs by MTT assay |
CHEMBL5104221 |
| HEK293 |
EC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay |
CHEMBL5104221 |
| HCT-116 |
Activity |
|
|
|
Cytotoxicity against human HCT-116 cells assessed as reduction on cell viability at 100 uM incubated for 48 hrs in presence of paclitaxel by MTT assay |
CHEMBL5104221 |
| HCT-116 |
Activity |
|
|
|
Cytotoxicity against human HCT-116 cells assessed as reduction on cell viability at 100 uM incubated for 48 hrs by MTT assay |
CHEMBL5104221 |
| HCT-116 |
Activity |
|
|
|
Cytotoxicity against human wild type HCT-116 cells assessed as reduction on cell viability at 100 to 200 uM incubated for 48 hrs in presence of paclitaxel by MTT assay |
CHEMBL5104221 |
| Unchecked |
Activity |
|
|
|
Cytotoxicity against paclitaxel-resistant human HCT116tax cells assessed as reduction on cell viability at 100 to 200 uM incubated for 48 hrs in presence of paclitaxel by MTT assay |
CHEMBL5104221 |
| P-glycoprotein 1 |
Inhibition |
|
|
% |
Inhibition of recombinant human P-gp ATPase activity in presence of MgATP preincubated for 40 min measured after 20 min by Pgp-Glo assay |
CHEMBL5104221 |
| SARS-CoV-2 |
EC50 |
= |
109500.0 |
nM |
Antiviral activity against SARS-CoV 2 nCoV-2019BetaCoV/Wuhan/WIV04/2019 infected in african green monkey Vero E6 cells measured after 48 hrs |
CHEMBL5113370 |
| Vero |
CC50 |
> |
400000.0 |
nM |
Cytotoxicity against African green monkey Vero cells by CCK8 assay method |
CHEMBL5113370 |
| ADMET |
Ratio IC50 |
> |
3.65 |
|
Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for antiviral activity against SARS-CoV 2 nCoV-2019BetaCoV/Wuhan/WIV04/2019 |
CHEMBL5113370 |
| HEp-2 |
CC50 |
> |
1000000.0 |
nM |
Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability |
CHEMBL5120906 |
| Respiratory syncytial virus |
IC50 |
= |
19000.0 |
nM |
Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect by CPE inhibition assay |
CHEMBL5120906 |
| ADMET |
Ratio CC50/IC50 |
> |
54.0 |
|
Therapeutic index, ratio of CC50 for Cytotoxicity against human HEp-2 cells to IC50 for Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells |
CHEMBL5120906 |
| Unchecked |
CC50 |
= |
1019700.0 |
nM |
Cytotoxicity against human Huh7-J20 cells assessed as reduction in cell viability by MTS assay |
CHEMBL5126587 |
| Hepatitis C virus |
Activity |
= |
80.0 |
% |
Antiviral activity against Huh 7.5 cell culture derived HCV genotype 2a (JFH-AM71) infected in human Huh7-J20 cells assessed as inhibition of viral replication at 100 uM treated for 72 hrs by SEAP reporter gene assay relative to control |
CHEMBL5126587 |
| Hepatitis C virus |
Activity |
|
|
|
Antiviral activity against Huh 7.5 cell culture derived HCV genotype 2a (JFH-AM71) infected in human Huh7-J20 cells assessed as inhibition of viral replication treated for 72 hrs by SEAP reporter gene assay |
CHEMBL5126587 |
| Hepatitis C virus |
IC50 |
= |
21780.0 |
nM |
Antiviral activity against Huh 7.5 cell culture derived HCV genotype 2a (JFH-AM71) infected in human Huh7-J20 cells assessed as inhibition of viral replication treated for 72 hrs by SEAP reporter gene assay |
CHEMBL5126587 |
| ADMET |
Ratio CC50/IC50 |
= |
46.8 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human Huh-7 J20 cells assessed as reduction in cell viability to IC50 for antiviral activity against Huh 7.5 cell culture derived HCV genotype 2a (JFH-AM71) infected in human Huh7-J20 cells assessed as inhibition of viral replication |
CHEMBL5126587 |
| Vero |
CC50 |
= |
1245000.0 |
nM |
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTS assay |
CHEMBL5126587 |
| Huh-7.5 |
CC50 |
= |
1654000.0 |
nM |
Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by MTS assay |
CHEMBL5126587 |
| Zika virus |
Activity |
= |
80.0 |
% |
Antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in human Huh7.5 cells assessed as inhibition of viral replication by measuring ZIKV E glycoprotein level at 100 uM incubated for 3 days by ELISA analysis relative to control |
CHEMBL5126587 |
| Zika virus |
Activity |
= |
80.0 |
% |
Antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring ZIKV E glycoprotein level at 100 uM incubated for 3 days by ELISA analysis relative to control |
CHEMBL5126587 |
| Zika virus |
IC50 |
= |
6900.0 |
nM |
Antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in human Huh7.5 cells assessed as reduction in viral titer incubated for 3 days by plaque assay |
CHEMBL5126587 |
| Zika virus |
IC50 |
= |
29900.0 |
nM |
Antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in African green monkey Vero cells assessed as reduction in viral titer incubated for 3 days by plaque assay |
CHEMBL5126587 |
| ADMET |
Ratio CC50/IC50 |
= |
41.6 |
|
Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability to IC50 for antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in African green monkey Vero cells assessed as reduction in viral titer |
CHEMBL5126587 |
| ADMET |
Ratio CC50/IC50 |
= |
239.7 |
|
Selectivity index, ratio of CC50 for cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability to IC50 for antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in human Huh7.5 cells assessed as reduction in viral titer |
CHEMBL5126587 |
| Vero C1008 |
CC100 |
> |
160.0 |
ug ml-1 |
Cytotoxicity against African green monkey Vero E6 cells measured after 72 hrs by MTT assay |
CHEMBL5137096 |
| BHK-21 |
CC100 |
> |
160.0 |
ug ml-1 |
Cytotoxicity against golden hamster BHK-21 cells measured after 6 days by MTT assay |
CHEMBL5137096 |
| Zika virus |
Inhibition |
> |
50.0 |
% |
Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis relative to control |
CHEMBL5137096 |
| Zika virus |
EC |
= |
40.0 |
ug ml-1 |
Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Zika virus |
Inhibition |
= |
55.0 |
% |
Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well at 12.4 to 100 ug/ml incubated for 72 hrs by crystal violet staining based assay relative to control |
CHEMBL5137096 |
| Zika virus |
EC |
= |
20.0 |
ug ml-1 |
Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well incubated for 72 hrs by crystal violet staining based assay |
CHEMBL5137096 |
| Dengue virus 2 |
Inhibition |
> |
50.0 |
% |
Antiviral activity against DENV2 infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis relative to control |
CHEMBL5137096 |
| Dengue virus 2 |
EC |
= |
40.0 |
ug ml-1 |
Antiviral activity against DENV2 infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Dengue virus 2 |
Inhibition |
= |
75.0 |
% |
Antiviral activity against DENV2 infected in golden hamster BHK-21 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well at 12.4 to 100 ug/ml incubated for 6 days by crystal violet staining based assay relative to control |
CHEMBL5137096 |
| Dengue virus 2 |
EC |
= |
5.0 |
ug ml-1 |
Antiviral activity against DENV2 infected in hamster BHK-21 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well incubated for 6 days by crystal violet staining based assay |
CHEMBL5137096 |
| Human herpesvirus 1 |
FC |
= |
10.0 |
|
Antiviral activity against HHV-1 29R strain infected in African green monkey Vero E6 cells assessed as reduction factor at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Human herpesvirus 1 |
EC |
= |
10.0 |
ug ml-1 |
Antiviral activity against HHV-1 29R strain infected in African green monkey Vero E6 cells assessed as concentration required for higher viral reduction factor measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Chikungunya virus |
FC |
= |
31.62 |
|
Antiviral activity against CHIKV infected in African green monkey Vero E6 cells assessed as reduction factor at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Chikungunya virus |
EC |
= |
10.0 |
ug ml-1 |
Antiviral activity against CHIKV infected in African green monkey Vero E6 cells assessed as concentration required for higher viral reduction factor measured after 72 hrs by crystal violet staining based inverted microscopic analysis |
CHEMBL5137096 |
| Zika virus |
EC50 |
= |
83000.0 |
nM |
Antiviral activity against Zika 459148 infected in African Green monkey Vero E6 cells assessed as reduction in plaque formation measured after 72 hrs by crystal violet staining based analysis |
CHEMBL5137096 |
| Vero C1008 |
CC50 |
> |
160000.0 |
nM |
Cytotoxicity against African green monkey Vero E6 cells infected with Zika 459148 measured after 72 hrs by MTT assay |
CHEMBL5137096 |
| Zika virus |
EC50 |
= |
101000.0 |
nM |
Antiviral activity against ZIKV COL345Si infected in African Green monkey Vero E6 cells assessed as reduction in plaque formation measured after 6 days by crystal violet staining based analysis |
CHEMBL5137096 |
| Vero C1008 |
CC50 |
> |
160000.0 |
nM |
Cytotoxicity against African green monkey Vero E6 cells infected with ZIKV COL345Si measured after 6 days by MTT assay |
CHEMBL5137096 |
| Influenza A virus |
IC50 |
= |
27760.0 |
nM |
Antiviral activity against Influenza A virus A/WSN/33 (H1N1) infected in HEK293T cells by Gaussia luciferase reporter assay |
CHEMBL5143634 |
| HEK-293T |
CC50 |
> |
100000.0 |
nM |
Cytotoxicity against human HEK293T cells assessed as cell viability after 48 hrs by CCK-8 assay |
CHEMBL5143634 |
| ADMET |
Ratio CC50/IC50 |
= |
3.67 |
|
Selectivity index, ratio of CC50 for human HEK293T cells to IC50 for antiviral activity against Influenza A virus A/WSN/33 (H1N1) infected in HEK293T cells |
CHEMBL5143634 |
